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Abstract 
Schizophrenia is a psychiatric disorder affecting about 1% of the world‟s 
population and manifests itself as positive symptoms (eg. hallucinations), 
negative symptoms (eg. social withdrawal) in conjunction with cognitive 
impairments (eg. working memory).  Evidence suggests that schizophrenia is, in 
part, a heritable disease.  Candidate susceptibility genes implicate the 
glutamatergic neurotransmitter system, reinforcing clinical observations of N-
methyl-D-aspartate receptor (NMDAR) hypofunction in schizophrenia.  One of 
those genes, D-amino acid oxidase (DAO), is genetically associated with 
schizophrenia and its function includes degradation of D-serine, the NMDAR co-
agonist.  DAO is a candidate gene of high interest due to schizophrenic patients‟ 
manifestation of reduced D-serine levels, increased DAO expression and 
increased DAO activity.   
 Despite mounting evidence for DAO involvement in schizophrenia, its 
regulation is poorly understood.  Characterization of DAO may lead to a more 
thorough understanding of its function and biology and ultimately to the 
identification of novel targets for this disorder. To this end, DAO-specific 
antibodies were utilized to identify DAO-interacting proteins through co-
immunoprecipitation from rat cerebellum, where DAO expression is especially 
high.  Subsequent mass spectroscopy analysis of associating proteins yielded 
twenty-four putative DAO interactors.  The most abundant and interesting 
interactors include known presynaptic active zone members such as bassoon 
(BSN) and piccolo (PCLO).  The DAO interaction with BSN was confirmed 
through co-immunoprecipitation and both proteins were shown to localize in the 
presynaptic junction.  These data suggest that BSN is a novel DAO interactor and 
defines a previously unappreciated localization of DAO perhaps as a result of a 
physiologically important interaction with BSN.  Furthermore, BSN was found to 
partially inhibit DAO enzymatic activity in transiently transfected human 
embryonic kidney (Hek293) cells.  Collectively these novel findings suggest that 
synaptic D-serine concentration may be under tight regulation by BSN via 
proximally localized DAO.  DAO may thus play a role in modulating the 
functions of the presynaptic active zone via its interaction with BSN.  
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1.1 Schizophrenia symptoms, diagnosis, and costs 
Schizophrenia is a chronic, severe, disabling brain disorder that generally 
has an onset in the early adulthood and may persist throughout life (Lewis and 
Lieberman, 2000).  It affects around 1% of the population worldwide (Harrison 
and Owen, 2003) and is highly heritable (80%) with a concordance rate of 
approximately 50% in monozygotic twins, 12% to 17% for dyzygotic twins and 
first-degree relatives (Gotesman, 1991; Sullivan et al., 2003).  The lack of 
complete concordance rate in identical twins suggests that environmental and 
epigenetic factors influence the phenotype with strong evidence for perinatal 
insults (Tsuang, 2000). 
Schizophrenia manifests itself through positive symptoms including 
delusions, hallucinations, and though disorder; negative symptoms such as 
flattening of emotional responses, apathy and social withdrawal (Andreasen, 
1995; Crow, 1985); and cognitive symptoms with impairments in attention, 
memory and executive functions (Elvevag and Goldberg, 2000).  The disease is 
heterogeneous and the diagnosis is based on symptoms and their progression 
(Andreasen, 1995) classified by the Diagnostic and Statistical Manual (DMS-IV; 
American Association of Psychiatry, 1994; Table 1.1).   
Schizophrenia is burdensome on the patient as well as the society as the 
disease has economical implications through productivity loss of the patient and 
the immediate family, cost of law-enforcement, homeless shelters, hospital stay 
and treatment.  It is estimated that schizophrenia is the seventh most costly 
medical illness in the world (Freedman, 2003).  In the United States alone the 
economic burden associated with schizophrenia in 2002 was estimated at $62.7 
billion with about 9% of that sum made up by cost of drugs (Wu et al., 2005).  
The data highlights the need for a pharmacological intervention in treatment of 
this debilitating disease. 
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Table 1.1: DSM-IV Diagnostic criteria for schizophrenia 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from American Association of Psychiatry, 1994 
 
A. Characteristic symptoms.  Two (or more) of the following, each present for a significant portion of time 
during a 1 month period (or less if successfully treated). 
a. Delusions 
b. Hallucinations 
c. Disorganized speech (e.g. frequent derailment of incoherence) 
d. Grossly disorganized or catatonic behavior 
e. Negative symptoms, i.e. affective flattening, alogia or avolition 
B. Social/occupational dysfunction.  For a significant portion of the time since the onset of the disturbance, 
one or more major areas of functioning such as work, interpersonal relations, or self-care are markedly 
below the level achieved prior to the onset (or when the onset is in childhood or adolescence, failure to 
achieve the expected level of interpersonal, academic or occupational achievement). 
C. Duration. Continuous signs of the disturbance persists for at least 6 months.  This6-month period must 
include at least 1 month of symptoms (or less if successfully treated) that meet criterion A (i.e. active-
phase symptoms) and may include periods of prodromal or residual symptoms.  During these 
prodromal or residual periods, the signs of the disturbance may be manifested by only negative 
symptoms or two or more symptoms listed in Criterion A present in an attenuated from (e.g. odd 
beliefs, unusual perceptual experiences). 
D. Schizoaffective and Mood Disorder exclusion.  Schizoaffective Disorder and Mood Disorder with 
Psychotic Features have been ruled out because either  
a. No Major Depressive, Manic, or Mixed episodes have occurred concurrently with the active-
phase symptoms; or 
b. If mood episodes have occurred during active-phase symptoms, their total duration has been 
brief relative to the active and residual periods. 
E. Substance/general medical condition exclusion.  The disturbance is not due to the direct physiological 
effects of a substance (e.g. a drug of abuse, a medication) or a general medical condition. 
F. Relationship to a Pervasive Developmental Disorder.  If there is a history of Autistic Disorder or 
another Pervasive Developmental Disorder, the additional diagnosis of Schizophrenia is made only if 
prominent delusions or hallucinations are present for at least a month (or less if successfully treated). 
Diagnostic criteria for Schizophrenia subtypes 
1. Paranoid Subtype.  A type of schizophrenia in which the following criteria are met: 
a. Preoccupation with one or more delusions or auditory hallucinations 
b. None of the following is prominent: disorganized speech, disorganized or catatonic behavior, 
or flat or inappropriate affect 
2. Disorganized subtype.  A type of Schizophrenia in which the following criteria are met: 
a. All of the following are present; i)Disorganized speech; ii)Disorganized behavior; iii) flat or 
inappropriate affect 
b. The criteria are not met for catatonic type 
3. Catatonic Subtype.  A type of schizophrenia in which the clinical picture is dominated by at least two of 
the following: 
a. Motoric inability as evidenced by catalepsy (including waxy flexibility or stupor) 
b. Excessive motor activity (that is apparently purposeless and not influenced by external stimuli) 
c. Extreme negativism (an apparently motiveless resistance to all instructions or maintenance of 
a rigid posture against attempts to be moved) or mutism 
d. Peculiarities of voluntary movement as evidenced by posturing (voluntary assumption of 
inappropriate or bizarre postures), stereotyped movements prominent mannerisms, or 
prominent grimacing 
e. Echolalia or echopraxia 
4. Undifferentiated subtype.  A type of Schizophrenia in which the symptoms that meet Criterion A are 
present but the criteria are not met for the Paranoid, Disorganized, or Catatonic Type. 
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1.2  Major pathways associated with schizophrenia  
Dopamine research has been recognized to be central to schizophrenia 
studies for many years and resulted in development of several drugs that treat the 
disease (outlined in dopamine hypothesis of schizophrenia section 1.2.1 and in 
treatment of schizophrenia section 1.4).  Abnormalities in glutamate 
neurotransmission have been highlighted more recently but have already been 
implicated in schizophrenia especially in symptoms where the dopaminergic 
treatment has limitations.  The glutamate neurotransmission deficits are 
complementary to the dopaminergic hypothesis and also impinge upon other 
important neurotransmitters such as GABA described below. 
 
1.2.1  Dopamine hypothesis of schizophrenia 
For nearly half a century, schizophrenia was though to be a disease of 
dopaminergic neurotransmission dysregulation (Carlsson, 1988).  The dopamine 
hypothesis was based upon two fundamental observations.  First, blocking 
dopamine re-uptake and increasing dopamine release through psycho stimulants 
such as amphetamine and cocaine can cause psychosis in healthy volunteers that 
resemble the positive symptoms of schizophrenia while exacerbating those 
symptoms in schizophrenic patients (Bunney et al., 1973; Einhorn et al., 1988; 
Lieberman et al., 1987; Satel and Edell, 1991; Shi et al., 2000).  Secondly, the 
typical antipsychotic medications such as haloperidol and chlorpromazine block 
dopamine D2 receptors.  Their affinity at the D2 receptors, in turn, highly 
correlates with their clinical potency in psychosis relief (Creese et al., 1976; 
Kapur et al., 2000; Peroutka and Synder, 1980; Seeman et al., 1976).  Thus the 
dopamine hypothesis of schizophrenia was based on the dopamine hyperactivity 
resulting in symptoms of schizophrenia (Matthysse, 1973).   
There are four main dopaminergic pathways in the brain that impinge on 
abnormalities found in schizophrenic patients.  They include the mesocortical, 
mesolimbic, tuberoinfundibular and nigrostriatal tracts.  The origin and respective 
target regions for each is highlighted in Figure 1.1.  The mesolimbic pathway is 
important for memory and for motivating behavior.  Through blockage of this 
pathway antipsychotics reduce intense emotions associated with schizophrenia.  
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Overactive mesocortical pathway is though to result in hallucinations and 
disorderly thinking thus toning down this pathway through antipsychotics may 
have a desirable effect in schizophrenic patients.  The nigrostriatal pathway is 
involved in motor control and excessive dopaminergic inhibition may result in 
extra pyramidal side effects.  The tuberoinfundibular pathway plays a role in 
hormonal secretion such as prolactin.   
With additional data the focus of blocking dopamine receptors and 
limiting excess dopaminergic transmission shifted to a more compartmentalized 
approach (Davis et al., 1991; Matthysse, 1973; Snyder, 1976).  Specifically it was 
observed that the destruction of dopamine afferents within the prefrontal cortex 
resulted in a chronic subcortical dopamine hyperactivity which manifested as 
increased dopamine turnover and up-regulation of postsynaptic receptors (Pycock 
et al., 1980).  These findings are strikingly similar to those of schizophrenia 
postmortem findings (Weinberger and Kleinman, 1986).  Positron emission 
tomography (PET) suggested a regional brain dysfunction because of observed 
reduced cerebral blood flow in frontal cortex of schizophrenic patients (Meyer-
Lindenberg et al., 2002).  The single most widely replicated brain dopaminergic 
changes are from PET studies of acutely psychotic patients showing elevated 
presynaptic striatal dopamine (Howes and Kapur, 2009).  Consequently, the 
dopaminergic hyperactivity theory was then refined to suggest a hyperfunction of 
mesolimbic projections and a hypofunction of mesocortical projections as 
symptomatic of schizophrenia (Davis et al., 1991; Weinberger, 1987).   
The limitation of the dopamine hypothesis is that neither negative 
symptoms nor cognitive impairments are adequately treated with dopamine D2 
receptor antipsychotics (Laruelle et al., 1999; Meltzer, 1997).  Further 
undermining the importance of this hypothesis in schizophrenia were inconsistent 
findings in post mortem studies which were not able to demonstrate consistent up 
regulation or excessive activation of the D2 receptors (Farde et al., 1990; Howes 
et al., 2009).  Thus the disease as a whole is unlikely to be explained solely by the 
dopaminergic alterations (Carlsson et al., 2001).  
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Figure 1.1: The four dopaminergic pathways.   
 
 
Taken from thebrain.mcgill.ca 
 
 
 
 
1.2.2 Glutamate and schizophrenia 
Glutamate is the major excitatory neurotransmitter in the brain and is 
utilized by 40 percent of all synapses (Tsai and Coyle, 2002).  The postsynaptic 
effects of glutamate are mediated by three families of glutamate-gated ion 
channels: the AMPA, kainate and NMDA receptors.  The AMPA receptors are 
primarily involved in generation of the excitatory postsynaptic currents (EPSCs) 
which are responsible for initiating action potentials.  While the NMDARs also 
contribute to the EPSCs and dendritic spikes they are known to have a critical role 
in synaptic plasticity.  Kainate receptors are found in pre- and postsynaptic 
neurons (Huettner, 2003) where they can affect neurotransmitter release (Schmitz 
et al., 2001).  The fourth family of glutamate receptors is the 7-TM G-protein 
coupled metabotropic glutamate receptors (mGluRs), which are known to 
modulate glutamatergic neurotransmission both pre and postsynaptically (Coyle, 
2006; Halassa et al., 2007). 
 
Mesocortical tract: projects from VTA 
to cortical regions, especially the 
prefrontal cortex 
 
Mesolimbic tract: projects from VTA 
to limbic regions including 
hippocampus, nucleus accumbens and 
amygdala 
 
Nigrostriatal tract: projects from the 
substantia nigra to the caudate and 
putamen 
 
Tuberinfundibular tract: projects 
from the hypothalamus to the pituitary 
stalk 
 
 
 
 23 
1.2.2.1 N-methyl-D-aspartate receptor and schizophrenia 
Since NMDARs are central to my thesis they are described in more detail.  
NMDARs are voltage dependent ionotropic glutamate receptors responsible for 
synaptic plasticity and memory function (Li and Tsien, 2009).  NMDARs 
assemble as multi-subunit tetramers including at least one NR1 subunit and one or 
more NR2 or NR3 subunits. Seven subtypes (NR1a–g) of the NR1 subunit are 
generated by alternative splicing from a single gene while the NR2 and NR3 
subunits exist as multiple subtypes (NR2A-D and NR3A-B) each encoded by a 
distinct gene (Dingledine et al., 1999). The NR2 subunits contribute to functional 
diversity by conferring on NMDARs distinct biophysical and pharmacological 
properties (Cull-Candy and Leszkiewicz, 2004; Paoletti and Neyton, 2007).  
NMDAR subunits are organized into three functionally distinct domains, an 
extracellular N-terminal glutamate-binding domain, the transmembrane domain 
composed of three membrane-spanning helices containing the ion-channel pore 
forming loop, glycine/D-serine modulatory and kynurenic acid inhibitory sites 
and the cytoplasmic C-terminal tail that determines subcellular trafficking of the 
receptor and coupling to various intracellular signaling pathways (Figure 1.2).  
Occupancy of the modulatory site by glycine or D-serine affects channel open 
time and desensitization rate in the presence of glutamate but does not induce 
channel opening in the absence of glutamate, making these endogenous ligands 
obligatory co-agonists. Glutamate in concert with glycine/D-serine binding to the 
co-agonist modulatory site (GMS) leads to the induction of Ca
2+
 currents through 
the ionic pore of the NMDAR.  The Ca
2+
 influx, in turn mediates learning and 
memory, long-term changes in the synaptic plasticity and neural development 
(Oliet and Mothet, 2006). 
The NR1 subunit is expressed in neurons at all developmental stages 
throughout the mammalian brain while NR2 subunits display distinct regional and 
developmental expression patterns. The NR2B and NR2D subunits predominate 
in the embryonic brain while NR2A and NR2C are absent.  In the adult brain, 
NR2A is ubiquitously expressed, NR2B is restricted to forebrain areas and NR2C 
is highly enriched in the cerebellum (Akazawa et al., 1994; Monyer et al., 1994; 
 24 
Watanabe et al., 1992).  While the NMDARs also contribute to the EPSCs and 
dendritic spikes they are known to have a critical role in synaptic plasticity.   
 
Figure 1.2: Diagram of NMDAR and its modulatory sites. 
 
 
Taken from Institute of Organic Chemistry and Biochemistry AS CR. 
 
 
Considerable evidence has accumulated in support of glutamate 
hypofunction as a contributor to schizophrenia etiology.  Data from NMDAR 
antagonist studies, pharmacologic intervention studies, postmortem studies and 
genetic studies converged on and reinforced the NMDAR hypofunction 
hypothesis (Coyle, 2006).  In the 1950‟s and 60‟s dissociative anesthetics such as 
ketamine and phencyclidine (PCP) were observed to result in a psychotic 
syndrome in healthy individuals (Luby et al., 1959) and were found to exacerbate 
those symptoms in schizophrenic patients  (Itil et al., 1967; Lahti et al., 1995).   
Although Javitt and Zukin (Javitt and Zukin, 1991) proposed that PCP induced 
NMDAR blockade resulted in schizophrenia-like symptoms the NMDAR 
involvement in schizophrenia was not widely embraced until Krystal et al. 
(Krystal et al., 1994) demonstrated that administration of chronic low doses of 
ketamine led to negative and minor positive symptoms and subtle cognitive 
impairments in healthy volunteers.  Subsequently, declarative memory 
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(Newcomer et al., 1999), and thought disorders similar to those found in 
schizophrenia (Adler et al., 1999), were shown to be affected by administration of 
low doses of ketamine in healthy volunteers.  Together the NMDAR antagonist 
studies in humans suggested the glutamate receptor hypofunction with 
schizophrenic symptoms. 
To build on the glutamate receptor hypofunction hypothesis, 
pharmacological agents were used to reverse the deficit and ascertain their 
behavioral outcome in patients.  However, since direct activation of the NMDAR 
may lead to excitotoxicity and neuronal degradation (Lynch and Guttmann, 2001; 
Misztal et al., 1996; Wolf et al., 1990), NMDAR functional enhancement through 
application of co-agonists has been used.   D-cycloserine is a partial agonist at the 
NMDAR with 60% of the efficacy of glycine (Sheinin et al., 2001).  In clinical 
trials D-cycloserine administered at 50 mg/day in conjunction with typical 
antipsychotics to schizophrenic patients characterized with prominent negative 
symptoms resulted in reduction in negative symptoms and improvement in 
cognitive impairments but no relief of the positive symptoms (Goff et al., 1995; 
Heresco-Levy et al., 2002).  Increasing synaptic glycine concentration through 
inhibition of GlyT1 by administration of sarcosine was tested in patients with 
chronic schizophrenia as an adjunct to resperidone or typical antipshychtics.  
Significant reductions in negative symptoms, increase in cognitive performance, 
and improvement in positive symptoms were observed versus placebo-controlled 
patients (Tsai et al., 2004).  Similarly administration of glycine (30-60 g/day) in 
conjunction with typical antipsychotics to chronic schizophrenic patients showed 
significant improvements in negative symptoms and cognitive impairments 
(Leiderman et al., 1996).  Milacemide is an acetylated prodrug of glycine, which 
converts into glycine upon deacetylation (O'Brien et al., 1991).  When 
administered to drug-free patients milacemide did not improve psychotic 
symptoms (Rosse et al., 1991; Tamminga et al., 1992) however, co-administration 
with conventional antipsychotics may have a different outcome as seen with other 
NMDAR co-agonists.  While d-cycloserine and glycine administration had 
encouraging early outcomes recent CONSIST clinical trial showed data that 
neither of the two compounds had any affect on negative symptoms or cognitive 
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impairment in schizophrenic patients (Buchanan et al., 2007).  The CONSIST 
study had a differential response between inpatients versus outpatients and used a 
fixed dose of glycine at 60 g/day which may not be optimal for some patients 
(Buchanan et al., 2007).  While these recent results carry negative outcome for the 
glycine modulatory site (GMS) (see figure 1.2) modulation through 
administration of d-cycloserine and glycine other NMDAR co-agonists such as D-
serine and D-alanine were reported to have encouraging findings (described in D-
serine section 1.7).  The clinical application of GMS and their respective 
outcomes are summarized in table 1.2. 
Initial studies analyzing the CSF of schizophrenic patients reported 
decreased concentration of glutamate but this finding has not been consistently 
reproduced (Goff and Coyle, 2001; Kim et al., 1980).  Schizophrenic postmortem 
glutamate concentrations were found to be reduced in prefrontal cortex and 
hippocampus, brain regions implicated in schizophrenia, versus controls while 
NAAG, NMDAR antagonist and mGluR3 agonist, were increased in 
hippocampus of patients.  Furthermore, glutamate carboxypeptidase II (GCP II), 
which metabolizes NAAG to glutamate and NAA was reduced in frontal cortex, 
temporal cortex, and the hippocampus in patients (Tsai et al., 1995).  Through 
magnetic resonance spectroscopic studies the NAA levels were confirmed to be 
lower in schizophrenics (Bertolino et al., 2000).  Kynurenic acid, an NMDAR 
antagonist, was also increased in postmortem samples of schizophrenic 
hippocampus (Schwarcz et al., 2001).  Expression of NMDAR 2D subunit was 
increased in prefrontal cortex but the NR-1 subunit was decreased in the 
hippocampus of schizophrenic patients.  Despite this altered expression ligand-
binding studies did not indicate NMDAR alterations (Akbarian et al., 1996; Gao 
et al., 2000).  Some of the postmortem studies, while not always reproducible, 
support NMDAR involvement albeit indirectly through alterations in levels of 
glutamate receptor antagonists in schizophrenic patients.     
Schizophrenia appears to follow a complex inheritance pattern with 
multiple genes contributing small effects in the emergence of the phenotype 
(Kirov et al., 2005; Purcell et al., 2009).  Several possible risk genes based on 
linkage and association studies (highlighted in Table 1.4) have been implicated in 
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this disease.   Several of the candidate genes are known to modulate the NMDAR.  
For example, some dysbindin variants are concentrated on the presynaptic 
glutamatergic terminals where they modulate vesicular release of glutamate 
(Numakawa et al., 2004).  Furthermore, dysbindin expression in the prefrontal 
cortex and hippocampus of schizophrenics is reduced (Talbot et al., 2004; 
Weickert et al., 2004).  mGluR3 activity may be elevated in schizophrenia and the 
activation of mGluR3 is known to down regulate the release of glutamate 
providing supporting evidence for the glutamate hypofunction (Coyle, 2006). 
Neuregulin directly reduces NMDAR currents in cortical primary neurons (Gu et 
al., 2005) and animals with a null mutation in neuregulin display lower expression 
of NR1 subunit (Falls, 2003).  Both G72 and DAO have been implicated in 
NMDAR activation through metabolism of its mandatory co-agonist D-serine 
(Chumakov et al., 2002).  The association data is supportive of NMDAR 
importance in schizophrenia.  The risk genes, in general, are not directly 
associated with proteins within the serotonergic, muscarinic, histaminergic or 
dopaminergic systems. 
Several other observations, related to the NMDAR, suggest that glutamate 
alterations may play a critical role in brain development.  NMDAR are critically 
involved during development when they guide axons to their targets and continue 
to maintain synapses and influence synaptic plasticity (Coyle and Tsai, 2004a; 
Harrison et al., 2003) and NMDAR may be relevant in synaptic pruning 
(Feinberg, 1990).  This evidence is complementary to the neurodevelopmental 
hypothesis described in genetics and aetiology of schizophrenia section 1.5. 
Data suggest that the dopaminergic abnormalities observed in the 
schizophrenic patients may be accounted for by glutamatergic hypofunction.  
Dissociative anesthetics such as PCP and MK-801 were shown in preclinical trials 
to increase dopamine release in frontal cortex and ventral striatum to the same 
magnitude as amphetamine (Breier et al., 1998; Verma and Moghaddam, 1996; 
Vollenweider et al., 2000).  Likewise, antagonists at the glycine site of the 
NMDAR increased midbrain dopamine neuronal firing (Linderholm et al., 2007; 
Schwieler et al., 2006).  Inhibition of glutamate transmission in the ventral 
tegmental area was shown to result in increased dopaminergic release in the 
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mesolimbic pathway and reduced dopaminergic release in the mesocortical 
pathway (Takahata and Moghaddam, 2000).  Subanesthetic doses of ketamine 
produce an increased striatal release of dopamine in normal humans with 
amphetamine challenge similar to that of schizophrenic patients (Kegeles et al., 
2000).   
Likewise, glutamatergic hypofunction is complementary with the 
GABAergic deficits found in schizophrenia.  The GABA transporter 1 (GAT1) 
and glutamic acid decarboxylase (GAD67) have been shown to be expressed at a 
lower level in chronically treated rats with MK-801 reflecting observations made 
in schizophrenic patients (Guidotti et al., 2000; Paulson et al., 2003; Volk et al., 
2000).   
 
1.3  Brain regions implicated in schizophrenia 
 In addition to important pathways associated with this disorder, several 
brain regions have been identified as disease relevant through functional imaging, 
neuropathological findings and clinical observations.  Some of those regions 
include dorso-lateral prefrontal cortex (DLPFC) and hippocampus which have 
been implicated in cognitive, negative and positive symptoms of schizophrenia 
(Boyer et al., 2007; Harrison, 1999).  More recently, evidence suggests that the 
cerebellum may be an important brain region involved in cognition and displaying 
abnormalities in schizophrenia (Andreasen and Pierson, 2008).  Hence, the three 
brain regions are discussed below.  
 
1.3.1 DLPFC 
Any disease related changes within the DLPFC may be especially relevant 
for schizophrenia cognitive dysfunction as the DLPFC is known to participate in 
attention, executive function and working memory.  While schizophrenic patients 
show performance deficits in nearly all functional neuropsychological studies, 
working memory is generally most severely affected (Saykin et al., 1991; Saykin 
et al., 1994).  DLPFC gray matter volume is reduced in schizophrenic patients and 
positively correlated with cognitive dysfunction and severity of negative 
symptoms (Cannon et al., 2002).  
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Table 1.2: Antipsychotic effects of glycine site potentiators adopted from Shim 
(Shim et al., 2008) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical         Sample  Dur of  AD Clinical        Observ.  
Trials        size trial (weeks) observations 
 
Glycine 
(Waziri, 1988)         11   ~35      DR clin observ I psychotic/ 
           Psychosocial 
(Costa et al., 1990)     6     5       C BRPS   I 
(Potkin et al., 1992)   18     6      C CGI, SANS, BPRS I BPRS 
(Javitt et al., 1994)   14     8      C PANSS        I negative 
(Leiderman et al., 1996) 5     8     C/A PANSS/SANS  I negative 
(Heresco-Levy et al., 1996a; Heresco-Levy et al., 1996b)      
             11     6     C/A PANSS/BPRS  I negative 
(Heresco-Levy et al., 1999)    
             22     6     C/A PANSS/BPRS  I negative 
Milacemide 
(Rosse et al., 1990)     5     5     DR SANS/BPRS/CGI E negative 
(Rosse et al., 1991)     4     4     DR SANS/BPRS/CGI NI 
(Tamminga et al., 1992)  6     6     DR BPRS   NI 
 
D-serine 
(Tsai et al., 1998)     28     6  C PANSS, SANS, CGI, I cognitive 
        WCST, Ham-D 
D-Alanine 
(Tsai et al., 2006)     32     6  C PANSS, SANS, CGI I neg/cog/ 
                     psychopathology 
D-cycloserine 
(Simeon et al., 1970)   10    2-14 DR clin observ E 
(Cascella et al., 1994)  7     6      C CGI, SANS, BPRS E pos/neg/  
              gen psychopatholo 
(Goff et al., 1995)    9     2      C SANS, BPRS  E negative 
(Rosse et al., 1996)   13     4            molindone SANS, BPRS, CGI NI 
(van Berckel et al., 1996)7    3  C  PANSS, CGI  I negative 
(van Berckel et al., 1999)25   8  C PANSS, CGI  E pos/general  
Psychopathology 
(Goff et al., 1999)    39    8      C PANSS, SANS, GAS I negative 
        *cognitive, Ham-D 
(Heresco-Levy et al., 2002)        
                        16     6     C/A PANSS, SANS, Ham-D I negative 
(Duncan et al., 2004)   22     4      C PANSS, SANS, BPRS NI  
        *cognitive 
(Goff et al., 2005)     26    26      C PANSS, SANS, BPRS NI 
 
Sarcosine 
(Tsai et al., 2004)     38     6  C/risperid PANSS, SANS, Ham-D I  
positive/negative/ 
           general psychopathol 
(Lane et al., 2006)     65     6  risperidone PANSS, SANS   I positive/                           
    negative/general psychopathol 
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Rating scale: PANSS (positive and negative syndrome scale), SANS (scale for the 
assessment of negative symptoms), BPRS (brief psychiatric rating scale), CGI 
(clinical Rating scale: PANSS (positive and negative syndrome scale), SANS 
(scale for the assessment of negative symptoms), BPRS (brief psychiatric rating 
scale), CGI (clinical global impression), GAS (global assessment scale), Ham-D 
(Hamilton rating scale for depression), WCST (Wisconsin card sorting task, 
*cognitive (Abrams and Tayler rating scale, Sternbery memory/continuous 
performance)  
Symptoms outcomes: I (improved), E (exacerbated), NI (not improved) 
AD = antipsychotic drugs; DR = drug free; C = conventional; A = atypical 
 
 
Within layer III of schizophrenic patients DLPFC pyramidal cells are 
smaller (Pierri et al., 2001; Rajkowska et al., 1998), have decreased spine density 
(Glantz and Lewis, 2000), less dendritic arborization and complexity (Kalus et al., 
2000), decreased synaptic connectivity (Mirnics et al., 2001), and increased 
neuronal density (Selemon et al., 1998).  Likewise, similar findings were reported 
in layer V in respect to pyramidal cell soma size (Cotter et al., 2002) and dendritic 
spine density (Black et al., 2004).  Neuronal mis-connectivity may play a relevant 
role in schizophrenic DLPFC as evidenced by decreased levels of synaptic 
proteins such as SNAP-25 and synaptophysin (Karson et al., 1999; Thompson et 
al., 1998), complexin I (Sawada et al., 2002), synaptobrevin (Halim et al., 2003) 
and synapsin III (Porton and Wetsel, 2007).  Interestingly, both NMDA and 
AMPA receptors are enriched in the above mentioned DLPFC pyramidal cell 
layers (Beneyto and Meador-Woodruff, 2004; Conti et al., 1999; Huntley et al., 
1997) suggesting glutamatergic modulation may be relevant in this brain region 
and altered in patients.    
 
1.3.2  Hippocampus 
 The hippocampus plays an important role in memory consolidation, 
transfer of memory from short-term to long-term memory and navigation 
(Heckers and Konradi, 2002).  Single photon emission computed tomography 
(SPECT), PET and magnetic resonance imaging (MRI) functional studies suggest 
hypofunction of the hippocampus in schizophrenic patients which manifests in 
memory impairments (Weiss and Heckers, 2001). Other studies suggested 
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augmented hippocampal activity in medication-free schizophrenic patients (Lahti 
et al., 2006; Medoff et al., 2001; Nordahl et al., 1996; Weiss et al., 2006).  
Furthermore, anatomical hippocampal abnormalities in schizophrenia patients 
including decrease in area and volume were demonstrated (Harrison, 1999; 
Nelson et al., 1998; Weiss et al., 2005; Wright et al., 2000).  The volumetric 
decrease in schizophrenia was explained by neuronal loss (Falkai and Bogerts, 
1986), reduced neuronal size (Arnold et al., 1995), and pyramidal cell disarray 
(Conrad et al., 1991).  The reduced neuronal size is hypothesized to be a result of 
a less extensive or abnormal synaptic connections (Harrison and Eastwood, 2001).  
Also, decreased expression of synaptic proteins such as synaptophysin (Davidsson 
et al., 1999; Vawter et al., 1999), synapsins (Browning et al., 1993), SNAP-25 
(Young et al., 1998), complexins I and II (Sawada et al., 2005), and rab3a 
(Davidsson et al., 1999) provide more evidence of decreases in synapses.  
Abnormalities in the hippocampal architecture of schizophrenic patients have 
been observed (Arnold et al., 1997).   
 
1.3.3 Cerebellum 
The cerebellum has been primarily thought of as a coordinator of motor 
function.  However, recent neurodevelopmental and neuroimaging studies imply a 
much greater role of the cerebellum in cortical function as well as potential 
involvement in schizophrenia (Andreasen et al., 1996; Andreasen and Pierson, 
2008; Ichimiya et al., 2001; Weinberger et al., 1980).  The cerebellum and the 
prefrontal cortex are the only two brain regions greatly enlarged in the humans as 
compared to other higher primates (Middleton and Strick, 1994) suggesting an 
involvement and coordination of the two regions in higher level thinking 
associated with humans.  This hypothesis is supported by a positive correlation of 
intelligence and cerebellar volume in healthy individuals (Andreasen et al., 1993; 
Paradiso et al., 1997).   
The cerebellum is proposed to be the "cognitive coordinator" through the 
cortico-cerebellar-thalamo-cortical circuit (Figure 1.3).  Cerebellar atrophy has 
been shown to result in thought disorders and emotional disturbances 
(Schmahmann, 2004).  Functional MRI showed involvement of the cerebellum in 
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cognition and linked schizophrenic deficits in cognition to this brain region 
(Honey et al., 2005).  Working interactively with the cortex, cerebellum may help 
coordinate both motor and cognitive performance (Andreasen et al., 1996).  
Cerebellar involvement in coordination in part stems from the inhibitory Purkinje 
cells and the excitatory granule cells.  Working together, the Purkinje and granule 
cells help to modulate and coordinate the activity of the cerebral cortex by 
providing input to deep nuclei such as the dentate nucleus.  The deep nuclei, in 
turn, provide the sole output from the cerebellum to the cerebral cortex (Manto, 
2009).  Thus Purkinje cells have the important role of deciding what information 
is or is not returned to the cerebral cortex through inhibition of the output nuclei.  
Furthermore the Purkinje cells are implicated in schizophrenia because they 
display an eight percent reduction in size in schizophrenic patients (Katsetos et 
al., 1997; Tran et al., 1998).  The observed Purkinje cell size reduction may be at 
least in part due to drug use as there was a significant correlation with 
antipsychotic drug dose (Tran et al., 1998).  
Figure 1.3: The CCTCC pathway and alterations found within the pathway 
among schizophrenic patients primarily affected with positive and/or negative 
symptoms as compared to normal controls.   
 
Taken from Honey (Honey et al., 2005) 
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1.4  Treatment of Schizophrenia 
 Schizophrenia drug discovery research, in large part, focused on 
addressing deficits in the dopaminergic and glutamatergic pathways.  About sixty 
years ago, chloropromazine was one of the first generation typical antipsychotic 
and discovered by an accident as it was initially developed for surgical anesthesia 
but later found to be particularly effective in episodes of psychosis (Turner, 
2007).  Chloropromazine belongs to a group of drugs that share a common 
mechanism of action centered on blockade of dopamine D2 receptors (Snyder, 
2006).  Typical antipsychotics‟ affinity for the dopamine D2 receptor strongly 
correlates with their clinical potency (Kapur et al., 2000; Seeman et al., 1976).  
While the first generation antipsychotics are effective in reducing the positive 
symptoms they are associated with a propensity to cause extrapyramidal side 
effects (EPS), including tremor, rigidity, dystonia, bradykinesia and dyskinesia 
(Kurz et al., 1995; Peacock et al., 1996).   
 Second generation antipsychotics, including clozapine and olanzapine, 
also known as atypical antipsychotics have a more diverse pharmacological 
profile targeting for example several of the 5-HT receptors and their D2 affinity 
does not correlate as well with clinical efficacy (Kim et al., 2009).  The atypical 
antipsychotics came about due to the need for reduction in EPS associated with 
the typical antipsychotics (Farah, 2005).  As such the second generation 
antipsychotics have reduced risk for EPS but are associated with a greater risk for 
obesity, hyperlipidemia, and type II diabetes (Miyamoto et al., 2005).  Despite the 
claims of better atypical efficacy, in a head-to-head comparison between 
perphenazine, a typical antipsychotic, and the newer atypical antipsychotics no 
major differences in efficacy or tolerability were found in schizophrenic patients 
(Geddes et al., 2000; Leucht et al., 2009; Lieberman et al., 2005).  A notable 
exception to this finding was clozapine which has been shown to be effective in 
treatment resistant schizophrenics and particularly useful in targeting the negative 
symptoms (Davis et al., 2003; Kane et al., 1988; McEvoy et al., 2006).  The 
observed effectiveness of clozapine may stem from its modulation of the 
glutamatergic system (Coyle and Tsai, 2004b), however its applicability is limited 
by agranulocytosis, or a decrease in number of white blood cells, a potentially 
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dangerous side effect (Alvir et al., 1993).  In another comparative study, 
haloperidol, a typical antipsychotic was compared to several atypical drugs.  
Patients on haloperidol had significantly greater rate of discontinued treatment 
than atypicals but symptom reductions were the same in all groups suggesting that 
there may not be an advantage to atypical administration (Kahn et al., 2008).  
Similar findings were reported by Jones (Jones et al., 2006) where second 
generation antipsychotics excluding clozapine did not have the expected benefit 
over first generation antipsychotics.   
 Many patients fail to respond to current medications, are noncompliant 
due to adverse side effects, and even when the positive symptoms are treated the 
patients are for the most part still incapable of living a normal productive life 
(Browne et al., 1996; Conley and Buchanan, 1997; Fenton et al., 1997).  It 
became apparent that schizophrenia may have to be treated on the basis of 
individual symptoms of cognitive impairment, negative symptoms and positive 
symptoms instead of treatment of the disorder as a whole (Lewis and Gonzalez-
Burgos, 2006).  Based on this fractional approach alternative targets to the D2 
receptor became heavily researched including the glutamatergic system due to its 
likelihood of ameliorating negative and cognitive symptomology which have not 
been successfully addressed with either the typical or the atypical antipsychotics 
(as discussed in glutamate and schizophrenia section 1.2.2).    
To facilitate and guide the development of cognitive enhancing 
antipsychotic agenst in schizophrenia the National Institute of Mental Health 
(NIMH) Initiative, Measurement and Treatment Research to Improve Cognition 
in Schizophrenia (MATRICS) was designed.  The MATRICS Consensus 
Cognitive Battery (MCCB) was one objective for the consortium which allows for 
an evaluation of key cognitive domains relevant to schizophrenia (Table 1.3).  
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Table 1.3: MATRICS Consensus Cognitive Battery 
 
Speed of Processing 
Category Fluency 
Brief Assessment of Cognition in Schizophrenia (BACS) - Symbol-Coding 
Trail Making A 
Attention/Vigilance 
Continuous Performance Test – Identical Pairs (CPT-IP) 
Working Memory 
Verbal: 
Letter-Number Span  
Nonverbal: 
Wechsler Memory Scale (WMS) - III Spatial Span 
Verbal Learning 
Hopkins Verbal Learning Test (HVLT) – Revised 
Visual Learning 
Brief Visuospatial Memory Test (BVMT) – Revised 
Reasoning and Problem Solving 
Neuropsychological Assessment Battery (NAB) – Mazes 
Social Cognition  
Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) – Managing 
Emotions 
 
Taken from http://www.matrics.ucla.edu 
 
1.4.1  Advantages of allosteric modulation of ionotropic glutamate receptor 
 The advantage of a positive allosteric modulator (PAM) over an agonist is 
that it is unlikely to saturate the receptor with an allosteric modulator thus it is 
difficult to overdose and the receptor signal can be boosted under endogenous 
stimulation with a PAM instead of being continuously activated with an agonist 
(Yang and Svensson, 2008).  Full agonists have been shown to de-sensitize 
receptors while enhancement of the endogenous signal is unlikely to play that role 
(Kinney et al., 2005). This is especially relevant with the NMDAR where direct 
and persistent stimulation was shown to result in excitotoxicity, seizures, memory 
loss, and brain damage (Lynch and Guttmann, 2001; Misztal et al., 1996; Wolf et 
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al., 1990).  Finally PAMs are more likely to display better receptor subtype 
selectivity (Christopoulos and Kenakin, 2002). 
 NMDAR can be activated through PAMs on the NR1 subunit GMS.  It has 
been shown that both glycine and D-serine are obligatory co-agonists of the 
NMDAR at the GMS (Curras and Pallotta, 1996; Dingledine et al., 1990).  The 
NMDAR channel opens only when glycine/D-serine binds to the GMS on the 
NR1 subunit and simultaneously glutamate binds to the glutamate binding site on 
the NR2 subunit (Cull-Candy and Leszkiewicz, 2004; Curras and Pallotta, 1996).  
The combination of NR1 and NR2 subunits determines the affinity of glycine and 
D-serine.  Both of the obligatory co-agonists have a ten-fold higher affinity for the 
NR2B, NR2C or NR2D over NR2A (Buller et al., 1994; Laurie and Seeburg, 
1994; Matsui et al., 1995; Priestley et al., 1995).  This selectivity over NMDAR 
subunits suggests that instead of targeting ubiquitously expressed NR2A, D-serine 
and glycine selectively target NMDAR subunits enriched during embryonic brain, 
and adult forebrain and cerebellum. 
 
1.5  Genetics and Aetiology of Schizophrenia 
In large part (~80%), schizophrenia is believed to be a heritable disease.  
Twin studies show that environment and epigenetic factors also influence the 
phenotype (Sullivan et al., 2003).  Attempts to identify the genetics underlying 
schizophrenia have proven to be difficult.  Given the apparent genetic complexity 
involved in schizophrenia the most promising approach to identify the most 
relevant genes may be genome-wide and hypothesis-free taking into account all 
brain regions and all genes.  Such studies are likely to focus on regions most 
likely to host genes contributing to the manifestation of schizophrenia.  In fact, 
hot spots were identified through meta-analyses of over 30 studies in chromosome 
regions 2p, 6p, 8p, 20p, 1q, 5q, 11q, 13q, 14p and 22q which may contain one or 
more risk genes (Badner and Gershon, 2002; Lewis et al., 2003).  Since the above 
mentioned regions may each be encompassing multiple genes, association studies 
were undertaken to identify the most interesting candidates.  Association is 
analysis of transmission of single-nucleotide polymorphisms (SNPs) within a 
gene in a family or a control sample but in itself SNP may not be causative.  
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Several putative susceptibility genes were identified through association studies 
(Table 1.4) and are supportive of the glutamate hypothesis.  Contrary to these 
findings recent genome-wide assessment of SNPs and copy number variants 
(CNVs) concluded that very few schizophrenia patients share common genomic 
causative variants but instead very rare deleterious variants may be more 
important in schizophrenia predisposition (Need et al., 2009).  CNVs tend to be 
unique to families and are unlikely to account for more then a few percent of 
schizophrenia (2008; O'Donovan et al., 2008). 
 Non-genetic factors including maternal starvation (Susser et al., 1996), 
maternal infections (Brown et al., 2000; Buka et al., 2001a; Buka et al., 2001b; 
Mednick et al., 1988), Rhesus blood-type incompatibility (Hollister et al., 1996), 
perinatal anoxic birth injuries (Rosso et al., 2000; Zornberg et al., 2000), obstetric 
complications (Geddes, 1999; Verdoux et al., 1997), season of birth (Torrey et al., 
1996), and cannabis use in adolescence (Hall and Degenhardt, 2000; Veen et al., 
2004) have all been shown to increase the risk of developing schizophrenia.   
Individuals who went on to develop schizophrenia displayed subtle 
abnormalities in cognition, social interaction, motor function, and physical 
morphology prior to the onset of the disease suggesting that it is 
neurodevelopmental in nature (Niemi et al., 2003).  The hypothesis takes into 
account both the genetic and the environmental factors into the most likely 
pathogenic model of schizophrenia.  In this model, genetically predisposed 
individuals under the disadvantageous influence of environment beginning as 
early as in utero developed psychopathology which manifested most often 
between 15 and 24 years of age (Messias et al., 2007).   Both negative and 
cognitive symptoms are less common and less severe in the early stages of 
schizophrenia but are more likely to become prominently manifested as the 
disorder advances suggesting a neurodevelopmental aspect (McGlashan and 
Fenton, 1993; Wyatt, 1991).  The neurodevelopmental theory is further supported 
by brain imaging studies which showed a progressive enlargement of ventricles 
and reductions of cortical gray matter in schizophrenic patients (Davis et al., 
1998; Gur et al., 1998; Shenton et al., 2001).  The mechanism underlying the 
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observed phenotypic changes may be attributed to key schizophrenia genetic 
susceptibility factors such as NRG1 and DISC1 (Jaaro-Peled et al., 2009). 
 
1.6  Astrocytic involvement in NMDAR activity 
Astrocytes are proximally positioned to the synapse where they can 
participate in neurotransmission (Figure 1.4) by modulating neurons (Schousboe, 
2003).  Astrocytes express many key enzymes and transporters associated with 
maintaining glutamate, glycine and D-serine synaptic levels for optimal 
stimulation of the glutamate receptors.  Astrocytes provide glutamine for 
glutamate synthesis at the synaptic terminal, express EAAT1 and 2, the two 
glutamate transporters which protect against excitotoxicity by inactivating 
synaptic glutamate (Schluter et al., 2002).  The glycine transporter1 (GlyT1) 
responsible for synaptic glycine regulation (Zafra et al., 1995), serine racemase 
(SRR), which synthesizes D-serine and DAO, which breaks down D-serine have 
all been localized to astrocytes (Harrison and Weinberger, 2005; Kirkpatrick et 
al., 2001; Schell, 2004; Wolosker et al., 1999a).  Presynaptic mGluR3, 
responsible for down regulating glutamate release is activated by NAAG 
(Wroblewska et al., 1997).  NAAG, in turn is degraded by glutamate 
carboxypeptidase II (GCP II) which is concentrated in astrocytes (Berger et al., 
1999).  Astrocytes are the source of kynurenic acid, an endogenous competitive 
antagonist of the NMDAR at the glycine site (Jentsch and Roth, 1999).  This 
evidence suggests that astrocytes sense the level of synaptic activity and augment 
synaptic activity by release of neuromodulators (Haydon, 2001; Volterra and 
Meldolesi, 2005).   
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Table 1.4: Candidate schizophrenia susceptibility genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Straub (Straub and Weinberger, 2006).  Many of the identified 
genes are relevant to glutamate hypothesis. COMT, Catechol-O-methyl 
transferase; DTNBP1, dysbindin; NRG1, neuregulin; RGS4, regulator of G-
protein signaling; GRM3, metabotropic glutamate receptor 3; DISC1, disrupted in 
schizophrenia 1; DAOA (G72/G30), D-amino acid oxidase activator; PPP3CC, 
calcineurin gamma catalytic subunit; CHRNA7, alpha7 nicotinic acetylcholine 
receptor; PRODH2, proline dehydrogenase; AKT1, V-akt murine thymoma viral 
oncogene homolog 1; GAD1, glutamate decarboxylase 1; ERBB4, V-erb-a 
erythroblastic leukemia viral oncogene homolog 4; FEZ1, elongation protein zeta-
1; MRDS1, orofacial cleft 1; NPAS3, neuronal PAS domain protein 3; GRIK4, 
glutamate receptor, ionotropic, kainate 4. 
 
 
In addition to expressing key enzymes, in an eloquent study, astrocytes 
were shown to modulate neuronal activation via altering level of neuronal 
ensheathing.  NMDAR transmission in the supra-optic nucleus is dependent on 
astrocytic coverage of the synapse (Panatier et al., 2006).  During lactation, 
astrocytic ensheathing of neurons is reduced in the supra-optic nucleus resulting 
Gene   Locus Association with Linkage to  
     Schizophrenia  gene locus 
 
COMT   22q11 ++    ++++ 
DTNBP1  6p22  +++++   ++++ 
NRG1   8p12-21 +++++   ++++ 
RGS4   1q21-22 +++    +++ 
GRM3   7q21-22 +++    + 
DISC1  1q42  ++++    ++ 
DAOA(G72/G30) 13q32-34 +++    ++ 
DAO   12q24 ++    + 
PPP3CC  8p21  +    ++++ 
CHRNA7  15q13-14 +    ++ 
PRODH2  22q11 +    ++++ 
AKT1   14q22-32 +    + 
GAD1   2q31.1 ++ 
ERBB4  2q34  ++ 
FEZ1   11q24.2 ++ 
MUTED  6p24.3 ++++    ++++ 
MRDS1(OFCC1) 6p24.3 ++    ++++ 
NPAS3  9q34  ++ 
GRIK4  11q23 ++    + 
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in reduced NMDAR activation as compared to the virgin rats.  This reduced 
NMDAR activation was shown to be due to reduced D-serine release from the 
astrocytes (Panatier et al., 2006).  This data solidified an astrocytic role in 
postsynaptic control of excitatory neurotransmission by releasing D-serine.  
 
 
Figure 1.4 Electron micrograph (EM) showing the close association of astrocytes 
(blue) with the presynaptic axonal bouton (green) and postsynaptic dendrytic 
spine head (yellow) at the synapse in hippocampus of a mature rat.  Taken from 
Witcher (Witcher et al., 2007). 
 
 
 
 
1.7  D-Serine: the NMDAR obligatory co-agonist 
D-serine was thought of as an amino acid solely of bacterial origin so its 
presence in substantial quantities of about 300 nmol g
-1
 in the mammalian 
(Hashimoto et al., 1992; Hashimoto et al., 1993b; Hashimoto et al., 1993c; 
Hashimoto et al., 1995a; Hashimoto et al., 1995b) and about 100 nmol g
-1
 in 
human brain (Chouinard et al., 1993; Hashimoto et al., 1993a; Kumashiro et al., 
1995; Nagata et al., 1995) was initially surprising.  D-serine was also thought not 
to play a functional role in higher organisms (Corrigan, 1969) yet displacement of 
[
3
H]glycine by D-serine on the rat brain NMDARs (McDonald et al., 1990) 
sparked interest in the physiological role of D-serine in the human brain.  
Recombinant NMDARs were found to be stimulated by D-serine application 
(Hess et al., 1996; McBain et al., 1989; Priestley et al., 1995) suggesting that D-
serine may act as an NMDAR activator in vivo.  Furthermore, application of 
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exogenous DAO reduced NMDAR function in vivo and in vitro (Gustafson et al., 
2007; Mothet et al., 2000; Stevens et al., 2003; Yang et al., 2005). 
D-serine is found at much higher concentrations in the brain than it is in 
the periphery (Wolosker et al., 2008), for example, in the brain for every two L-
serine molecules there exists one D-serine molecule (Hashimoto et al., 1992; 
Hashimoto et al., 1993c).  Brain microdialysis experiments revealed extracellular 
concentration of D-serine to be twice that of glycine in the striatum and 
comparable in the cerebral cortex (Hashimoto et al., 1995b).  D-serine is enriched 
in rat forebrain areas abundant in NMDARs (Hashimoto et al., 1993a; Schell et 
al., 1997; Schell et al., 1995).  Despite the high D-serine concentration the 
NMDAR were found not to be saturated in vivo (Wood et al., 1989) because 
exogenously applied D-serine to rat cortical (Li and Han, 2007) and hippocampal 
slices (Martina et al., 2003) potentiated NMDARs.    
 D-serine was found to display up to threefold higher affinity for the 
NMDAR than glycine (Furukawa and Gouaux, 2003; Matsui et al., 1995).  
Through crystal structure examination it was noted that D-serine displaces a water 
molecule from the NR1 binding site and makes three additional hydrogen bonds 
than glycine explaining the higher D-serine affinity for NMDAR (Furukawa and 
Gouaux, 2003).  Furthermore, the L-serine isomer interacts unfavorably in the 
binding pocket due to the hydroxyl group specifically selecting for the D-serine 
isomer (Furukawa and Gouaux, 2003).  These bidning affinities and structural 
observations are consistent with experiments showing that D-serine is 100x more 
effective than L-serine in stimulating NMDAR (McBain et al., 1989; Wood et al., 
1990). 
The model for NMDAR activation is through a cascade initiated by 
neuronal glutamate release which stimulates AMPA/Kainate receptors on glial 
cells to release D-serine from glia (Kim et al., 2005; O'Brien and Bowser, 2006).  
D-serine, in turn, acts as the co-agonist on the strychnine-insensitive GMS on the 
NR1 subunit to enhance NMDAR functional flux of Ca
2+
 current through the 
ionic pore.  The Ca
2+
 influx mediates learning and memory, long-term changes in 
synaptic plasticity and neural development (Oliet and Mothet, 2006). 
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In vivo data from rodents is supportive of D-serine modulatory effects on 
the NMDAR. In rats the cognitive impairment induced by PCP could be reversed 
by treatment with D-serine (Andersen and Pouzet, 2004) while fMRI experiments 
in rats showed that administration of D-serine leads to an increase in hippocampal 
activity (Panizzutti et al., 2005).  D-serine from glial cells seems to play a role in 
synaptic plasticity because synapses with reduced astrocytic coverage showed less 
NMDA-dependent activity and this activity could be restored by D-serine addition 
(Panatier et al., 2006) as discussed earlier. 
 
1.7.1  Schizophrenia and D-serine 
Multiple publications suggest deficits in D-serine levels in schizophrenia.  
Serum levels of D-serine in schizophrenic patients were significantly lower than 
those of healthy controls (Hashimoto et al., 2003).  Schizophrenic CSF samples 
displayed reduced D/total (D+L) serine, but not D-serine levels per-se as 
compared with control subjects (Hashimoto et al., 2005b).  Complementary to this 
observation was a significant 25% decrease in CSF D-serine levels in 
schizophrenia patients versus healthy control subjects (Bendikov et al., 2007).  
However, some studies did not correlate initial observations of altered D-serine 
plasma and CSF levels (Fuchs et al., 2008; Hons et al., 2008). While CSF and 
serum D-serine concentrations were found to be inconsistent, brain tissue D-
serine concentration has been found to be unaltered (Bendikov et al., 2007; 
Hashimoto et al., 2003).  However, there was a significant positive correlation 
between serum D-serine levels and total scores, positive symptom scores, and 
negative symptom scores on the BPRS among medicated patients (Hashimoto et 
al., 2003).   
Since schizophrenic patients may have decreased brain D-serine levels, 
their antipsychotic medications were supplemented with D-serine treatment 
resulting in psychotic symptom reductions.  Chronic schizophrenia patients, 
poorly responsive to neuroleptics other then clozapine, with prominent negative 
symptoms were treated with administration of adjunct 30 mg/kg/day of D-serine.  
After six weeks of treatment the patients displayed significant reductions in 
negative symptoms, cognitive symptoms and positive symptoms.  The serum D-
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serine levels of patients were elevated 50-fold while serum glycine, glutamate, 
and aspartate levels were unchanged.  The broad improvement of the symptoms 
significantly correlated with the treatment and with the serum D-serine levels 
(Tsai et al., 1998) (see Table 1.2).  These clinical trials strongly suggest potential 
of NMDAR enhancement through D-serine administration as suitable adjunct 
treatment of schizophrenic symptoms.  A meta analysis of eighteen clinical trials 
with 343-randomized patients confirmed that D-serine is effective in reducing 
negative symptoms and trends toward effectiveness in cognitive symptoms 
(Tuominen et al., 2005). 
The clinical data with D-serine supplementation generated interest in 
proteins responsible for D-serine synthesis, transport and degradation.  As such 
serine racemase, alanine-serine-cysteine transporter-1 and DAO will be described 
individually in the next section where their impact on D-serine will be assessed. 
 
1.7.2  D-serine synthesis: Serine racemase (SRR) 
Serine racemase (SRR) is a 37 kDa protein that exhibits a high degree of 
interspecies similarity (92% identity between rat and human and 96% identity 
between rat and mouse) (Konno, 2003).  While multiple mRNAs have been 
proposed to encode SRR, only a single isoform appears to be expressed in the 
brain (Wolosker et al., 1999b; Xia et al., 2004; Yamada et al., 2005).  SRR can 
inter-convert L-serine to D-serine with a six fold higher preference for conversion 
of L- to D-form (Wolosker et al., 1999b).  Furthermore, SRR is highly selective 
toward L-serine as it fails to racemize other amino acids (Wolosker et al., 1999b).  
Regional localization of SRR coincides with that of D-serine suggesting a 
physiological role for D-serine synthesis (Wolosker et al., 1999a).  An in vivo role 
of serine racemase and its involvement in D-serine synthesis came from SRR 
knockout animals where the D-serine levels declined by 80-90% (Wolosker et al., 
2008).  As expected, the SRR homozygous knockout mice displayed decreased 
NMDAR transmission, impaired long term potentiation of synaptic activity in the 
hippocampus, attenuated synaptic plasticity and spatial memory deficit (Basu et 
al., 2009; Wolosker et al., 2008).  Recently an association between SRR and 
schizophrenia was found reinforcing the association of this enzyme in this 
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devastating disease (Labrie et al., 2009a).  SRR expression data from 
schizophrenic patients is mixed.  For example, SRR protein levels in 
schizophrenic patients were found to be marginally lower in the frontal cortex 
(BA9) and in the hippocampus (Bendikov et al., 2007).  However, in a separate 
study, SRR immunoreactivity was increased in schizophrenia in the DLPFC but 
not in cerebellum, while SRR mRNA was unchanged in both regions (Verrall et 
al., 2007).  More comprehensive SRR expression analysis is required to determine 
if SRR expression is linked to modified D-serine levels. 
 Several cofactors and modulators of SRR have been identified.  The 
purified SRR enzyme requires cofactor pyridoxal 5‟-phosphate (Wolosker et al., 
1999b) and ATP that is not hydrolyzed during SRR activation (De Miranda et al., 
2002).  Interestingly, phosphatidylinositol (4,5)-bisphosphate (PIP2) competes 
with ATP for SRR binding resulting in physiological inhibition of the catalytic 
activity (Mustafa et al., 2009).  The PIP2 inhibition has served as a bridge linking 
glutamate release with an increase in D-serine synthesis.  The mechanism of this 
coordinated action was shown to be mediated through metabotropic glutamate 
transmission via mGluR5 which upon activation stimulates phospholipase C, 
degrades PIP2 and disinhibits serine racemase (Mustafa et al., 2009).  NMDAR-
mediated calcium entry into postsynaptic neurons may contribute to SRR 
inhibition through activation of calcium/calmodulin-dependent neuronal nitric 
oxide synthase and generation of nitric oxide (Baumgart and Rodriguez-Crespo, 
2008).  The nitric oxide, in turn, nitrosylates SRR in the ATP-binding region and 
inhibits SRR catalytic activity.  Coincidentally, nitric oxide activates DAO 
activity further suppressing D-serine concentration (Shoji et al., 2006a; Shoji et 
al., 2006b).  Thus ATP binding or lack there of plays a significant role in SRR 
activity modulation.  Serine racemase is also positively modulated by divalent 
cations like Mg
2+
, Mn
2+ 
and Ca
2+
 (Cook et al., 2002; Neidle and Dunlop, 2002) 
while, glycine and L-aspartic acid metabolites such as asparagine and -threo-
3-hydroxyaspartic acid were found to competitively inhibit SRR (Dunlop and 
Neidle, 2005; Strisovsky et al., 2005).  A yeast two-hybrid screen identified 
glutamate-receptor-interacting protein (GRIP), a scaffolding protein for AMPA 
receptors as SRR interactor.  GRIP has been recognized as SRR activator leading 
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to a five-fold greater D-serine synthesis (Kim et al., 2005).  Furthermore, 
activation of AMPA receptors increases SRR activity probably through 
dissociation of GRIP from activated AMPAR enabling AMPA neurotransmission 
to enhance D-serine synthesis and release (Kim et al., 2005).   
 SRR has also been shown to have an additional function.  SRR was found 
to generate pyruvate and ammonia via -elimination of water from L-serine.  In 
fact the SRR elimination activity is stronger than racemization activity resulting 
in a synthesis of three pyruvate molecules per each D-serine molecule racemized 
(Strisovsky et al., 2003).  The dual functionality of the SRR is likely to be 
influenced by the cellular needs.  For example, the complex of ATP and Mg
2+
 was 
found to favor the elimination activity over the racemization activity (Foltyn et 
al., 2005).  The resulting pyruvate can be used for lactate synthesis which is 
known to provide neuroprotection against oxidative stress and used for neuronal 
energy needs (Foltyn et al., 2005).  D-serine was also shown to undergo -
elimination suggesting an alternative pathway for D-serine catabolism from that 
of DAO enzymatic breakdown (Foltyn et al., 2005). 
SRR has a critical function in regulation of D-serine concentration.  The 
modulation of SRR activity through the various protein interactions is a testament 
to the critical role SRR has in balancing D-serine levels.  Association and 
behavioral studies further support SRR involvement in NMDAR hypofunction 
disease suggesting that SRR may have a relevant role in schizophrenia.   
  
1.7.3  D-serine uptake: alanine-serine-cysteine transporter-1 (Asc-1) 
 The activity of the multi transmembrane-spanning amino acid uptake 
transporter of small neutral amino acids (Ala, Ser, Cys), Asc-1, has been shown to 
be a major mechanism for D-serine clearance from the extracellular space in 
forebrain and cerebellum.  Asc-1 has been cloned from mouse (Fukasawa et al., 
2000) and human (Nakauchi et al., 2000) and localized to presynaptic terminals, 
dendrites, and soma of neurons and glia where it could have the most impact on 
D-serine clearance from the synaptic cleft.  It operates via an exchange 
mechanism where upon uptake of one amino acid there is an efflux of another 
(Fukasawa et al., 2000; Helboe et al., 2003; Matsuo et al., 2004; Nakauchi et al., 
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2000).  Convincing data for a key role for Asc-1 in D-serine regulation comes 
from experiments in Asc-1 knockout mice which show that [
3
H]D-serine uptake 
in forebrain synaptosomes is significantly reduced (Rutter et al., 2007).  
Furthermore, the Asc-1 knockout animals had elevated circulating D-amino acids, 
including D-serine, in the brain (Rutter et al., 2007).  In fact, the elevated level of 
brain circulating D-serine may have lead to the seizure-propensity of these 
animals through over activation of the NMDAR (Xie et al., 2005). Administration 
of MK-801 to the KO animals significantly reduced the seizures suggesting that 
they were due to excessive NMDAR stimulation (Xie et al., 2005). 
Interestingly, Asc-1 immunoreactivity was found to be decreased in 
schizophrenic DLPFC and cerebellum independent of drug treatment (Burnet et 
al., 2008b) suggesting that the NMDAR hypofunction is not due to excessive 
reuptake.  Furthermore it may be a compensatory effect in response to reduced D-
serine concentration found in schizophrenics.  However, decreased Asc-1 
expression may not be necessary or sufficient for altered transporter activity 
(Aragon and Lopez-Corcuera, 2003; Zahniser and Doolen, 2001).  Although 
protein expression has been shown to be reduced, the same brain regions did not 
display a complementary decrease in Asc-1 mRNA suggesting that translational 
or post-translational modifications are responsible for the reduced protein 
expression (Burnet et al., 2008b). 
 
1.7.4 D-serine degradation: D-amino acid oxidase (DAO) 
Human DAO is 347 amino acids long protein (Momoi et al., 1988) 
encoded by a single gene found on chromosome 12 (Konno, 2001).  It is 
composed of 11 exons and spans 20 kb (Fukui and Miyake, 1992).  DAO is a 
flavoenzyme oxidase whose main function is degradation of certain D-amino 
acids selectively targeting those with small, neutral side chains such as D-serine 
and D-alanine (Leighton et al., 1968) with affinity (Km) of 1 to 10 mM (Kawazoe 
et al., 2007; Molla et al., 2006).  The amino acids are degraded into imino acid 
and consequently into -keto acids through hydration (Figure 1.5) (Pollegioni et 
al., 2007).  During the amino acid oxidation the flavin adenine dinucleotide 
(FAD) is reduced which upon reoxidation generates hydrogen peroxide.  FAD 
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may play a relevant role in modulating DAO‟s activity as it was observed that 
FAD-unbound DAO may be catalytically inactive (Caldinelli et al., 2009).  In 
humans, FAD is weakly bound to DAO suggesting a mechanism for DAO 
regulation (Caldinelli et al., 2009). 
DAO has been detected in kidney, liver, brain and at low concentration in 
leukocytes (Cline and Lehrer, 1969; Robinson et al., 1978), small intestine, 
epididymis (Gossrau, 1991), and preputial and adrenal glands (Goldenberg et al., 
1975).  Within the central nervous system of rats, DAO has been shown to be 
more abundant in the cerebellum and brainstem then in the forebrain (Horiike et 
al., 1994).  While rat DAO was initially exclusively localized to astrocytes but not 
other glial cells or neurons (Arnold et al., 1979; Horiike et al., 1987) it was later 
found in humans and rats to be expressed in both neuronal and glial cells (Moreno 
et al., 1999; Verrall et al., 2007).  However, human DAO regional expression 
differences were noted including predominant neuronal expression in DLPFC, 
and hippocampus, predominant glial in cerebellum and both neuronal and glial in 
substantia nigra pars compacta (Verrall et al., 2007).  Furthermore, DAO 
expression is likely to be neurodevelopmentally regulated as kidney DAO activity 
is low at birth but reaches a maximum in 2-4 week old rats (Johkura et al., 1998; 
Stefanini et al., 1994).  Likewise, a similar pattern of DAO expression was 
observed in the rat cerebellum where at birth no detectable DAO activity was 
found but by 3-4 weeks of age mice were expressing DAO at maximum levels 
(Wang and Zhu, 2003). 
On a cellular level, DAO was first reported to be localized within 
peroxisomes (De Duve and Baudhuin, 1966).  While in the periphery DAO has 
been confirmed to be confined to the peroxisomes in rat liver through enzymatic 
histochemical, immunohistochemical and electron microscopy imaging 
(Angermuller and Fahimi, 1988; Stefanini et al., 1985; Usuda et al., 1986) the 
brain expression may not be limited to this organelle.  This observation is 
supported by a pericellular immunostaining of DAO brain samples from DLPFC, 
cerebellum, and hippocampus (Verrall et al., 2007) and lack of DAO expression 
overlap with peroxisomal markers (Sacchi et al., 2008).  A pericellular 
distribution, potentially outside of the peroxisome, suggests that DAO may be 
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able to directly influence how much D-serine is being released perhaps into the 
synapse.  The proposed mode for the altered DAO expression outside of the 
peroxisome is proteolysis of the peroxisomal targeting area from the c-terminal 
end of DAO (Campaner et al., 1998; Pollegioni et al., 1995) which in case of 
porcine (Tarelli et al., 1990) and yeast DAO (Yurimoto et al., 2000) have been 
shown to yield active DAO enzymes.  An expression profile outside of the 
peroxisome may have very important consequences for the proposed interaction 
study as it exposes DAO to an alternative set of putative interacting proteins.  An 
extra-peroxisomal localization also suggests an altered function or regulatory role 
for DAO which may be derived from the interactor study. 
In schizophrenic patients where decreased levels of D-serine were 
reported DAO may exacerbate the NMDAR hypofunction (Bendikov et al., 2007; 
Hashimoto et al., 2003).  In fact, DAO mRNA was increased in patients with 
schizophrenia as compared to control individuals while DAO immunoreactivity in 
the cerebellum showed a trend to being increased in schizophrenic patients 
(Verrall et al., 2007).  In the DLPFC, where DAO is expressed to a lesser extent 
than in the cerebellum, DAO mRNA was unchanged in schizophrenia (Verrall et 
al., 2007).  Furthermore DAO activity was increased as much as two-fold in the 
cerebellum in schizophrenia and DAO activity increased with duration of illness 
(Burnet et al., 2008a; Burnet et al., 2008b; Madeira et al., 2008).  Hippocampa 
CA4 DAO mRNA levels were found to be increased in schizophrenic patients 
(Habl et al., 2009).  Consistently with the increased mRNA expression, 
hippocampal DAO protein levels in schizophrenics significantly correlated with 
duration of illness but not with age, suggesting the possibility that increased 
breakdown of hippocampal D-serine is associated with the progressive nature of 
the severity of schizophrenia (Bendikov et al., 2007).  DAO levels were unaltered 
in antipsychotic treated animals suggesting that the duration of illness correlation 
study is independent of drug use (Verrall et al., 2007).    
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Figure 1.5 Schematic diagram of d-amino acid catalyzed by DAO.  
 
Taken from Pollegioni (Pollegioni et al., 2007) 
 
In addition, a mutant mouse line has been important for looking at DAO 
function in vivo.  This naturally occurring strain of mice with an inactive DAO 
enzyme (Konno and Yasumura, 1983) due to a glycine 181 to arganine mutation 
(Sasaki et al., 1992) has been identified but the expression of the inactive enzyme 
was found not to be altered in the mutated strain versus wildtype (Konno et al., 
1991).  These mice were examined for D-amino acid levels and compared to the 
wildtype mice.  D-serine concentrations were largely unchanged in most brain 
regions tested including cerebrum and hippocampus, while, it was increased about 
ten-fold in the cerebellum and medulla oblongata.  More interestingly, D-alanine, 
a good DAO substrate (D'Aniello et al., 1993), levels in the mutant mice were 
elevated on average four-fold in all seven brain regions tested.  Increased D-
alanine concentration was also found to be elevated fifteen fold in the mutant 
mice serum suggesting that catalytically inactive DAO throughout the body 
contributed to the increased D-alanine concentration by allowing for 
accumulation of D-alanine (Hamase et al., 2005).  The increased D-alanine levels 
in DAO mutant mice may be relevant to the disease state in schizophrenia as D-
alanine was found to act as an NMDAR co-agonist (Sakata et al., 1999; Tanii et 
al., 1994).  The concentration of D-aspartate, known to be oxidized by D-aspartic 
acid oxidase (DDO) and not DAO, was not altered in the mutant mice (Hamase et 
al., 2005) suggesting that there are no compensatory changes in the mutant mice.   
 Mice lacking the DAO catalytic activity displayed diminution of 
stereotypy and ataxia elicited by MK-801 compared with wild-type mice 
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(Hashimoto et al., 2005a).  Independently another group confirmed the observed 
increased occupancy of the NMDAR GMS as shown by attenuated effects of L-
701,324, a NMDAR glycine site antagonist in the DAO mutant mice (Almond et 
al., 2006).  DAO KO mice display enhanced spatial learning and long-term 
potentiation (LTP) in the hippocampus (Maekawa et al., 2005) suggesting that the 
increased D-serine/D-alanine levels at the NMDAR GMS could have contributed 
to enhanced behavioral responses relevant to schizophrenia.  This suggestion was 
confirmed by pharmacologically blocking NMDAR in wildtype mice and 
reversing schizophrenia-like behaviors including hyperlocomotion, stereotypy, 
and ataxia through D-serine/D-alanine administration (Tanii et al., 1994).  Double 
mutant mice, with the DAO mutation and NR1 aspartate 481 to asparagine 
mutation, which is characterized by a reduction in NMDAR glycine affinity, were 
found to outperform single mutant NR1 mice in tasks related to negative and 
cognitive symptoms of schizophrenia (Labrie et al., 2009b).  Taken together, 
these animal data suggest that DAO may play a role in NMDAR regulation and 
pharmacological inhibition of DAO may be therapeutically relevant for 
schizophrenia.   
 Due to the evidence of DAO involvement in schizophrenia 
pharmacological inhibitors including AS057278 (5-methylpyrazole-3-carboxylic 
acid), CBIO (6-chlorobenzo[d]isoxazol-3-ol) and Merck Compound 8 (4H-
thieno[3,2-b] pyrrole-5-carboxylic acid) were developed and tested in animal 
behavioral models (Hashimoto et al., 2009; Marino et al., 2008; Smith et al., 
2009).  All three compounds were found to increase peripheral and CNS D-serine 
levels with the exception of CBIO which only raised peripheral D-serine level 
(Williams, 2009).  AS057278 was found to acutely and chronically normalize PPI 
in PCP induced mice and chronic but not acute PCP induced hypercolomotion 
(Marino et al., 2008).  CBIO was found to potentiate D-serine attenuation of MK-
801 induced PPI deficits (Hashimoto et al., 2009).  When treated acutely with 
Merck Compound 8 rats displayed no effect in amphetamine-induced 
psychomotor activity, nucleus accumbens dopamine release, or a MK-801 
induced deficit in novel object recognition (Smith et al., 2009).  Pharmacological 
inhibition of DAO provides a mixed support for the therapeutic mechanism 
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inhibition of DAO in vivo at least when acutely treated but together with the DAO 
point mutant mice data, suggest that chronic DAO inhibition may be a suitable 
treatment alternative. 
 
1.7.4.1 G72 and DAO protein-protein interaction suggests DAO involvement 
in schizophrenia  
 Considerable evidence exists for association of a molecule known as D-
amino acid oxidase activator (DAOA), or G72, and schizophrenia.  Association of 
G72 to schizophrenia was first demonstrated by Chumakov through high-density 
mapping of SNPs to a chromosome 13q region which is linked to schizophrenia 
(Chumakov et al., 2002).  Markers in the 3‟ region of G72 such as M23 
(rs3918342) and M24 (rs141292) were found to be particularly strongly linked to 
schizophrenia (Chumakov et al., 2002). Subsequent association studies have in 
most cases confirmed the association in a wide range of populations including, for 
example, Palestinian Arabs, Chinese, Scottish, and German subjects  
(Korostishevsky et al., 2006; Liu et al., 2006; Ma et al., 2006; Mulle et al., 2005; 
Schumacher et al., 2004; Wang et al., 2004; Zou et al., 2005).  Furthermore, meta-
analysis of association studies concluded that genetic variation in G72 and in 
particular in M23/M24 region supports schizophrenia association (Detera-
Wadleigh and McMahon, 2006; Li and He, 2007; Shi et al., 2008).  Likewise 
DAO has been shown to be associated with schizophrenia (Corvin et al., 2007; 
Liu et al., 2004; Schumacher et al., 2004; Wood et al., 2007) albeit weakly as a 
recent meta-analysis of 18 association studies found a significant DAO 
association in three of them (Shi et al., 2008). 
 Interest in DAO as a schizophrenic candidate gene grew as a direct 
consequence of identification of DAO as an interacting partner for G72 
(Chumakov et al., 2002).  Initially, through yeast-two-hybrid screen DAO was 
shown to interact with G72 and purified G72 increased the catalytic activity of 
DAO in vitro (Chumakov et al., 2002).  This modulation, in turn, was 
hypothesized to be responsible, in part, for a lower D-serine concentration and 
consequently NMDAR hypoactivity.  In contrast to the initial observations, it was 
reported that G72 does not bind with DAO (Kvajo et al., 2008). However, others 
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have since suggested that G72 inhibits DAO activity in vitro and in vivo when 
both G72 and DAO are overexpressed in U87 cells (Pollegioni et al., 2007; Sacchi 
et al., 2008).  An interaction between the two proteins in vivo is likely as DAO 
was shown to co-immunoprecipitate with G72 from human cortex and both 
proteins were shown via immunohistochemistry to co-localize in cortical 
astrocytes slices from human brain (Sacchi et al., 2008).  The proposed inhibitory 
activity of G72 on DAO may be relevant to NMDAR hypofunction if in the 
schizophrenic brain G72 is down regulated (Sacchi et al., 2008).  While G72 
expression in the dorsolateral prefrontal cortex of schizophrenia patients was 
shown to be increased in one study (Korostishevsky et al., 2004), G72 mRNA and 
protein from schizophrenic and control human brains were not quantifiable in 
another (Benzel et al., 2008).  Taken together, the reported observations made it 
difficult to propose a satisfying explanation for the involvement of the two 
proteins in schizophrenic brain.  Conflicting data in terms of the interaction, 
functional implication for such an interaction and the level of G72 expression in 
vivo has been used to question the validity and proposed implications of this 
interaction.   
 As G72 is only found in anthropoid primates (Chumakov et al., 2002), 
G72 overexpressing transgenic mice were generated in order to test behavioral 
changes associated with G72 expression (Otte et al., 2009).  Interestingly, the 
mice were found to have impaired sensorimotor gating which was normalized 
with haloperidol treatment.  Sensorimotor gating enables the organism to filter 
external information and was found to be impaired in schizophrenia (Braff et al., 
2001).  They were also more sensitive to PCP treatment suggesting NMDAR 
hypofunction in the transgenic mice or altered receptor expression.  It remains to 
be seen whether DAO activity is altered in the transgenic animals and if the 
behavioral abnormalities are result of altered D-serine concentration. 
 
1.8  Objectives and aims of this thesis 
 NMDAR hypofunction has been implicated through NMDAR antagonist 
studies, GMS pharmacological intervention studies, postmortem studies, DAO 
transgenic animal characterization and genetic studies as a significant contributor 
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to schizophrenia pathology.  One way to restore NMDAR hypofunction is to 
increase the concentration of NMDAR co-agonists such as D-serine.  In fact, this 
obligatory co-agonist has been shown to be reduced in schizophrenic patients‟ 
CSF and serum which may be a function of increased DAO activity.  Supporting 
this hypothesis are findings of increased DAO activity in schizophrenic patients 
which is possible due to an increased DAO expression or potentially changes in 
activating pattern.   
 While DAO linkage and association studies had mixed results they were 
mostly suggestive of no linkage between DAO and schizophrenia.  Yet G72, the 
putative DAO interactor, through positive linkage with schizophrenia implicates 
DAO in the disease.  A case for DAO is somewhat like that for NMDAR which in 
itself did not genetically associate with schizophrenia yet many of the genes that 
do are modulators of the NMDAR.  Through characterization of DAO interacting 
proteins we aim to increase our understanding of DAO function, biology and to 
identify novel schizophrenia targets. We hope to ascertain DAO‟s intracellular 
localization and the mechanism responsible for its presence outside of the 
peroxisome.  Furthermore, we will explore the potential DAO interacting proteins 
for a modulatory role on DAO enzymatic activity resulting in the schizophrenic 
phenotype.  
 As part of our studies we set out to expand upon and identify additional 
potential DAO interacting proteins.  To do this, two independent approaches were 
undertaken; a yeast-two-hybrid screen against a human fetal brain library using 
DAO as the bait protein and an immunoprecipitation mass spectroscopy approach 
from rat cerebellum.  While the yeast-two-hybrid screen identified fifteen putative 
interactors, the samples generated from rat cerebellar co-immunoprecipitation 
against DAO antibody resulted in identification of twenty-four proteins likely to 
be interacting with DAO directly or through association of a complex of proteins 
one or more of which were interacting with DAO.  In this thesis I will outline and 
describe novel DAO interacting proteins with an emphasis on DAO‟s interaction 
with BSN, a presynaptic active zone member, and suggest a novel DAO 
localization as a result of this interaction which is likely to be relevant in 
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monitoring synaptic D-serine concentrations and in understanding more fully the 
role of DAO in disease. 
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2. Generation of a DAO stable cell line and purification of DAO protein 
from bacterial cells    
 
This chapter will focus on establishing tools necessary for validation of 
putative DAO interacting proteins and measuring functional effects they may 
have on DAO activity.  An AmplexRed functional assay was established to 
ascertain the implications of interacting proteins on DAO‟s activity.  Both hDAO 
and rDAO stable lines were established as well as purified hDAO enzyme to 
allow for in vitro experiments with putative interacting proteins. 
       
  2.1  AmplexRed functional assay for analysis of DAO activity 
To ascertain the activity of DAO either in a stable cell line or as a purified 
enzyme and to enable the examination of the impact of DAO interacting proteins 
on the enzymatic activity of DAO, an in vitro assay was required.  DAO catalyzes 
the degradation of D-amino acid substrates such as D-serine or D-alanine by 
oxidative deamination, yielding reaction products including pyruvate, ammonia 
(NH3) and hydrogen peroxide (H2O2) (Pollegioni et al., 2007) (Figure 2.1).  For 
each substrate molecule that DAO degrades, one molecule of hydrogen peroxide 
is released.  In order to measure the production of substrates, a coupled reaction in 
which the hydrogen peroxide was utilized by horseradish peroxidase (HRP) in a 
one-to-one stoichiometric ratio converts Amplex Red (10-acetyl-3,7-
dihydroxyphenoxazine), a non-fluorescent substrate, into resorufin, a red-
fluorescent (544 nm excitation, 590  nm emission) product (Zhou et al., 1997).  
Thus, this assay is dependent on the activity of two enzymes, DAO and HRP, and 
the fluorescent signal is directly proportional to the rate at which DAO 
deaminates D-serine/D-alanine as illustrated in Figure 2.1.  Should an interactor 
alter DAO configuration or modify substrate access to the catalytic site, the rate of 
reaction may be altered and measured using the Amplex Red assay. 
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Figure 2.1:  Amplex Red assay measures the production of resorufin, a 
fluorescent molecule.  DAO catalyzes the oxidative deamination of D-amino 
acids including D-alanine into pyruvate, ammonia and hydrogen peroxide.  In the 
presence of horseradish peroxidase (HRP) the Amplex Red substrate (10-acetyl-
3,7-dihydroxyphenoxazine) reacts with hydrogen peroxide with a one to one 
stoichiometry to produce resorufin, a fluorescent product.  The rate of resorufin 
production is proportional to the D-alanine deamination reaction rate. 
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2.2 Selection of host cell type line for the DAO stable lines 
 In order to enable the assessment of DAO activity in a cellular context, 
ten host cell lines were considered for the generation of human and rat DAO 
stable cell lines.  All of the lines were first examined in the Amplex Red assay 
with D-serine, D-aspartate and with no substrate and compared to signal 
generated without any cells (Figure 2.2) in order to choose a host cell line with the 
best signal to noise ratio and to identify lines that may already be expressing 
native DAO or D-aspartate oxidase (DDO), which shares a high homology with 
DAO sequence.  In this respect, no substrate was used as negative control while 
D-aspartate as the substrate for DDO.  Human embryonic kidney (Hek293) cells 
were selected as the line of choice as they produce the best balance of useful 
properties as they are readily adaptable to generation of stable cell line and had a 
low basal response in buffer as well as with treatment of D-serine and D-
aspartate.  While clonal rat pituitary tumor (GH4C1) cells and Chinese hamster 
lung (CHL) cells both had relatively low RFUs resembling that of the no cell 
control, GH4C1 are known to be slow growers and difficult to generate stable cell 
lines while CHL cells grow best as free floating cells which do not lend 
themselves well to high-throughput plate based assay formats in common use.  
The lines with the highest background noise were human cervical cancer cells 
taken from Henrietta Lacks (HeLa) and Chinese hamster ovary (CHO K1) cells.  
Baby hamster kidney (BHK-21) cells may naturally express some DAO as the 
signal from D-serine is twice that of D-aspartate or buffer.  DAO is known to be 
highly expressed in the kidney (Koibuchi et al., 1995) so this finding may suggest 
functional DAO presence within this line.  Confirmation of this activity could be 
made with a DAO specific inhibitor but we are interested in human and rat lines.  
Mouse embryonic fibroblast (NIH 3T3) cells may naturally express DDO since 
the responses of this line were elevated with the treatment of D-aspartate but not 
with buffer or D-serine.   
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Figure 2.2:  Ten different host lines were examined for spontaneous activity with 
D-serine (blue), D-aspartate (maroon) and buffer (yellow) in the AmplexRed 
assay to identify the best candidate for the DAO stable cell line.  The highest 
spontaneous activity using the Amplex Red assay was observed in CHO K1 cells 
while the lowest in CHL cells.  Hek293 line was selected due to comparable 
RFUs to that of buffer alone, low maintenance and high probability of stable cell 
line generation.  
 
 
 
Selection of Suitable Host Line for DAO Stable 
Cell Line
0
100000
200000
300000
400000
500000
600000
700000
800000
900000
H
eL
a
H
ek
29
3
G
H
4C
1
C
H
L
U
2O
s
B
H
K
-2
1
C
H
O
 K
1
LM
TK
(-)
C
O
S7
N
IH
 3
T3
B
uf
fe
r
R
F
U
Ser
Asp
Buffer
 
 
 
 
 
 
 
 
 
 
 
  
 
 59 
2.3 Identification of DAO stable cell lines 
For the purpose of generating stable lines, both hDAO and rDAO inserts 
were independently cloned into pcDNA3.1 vectors which contain a hygromycin 
resistance selection marker.  The DAO constructs were transfected into Hek293 
cells through electroporation.  Stable integration of the constructs in the cells was 
accomplished by subsequent selection for clones in hygromycin containing media 
over a three week span.  Since transcription of DAO and hygromycin resistance 
were under two independent mammalian promoters and generation of stable line 
involves incorporation of the construct into the cell‟s genome some of the 
colonies may express hygromycin resistance without expressing DAO enzyme.  
However, sufficient numbers of clones were examined to guarantee that some 
may express both genes by virtue of a close proximity of the genes on the 
pcDNA3.1 constructs.  
Nine hygromycin resistant colonies were examined for functional hDAO 
activity utilizing the Amplex Red assay with D-alanine as substrate.  One of the 
nine colonies, designated hDAO #1, displayed a particularly high level of 
functional DAO activity as compared to Hek293 and buffer only controls (Figure 
2.3 A).  The remaining eight colonies displayed very modest functional increases 
over their respective controls and were deemed as not suitable for further analysis.  
Likewise, sixteen rDAO colonies were examined for functional DAO activity.  
The highest expressing lines were identified as rDAO #12 and #24 (Figure 2.3 B) 
with stable cell lines expressing intermediate and moderate levels of DAO activity 
identified as well.  The functional activity of hDAO #1 is comparable to that of 
rDAO#12 and #24 as measured by the Amplex Red assay.  The highest 
expressing lines were selected because they provide the best signal to noise ratio. 
 In order to confirm that the increased response in the selected hDAO and 
rDAO stable lines was due to DAO activity, WAY-396964, a tool DAO inhibitor 
originally made by the company Sepracor, was used to block the response (Fang 
et al., 2005).  Because this compound specifically inhibits DAO enzymatic 
activity by competing with DAO‟s substrate a dimunition of the Amplex Red 
assay in a dose dependent fashion by the inhibitor implies that the activity is that 
of DAO (Fang et al., 2005).  The inhibitor was shown to have an IC50 of 163 nM 
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against hDAO #1 (Figure 2.4 A) and 108 nM against rDAO #12 (Figure 2.4 B) 
suggesting that both of those stable lines are expressing a functional DAO enzyme 
and that the inhibitor has about equal affinity for both DAO enzymatic species. 
 
2.4 Purification of DAO from BL21 bacteria strain 
Escherichia coli (E. coli) cells have been used routinely to successfully 
synthesize mammalian proteins (Liu et al., 2009).  In order to generate DAO 
protein, BL21 DE3 cells were transformed with an inducible pTYB2 vector 
containing DAO construct encoding human DAO-intein fusion.  Use of this 
vector allows for the bacterial over expression of target gene as a fusion construct 
with a 55 kDa self-cleavable intein affinity tag.  As depicted in Figure 2.5, an 
intein has a high affinity for a chitin column which can be used to purify the 
fusion construct from the bacterial lysate.  After selective retention of the fusion 
construct through the intein-chitin affinity and subsequent wash steps purified 
DAO enzyme was cleaved from intein through treatment with DTT whereby 
purified DAO was released leaving the intein on the chitin column.   
In order to assess the efficacy of the purification procedure, samples from 
each step in the purification of hDAO were resolved by SDS-PAGE and stained 
using Coomassie blue (Figure 2.6).  Within that figure a progression from total 
bacterial proteins representing the input, to those proteins retained on the chitin 
column, removed by the washing and finally resulting in collection of purified 
hDAO enzyme are shown.  The concentration of purified hDAO was highest in 
the initial fractions and it gradually decreased until all of the cleaved DAO was 
eluted from the column.  In fact, post elution beads show that most of the DAO 
was eluted off with the DTT cleavage.  As a positive control and for the purposes 
of purity comparison a commercially available Sigma porcine DAO was used.  
The purity of the final DAO as determined by Coomassie stain is very good and 
compares very well with a commercially available porcine DAO enzyme.  
Whereas the commercial enzyme has visible contaminating bands at 51 kDa, 28 
kDa and 20 kDa the human DAO generated through the intein pull-down does not 
have any visible contaminating bands. 
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Figure 2.3:  The hDAO (A) and rDAO (B) stable lines were established in 
Hek293 cell line and selected based on functional activity through the Amplex 
Red assay.  Several DAO colonies were identified and tested for functional 
expression of DAO enzyme.  Human DAO stable line #1 was particularly active 
as compared to the Hek293 and buffer alone controls.  Rat DAO stable line #12 
and #24 represented the high expressing DAO lines.  The other lines tested had 
intermediate to moderate enhancement of Amplex Red activity.  Sigma porcine 
DAO was used as a positive control. 
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Figure 2.4:  WAY-396964, a DAO inhibitor, completely abolishes hDAO #1 (A) 
and rDAO #12 (B) activity as determined by the Amplex Red assay.  The 
respective IC50s generated against hDAO #1 and rDAO #12 are 163 nM and 108 
nM.    
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 The protein concentration of eluates representing fractions #1 through #3 
and illustrated by lanes 7 through 9 on the Coomassie gel in Figure 2.6 were 
measured with Bradford protein assay (compared to a standard curve prepared 
using BSA according to manufacturers instructions, Biorad) to determine the 
yield of purified hDAO from 750ml of bacteria media or 7.5g of wet mass.  The 
yield from each fraction is listed in Table 2.1. The total hDAO yield was 2.69 mg 
with estimated purity of 100% as determined by absence of contaminating band 
on SDS-PAGE gel stained with Coomassie blue (Figure 2.6). 
 
 
Table 2.1:  hDAO purified enzyme yield from the intein column purification.  
Most of the soluble protein (~90%) was found in the first two eluates with a steep 
drop in yield between the second and third eluate.   
 
 Collection volume 
(ml) 
Concentration 
(mg) 
Yield 
(mg/ml) 
Fraction #1 211 6.80 1.43 
Fraction #2 156 6.67 1.04 
Fraction #3 138 1.59 0.22 
Total   2.69 
 
 
 The purified DAO fractions were tested in the Amplex Red assay to 
determine if the purified DAO enzyme is functionally active and if the activity 
would correspond to the DAO concentrations found on the Coomassie gel.  Figure 
2.7 outlines the favorable outcome of this study showing a robust DAO activity 
especially in the first two fractions where most of the hDAO was found.  The 
third fraction has some DAO activity while none is found in the fourth and last 
fraction.  All of the DAO activity is inhibited by 10  WAY-396964, a DAO 
inhibitor, proving that the activity seen in the Amplex Red assay is due to DAO.   
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As part of our purification procedure we calculated how well DAO protein 
was purified in the final eluates as compared to the initial bacterial lysate and at 
what yield.  With 7 ng of purified hDAO incubated for 30 minutes in the 
AmplexRed assay an output of about 300,000 RFUs was generated.  This RFU 
corresponded with about 15 M resorufin (see resorufin standard curve Figure 
2.8).  Consequently, the hDAO was generating about 15 M of resorufin in 30 
min or 0.5 M/min.  Since the volume in both the hDAO and resorufin was 40 l 
then the hDAO was driving the production of 20 mol resorufin/min.  Finally, if all 
of the 2.69 mg of purified hDAO were to be used instead of the 7 ng then about 
7.68 million mol of resorufin/min could be generated with a specific activity of 
about 2.8 million mol of resorufin/min/mg.  Same calculations were performed 
for the other samples in Table 2.2. 
 
2.5 Conclusions 
 Through application of the Amplex Red assay a DAO assay suitable for 
use with purified enzyme and stable cell lines was generated.  This assay was 
used to select HEK293 cells as host cell line with the least amount of background 
activity for the generation of hDAO and rDAO stable lines.  DAO stable cell lines 
with significant and specific D-alanine Amplex Red signal were identified from 
among all of the colonies that grew in selective media and confirm their 
functional DAO expression by generating IC50‟s with a known DAO inhibitor, 
WAY-396964, in line with published data.  Using these reagents functional 
hDAO enzyme was purified to homogenity.  These tools will be used for analysis 
of the effects of DAO interactors on DAO enzymatic activity.  
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Figure 2.5: Schematic diagram for the hDAO intein tag purification.  DAO fusion 
protein was expressed in BL21 E. coli cells and a chitin column was used to 
purify functional DAO enzyme.  Taken from New England BioLabs Impact kit 
manual. 
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Figure 2.6: Coomassie stain of hDAO chitin column purification and the 
intermediate steps.  Human DAO-intein fusion construct was expressed in 
bacteria and the bacterial lysate was applied to the chitin column.  After washes 
with Buffer A and B (lanes 5 and 6) the columns containing chitin-hDAO were 
treated with DTT to cleave off hDAO.  Fractions #1 through #3 (lanes 7-9) 
contain eluates of the purified hDAO which was used in subsequent enzymatic 
studies.  As a control commercially available Sigma porcine DAO was used (lane 
12). 
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Legend:       
Ln1:  Protein ladder     Ln7:  Fraction #1 post DTT cleavage 
Ln2:  Cell lysate     Ln8:  Fraction #2 post DTT cleavage 
Ln3:  Lysate after sonication / centrifugation  Ln9:  Fraction #3 post DTT cleavage 
Ln4:  Lysate after chitin bead    Ln10:Fraction #4 post DTT cleavage 
Ln5:  Elution from Buffer A wash   Ln11:Chitin beads post DTT cleavage 
Ln6:  Elution from Buffer B wash    Ln12:Sigma porcine DAO 
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Figure 2.7:  Functional analysis of hDAO purified enzyme generated through the 
intein fusion protein.  The four fractions correspond to the fractions outlined in 
Figure 2.6 on lane 7 through 10 where most of the DAO staining is found in the 
first two fractions with some in the third fraction and none in the fourth fraction 
were used at 5 l per sample in the AmplexRed assay.  This DAO distribution 
corresponds well with the DAO activity and the two observations confirm each 
other.  All of the activity is inhibited by 10 M DAO inhibitor, WAY-396964.  
Sigma porcine DAO was used as a control. 
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Figure 2.8: Resorufin standard curve.  The resorufin standard curve was used to 
estimate the amount of resorufin hDAO enzyme generates in any given period of 
time. 
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Table 2.2: Specific activity of the purified hDAO fractions.  Based on the specific 
activity of the final DAO eluate in comparison to the bacterial lysate input we 
concluded that the DAO was purified about 1850 times with a yield of about 67% 
of the total DAO enzyme.   
 
 Protein 
(mg) 
Total Activity 
(mol Resorufin/min) 
Specific Activity 
(mol Resorufin/min/mg) 
Fold  
Purification 
Lysate 7500 11,461,844 1,528 1 
Flow 
through 
7056 N/A N/A N/A 
DTT eluate 2.69 7,685,714 2,857,142 ~1870 
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3. Production and characterization of DAO polyclonal antibodies to 
identify DAO interactors and investigate DAO localization 
 
 
3.1 Identification of DAO specific sites for immunization 
One of the most important tools necessary for the investigation of DAO 
localization and identification of DAO interactors through co-
immunoprecipitation is a specific and reliable DAO antibody. In order to obtain 
such a valuable reagent, commercially available antibodies were tested but none 
of them recognized rat species DAO on a western blot (Figure 3.1).  While 
recognizing that lack of a signal on a western blot does not preclude an antibody 
from recognizing an undenatured DAO enzyme we were in need of an antibody 
which would recognize DAO in its denatured state on a western blot as well as 
natural enzymatic configuration for the immunoprecipitation experiments.    
Antibodies can be made against either whole proteins or short peptides 
with distinct advantages and disadvantages for each method.  A pure solution of 
recombinant proteins is necessary for a successful and specific immune response.  
At the time of antibody generation the purified hDAO enzyme utilized in Chapter 
2 was not available and the commercially available porcine DAO was found not 
to be pure enough (Figure 2.6, lane 12).  Furthermore, the objective was to 
generate a rat specific DAO antibody as rat brain tissue was readily available for 
the proposed experiments.  Using the whole DAO protein as the antigen the 
tertiary structure of the enzyme and any post translational modifications would 
likely be part of the purified enzyme and result in antibody generation.  However 
there would not have been any control over the region responsible for the 
immunogenicity, potential cross reactivity of the antibody with structurally 
similar proteins, and purification of the antiserum would be challenging from the 
perspective of preserving antigen configuration on the purification column.  Since 
the full length of DAO and its three dimensional structure was published 
(Kawazoe et al., 2006; Mizutani et al., 1996) and many consensus post 
translational modification sequences are known (Bairoch, 1992) suitable peptides 
can be selected which are likely to be exposed to elicit an immune reaction, are 
unlikely to be found in other proteins and do not undergo post translational 
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modifications.  After taking all of this information into consideration short 
polypeptides were utilized because polypeptides are relative easy to generate and 
use for immunization.   
Two peptides corresponding to amino terminal sequences from rat DAO 
were selected as antigens for use in generating immune response in rabbits.  
Peptide #1 (amino acid 21-38 ERYHPAQPLHMKIYADRF) was selected based 
on a proprietary analysis of DAO (Open Biosystems) which suggested that this 
region was unique to DAO and likely to be accessible to an antibody within the 
DAO enzyme.  Peptide #2 (amino acid 49-69 
GLWQPYLSDPSNPQEAEWNQQ) corresponds to the sequence of a mouse 
DAO peptide that was previously generated against mouse DAO and shown to 
yield a DAO specific antibody as determined by a western blot (Almond et al., 
2006).  As only one amino acid is different between the rat and the mouse Peptide 
#2 sequence (Figure 3.2) it was anticipated that a suitable DAO antibody may be 
generated against the rat peptide as was the case for the mouse DAO.   
The rat DAO peptide sequences were compared to corresponding mice 
and human DAO sequences for the purpose of future antibody validation.  Both of 
the peptides selected against the rat DAO show about 95% amino acid similarity 
with the mouse sequence.  In contrast, the human DAO differs considerably 
especially in the case of peptide #1 where five of the eighteen amino acids 
(~28%) were different and an extra leucine exists in the human DAO sequence.  
Peptide #2 was more conserved between the rat and the human DAO with three of 
the twenty-one amino acids differing (~17%).  Furthermore, the three amino acid 
changes retained the same polarity and electrical charges suggesting that Peptide 
#2 in rat and human are functionally conserved. 
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Figure 3.1: Comparison of commercial DAO antibodies on SDS-PAGE gel 
against 20 g of (ln1) DAO Hek293 and (ln2) Hek293 lysates.  Expected 
molecular weight of DAO is indicated by the arrow. 
 
 
 
 
 
 
Figure 3.2:  Comparison of amino acid sequences between rat, mouse and human 
DAO regions selected for polyclonal antibody synthesis.  Both of the sequences 
are found on the N-terminus of the rat DAO with Peptide #1 spanning amino 
acids 21 through 38 and Peptide #2 ranging from 49 through 69. Amino acid 
differences between the sequences are highlighted in yellow and an additional 
leucine residue in the human Peptide #1 is highlighted in red. 
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3.2 Generation of DAO specific antibodies 
Rabbits were immunized with Keyhole Limpet Hemocyanin (KLH) 
conjugated rDAO peptide #1 or peptide #2 according to the schedule in Table 3.1 
where the initial immunization was followed by three independent boosts (Open 
Biosystems).  Crude unpurified serum samples from day 70 collection were 
obtained and used to probe western blots of crude extracts containing rat DAO 
expressed in human embryonic kidney (Hek293) cells and rat cerebellar lysates to 
determine if the rabbits generated antibodies against DAO. 
 
3.3 Characterization of crude DAO polyclonal antibody 
Crude polyclonal antiserum obtained from rabbit immunized with Peptide 
#1 was tested for its ability to detect rat DAO expressed in Hek293 cell extract by 
western blotting analysis.  The Peptide #1 antiserum did not result in a successful 
DAO antibody generation because a 39 kDa band corresponding to the expected 
mobility of DAO unique to the DAO Hek293 lysate was not detected (Figure 
3.3A, lane 1).  Although immunoreactivity against DAO Hek293 lysate is present 
around 39 kDa, a similar response is apparent in the Hek293 cell lysate at the 
same molecular weight (Figure 3.3A, lane 2) suggestive of a lack of a specific 
DAO antibody signal.  The immunoreactivity in both of the samples was very 
similar suggesting that the antibody responsible for the signal was against a 
protein expressed in the host Hek293 cells, unlikely to be DAO.   
A murine version of Peptide #2 had previously been shown to successfully 
generate a rabbit polyclonal against mice DAO (Almond et al., 2006).  The 
polyclonal antiserum generated against rat Peptide #2 detected a specific 39 kDa 
band in rat DAO lysate and rat cerebellar lysate not present in Hek293 or rat 
spleen lysate (Figure 3.3, B).  Both Hek293 and rat spleen lysate were used as a 
negative control as both are known not to express DAO.  This evidence is 
strongly suggestive of the presence of DAO antibodies in the crude antiserum.  
The additional bands on the gel were presumed to be from contaminating 
antibodies from the rabbit serum.  The serum collected from rabbit immunized 
with Peptide #2 was likely to result in a working DAO antibody upon further 
purification. 
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Table 3.1:  Rabbit immunization schedule for DAO antibody generation.  A 70 
day protocol involving an initial immunization followed by three independent 
boosts was utilized for generation of DAO antiserum.  Peptide synthesis and 
immunization conducted by Open Biosystem. 
 
 
 
 
 
 
 
 
 
 
 
 
Procedure Protocol Day Description 
Control serum Collection Day 0   
 Primary injection Day 1 
Primary Immunization with 0.25 mg KLH 
emulsified with Freund's complete adjuvant, 
SQ 4 sites 
1st Booster Day 14 Boost with 0.10 mg KLH emulsified with 
Freund's incomplete adjuvant. 
Serum Collection Day 28 ~25mls per rabbit 
2nd Booster Day 42 Boost with 0.10 mg KLH emulsified with 
Freund's incomplete adjuvant. 
Serum Collection Day 56 ~25mls per rabbit 
3rd Booster Day 56 Boost with 0.10 mg KLH emulsified with 
Freund's incomplete adjuvant. 
Serum Collection Day 70 Large-volume production bleeds (~50mls per 
rabbit) 
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Figure 3.3:  Western blot probed with crude unpurified DAO antiserum generated 
against Peptide #1 (A) and Peptide #2 (B).  DAO antiserum generated against 
Peptide #1 does not detect rat DAO at the expected molecular weight of 39 kDa 
(indicated by the arrow).  DAO antiserum generated against Peptide #2 detects 
band on a Western blot in rDAO Hek293 cells and in rat cerebellum 
corresponding to DAO molecular weight (indicated by the arrow) not present in 
Hek293 cells or in rat spleen.  Additional bands are present presumably 
corresponding to contaminating antibodies in the crude sample.  
 
 
 
 
                                                            
                                                            
                 
 
 
 
 
 
 
 
MW 
 
188 
 
98 
 
62 
 
49 
 
38 
 
28 
 
17 
    1     2    1      2       3      4 
MW 
 
 
 
191 
 
 
97 
 
 
64 
 
51 
 
 
39 
 
28 
 
 
17 
 
 
A B 
Legend: 
Ln1:  20 g rDAO Hek293 
Ln2:  20 g Hek293 
Ln3:  40 g rat cerebellar lysate 
Ln4:  40 g rat spleen lysate 
DAO 
DAO ? 
 75 
3.4  Purification of DAO antibody against immunizing peptide 
 Due to the apparent success of the early characterization of the DAO 
polyclonal antibody from the rabbit immunized with Peptide #2, the serum was 
purified against a DAO peptide-affinity column against the immunizing peptide 
(performed by Open Biosystems).  The resulting purified DAO antibody solution 
was tested by western blotting of crude lysates containing rat or human DAO 
expressed in Hek293 cells and rat cerebellar lysate.  A pronounced DAO band of 
39 kDa, predicted to be DAO, was identified in the three DAO containing 
samples and was absent in sham transfected Hek293 and rat spleen lysates (Figure 
3.4) indicating that the DAO antibody reliably detects both rat and human DAO 
when over-expressed in Hek293 cells.  This finding was expected given the 
similarity between rat and human DAO sequence within the Peptide #2 region 
(see Figure 3.2).  In order to further test the specificity, the purified antibody was 
preincubated with the immunizing peptide at 1/10
th
 the weight of the antibody 
before probing the blot.  The 39 kDa band was not present, strongly suggesting 
that the band corresponds to DAO.  In addition to the expected DAO band, 
additional bands which migrated at about 64 kDa and 97 kDa were identified in 
the DAO Hek293 and Hek293 lysates.  All of the bands were also pre-absorbed 
with the peptide suggesting that the purified DAO antibody solution has 
contaminating antibodies with affinity to the immunizing peptide or yet unknown 
DAO variants or post-translational modifications. 
BLAST analysis of the region selected for the immunizing Peptide #2 
provides alignment only to DAO suggesting that DAO should be the only protein 
detected as a result of the production of antibodies by immunization with this 
peptide.  The presence within the purified DAO antibody solution of antibodies 
capable of detecting proteins other than DAO suggests that the peptide could have 
formed a tertiary configuration resulting in the production of unexpected 
antibodies after exposure to the rabbit immune system.  These non-DAO peptide 
configurations may have been present as well in the DAO-peptide affinity column 
used to purify the crude serum thus retaining the contaminating antibodies within 
the DAO antibody solution.   
 
 76 
 
 
Figure 3.4: Western blot probed with crude polyclonal serum purification against 
the immunizing peptide resulted in a cleaner DAO antibody preparation.  Western 
blot analysis of peptide purified DAO antiserum confirmed presence of DAO 
antibody in the crude serum because its signal is blockable by pre-absorbtion with 
the immunizing peptide.  Furthermore, evidence in lane 5 suggests that the 
antibody generated against Peptide #2 is suitable for detection of human DAO in 
Hek293 cells.  Additional contaminating antibodies are present as depicted by 
unexpected bands at 64 kDa and 97 kDa.  All of the unknown bands are blocked 
by preabsorbtion of the antibody with the peptide suggesting that the 
corresponding antibodies are specific to the immunizing peptide.  The expected 
molecular weight of DAO protein is indicated by the arrow. 
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3.5 Purification of DAO antibody against purified human DAO 
enzyme  
Since the DAO polyclonal antibody isolated through the immunizing 
peptide purification retained contaminating antibodies and the DAO antibody was 
shown to recognize both rat and human DAO enzymes the antibody preparation 
was subsequently purified against a pure human DAO enzyme to try to get 
additional purity of the preparation.  Given the similarity of the two species at the 
immunizing peptide sequence level purification against the human or rat DAO 
purified protein should result in generation of purified DAO antibody.  
Furthermore, unlike the peptide alone purification where the peptide can 
apparently form unexpected configurations, the configuration of the DAO enzyme 
is conformationally restrained and is likely to result in a more specific antibody 
pool (Kaumaya et al., 1992). 
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After the second purification against purified hDAO, the antibody solution 
as tested by western blotting detected no contaminating protein bands in any of 
the negative controls, suggesting we had obtained a very pure DAO antibody 
preparation (Figure 3.5).  In particular the unknown protein bands migrating at 
about 64 kDa and 97 kDa were not observed (see Figure 3.4).  Bands were only 
present in DAO containing samples including human DAO Hek293 and rat 
cerebellar lysates.  Furthermore, the DAO bands were blocked by preincubating 
the antibody with the immunizing peptide.  Unexpectedly, two 39 kDa bands were 
detected in the human DAO Hek293 sample, rather than the single protein 
corresponding to human DAO expressed in the construct that was introduced via 
transient transfection in the Hek293 cells.  The presence of two bands in the DAO 
Hek293 but none in Hek293 and the fact that both of them were blocked with the 
peptide preincubation suggests that both bands were DAO.  One potential 
explanation for the presence of two forms of DAO is the incorporation of the 
DAO coding sequence into an expression construct in a region with an additional 
start codon resulting in the transcription of the original message as well as a 
somewhat longer message consisting of the original message plus a short 
fragment of Hek293 genome.  Alternatively, DAO may have undergone a post-
transcriptional modification such as a phosphorylation or glycosylation that takes 
place in Hek293 cells or underwent a c-terminal cleavage discussed in the 
introduction.  However, it should be noted that the rat cerebellar lysate contained 
only one band corresponding to DAO.  However, post-translational modification 
cannot be ruled out because human DAO may differ from the rat DAO in a key 
sequence exposing it to a post-translational modification, which may not be the 
case for rat DAO.      
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Figure 3.5: “Double” purified DAO antibody specifically detects DAO in human 
DAO Hek293 cell line and in rat cerebellar lysate on a western blot (indicated by 
the arrow). Membrane was probed with DAO antibody purified against the 
purified hDAO enzyme.  Immunoreactive bands are not seen when the antibody is 
blocked by its peptide. 
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3.6 DAO antibody validation against DAO KO mice lysate 
The purified DAO antibody solution was tested against a DAO KO mice 
cerebellar lysate (a kind gift from Christine Strick, Pfizer) to further test its 
specificity.  The KO mice were generated by knocking out exons 7-8 completely 
and part of exon 6 and 9 which should cause a frame shift beyond exon 9 and 
result in a truncated DAO protein encoding through exon 6 (manuscript in 
preparation).  The resulting protein is expected to weight about 20 kDa, or half of 
the full length DAO.   
 Two bands around 39 kDa were observed in the WT mice cerebellar lysate 
(Figure 3.6 lane 1) which suggests posttranslational modifications in mice.  This 
was not observed with the rat cerebellar lysate (Figure 3.5 lane 3) suggesting that 
the mice DAO construct may contain for example a phosphorylation sequence 
which is not found in the rat DAO sequence.  Alternatively, the two bands are 
representation of the full length DAO and the proposed c-terminal truncated DAO 
(Campaner et al., 1998; Pollegioni et al., 1995).  Both bands decrease in intensity 
in the HET mice (Figure 3.6 lane 2) but with a much more significant decrease in 
the lower molecular band intensity.  In the KO mice both bands completely 
disappeared (Figure 3.6 land 3).  Taken together these data suggest that both 
bands are corresponding to DAO.  Furthermore, there is no evidence of a 
truncated DAO in the HET and KO mice, which, if expressed, should be 
detectable with the N-terminal DAO antibody.  Consequently, either truncated 
DAO protein is degraded altogether or it is not synthesized at all.  The KO mice 
were not available until the very end of my thesis hence these animals were not 
used through out my experiments as a negative control. 
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Figure 3.6:  Examination of cerebellar lysate from DAO KO mice with the DAO 
antibody.  WT, HET and KO mice cerebellar lysates were probed with the DAO 
antibody on an SDS-PAGE gel.  The expected outcome would be no detectable 
DAO at 39 kDa but a band at ~20 kDa in the lysate from the KO mice.  As 
expected the band corresponding to the full length DAO at 39 kDa in the KO 
mice lysate was not present indicating a successful KO. There was no evidence of 
a 20 kDa band in the cerebellar lysate from the KO mice either.  In the HET 
cerebellar lysate where both 39 kDa and 20 kDa bands were expected at about 
half the intensity of the bands found in the WT mice a dimunition of the 39 kDa 
signal was observed without any evidence of 20 kDa band.  Actin was used as a 
control to show that same protein concentrations were loaded for each sample.  
DAO is indicated by the arrow. 
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Legend: 
Ln 1: 20 g mice WT cerebellar lysate 
Ln 2: 20 g mice HET cerebellar lysate 
Ln 3: 20 g mice KO cerebellar lysate 
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3.7 Optimization of DAO immunoprecipitation procedures 
Once the DAO antibody was shown to be effectively and specifically 
recognizing DAO it was tested in immunoprecipitation experiments to determine 
if it would recognize undenatured DAO enzyme in complex co-
immunoprecipitation experiments.  Magnetized Dynal Protein A (Invitrogen) 
beads were used as a matrix for capturing and retaining the DAO antibody as 
outlined in Figure 3.7.  The bead-antibody complex was than used to 
immunoprecipitate DAO from various lysate solutions.   
The Dynal beads are precoated with Protein A, which has a very high 
affinity for most rabbit IgG antibodies (Deisenhofer, 1981).  The beads were 
mixed with the purified antiserum to allow for capture of the antibodies by protein 
A.  The two were then covalently crosslinked with dimethyl pimelimidate 
dihydrochloride (DMP) to prevent the antibodies from dissociating from the beads 
during washing and especially during the elution of the antigen.  The beads were 
convenient because they can be gently separated from the rest of the solution 
utilizing a magnet.  This allowed for retention of protein complexes, which might 
be otherwise disrupted during other co-immunoprecipitation procedures 
employing procedures such as centrifugation.  In addition, the Dynal beads 
allowed for removal of all the wash solutions ensuring thorough washing without 
losing the beads.   
 To test the ability of the DAO antibodies coupled to Dynal beads to 
immunoprecipitate DAO, lysates from human DAO Hek293 cells were first used 
as an input for the immunoprecipitation.  Increasing total protein amount from 50 
g to 750 g of lysate were used per set of bead/antibody ratio to determine the 
maximal amount of DAO that can be immunoprecipitated.  As seen in Figure 3.8, 
lanes 2 through 6, DAO antibody was able to successfully immunoprecipitate 
DAO enzyme.  At about 100 g of DAO Hek293 lysate (lane 3) the amount of 
DAO antibody was saturated as compared to 50 g (lane 2) and 250 g (lane 4).  
This bead/antibody set was used throughout further experiments and was able to 
pull-down as much DAO as was found in 25 g of DAO Hek293 lysate as  
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Figure 3.7:  Schematic diagram for preparation of DAO polyclonal antibody 
immunoprecipitation column.  The column is composed of Dynal Protein A beads 
which act as a matrix for the DAO antibody.   
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determined the by positive control with 2.5 g of DAO-Hek293 lysate in lane 1.  
The additional bands found in lanes 2 through 6 around 50 kDa were probably 
that of the heavy IgG chain.  Some of the antibody may have eluted off during the 
elution step despite cross-linking to the beads.  Samples from lanes 7 and 8 were 
prepared in the same way as the other immunoprecipitation samples but prior to 
the addition of DAO Hek293 lysates, immunizing peptide was used to preabsorb 
the antibody.  Lane 7 shows that 1 g of immunizing peptide could completely 
block the DAO antibody from capturing DAO protein from DAO Hek293 lysate.  
However, at one-tenth of the peptide concentration, as depicted in lane 8, some of 
the DAO protein was captured and retained by the DAO antibody beads.  Due to 
the concentration gradient of the blocking peptide the two lanes further 
underscore that the band being immunoprecipitated was DAO.  The protein smear 
migrating around 62 kDa in the peptide blocked samples was perhaps the result of 
trace amounts of the immunizing peptide.  This argument was justified by 
considering that in lane 8 where one-tenth of the amount used in lane 7 peptide 
was used was of lower intensity.  Some of the high molecular weight signal may 
be due to antibody elution from the column and subsequent recognition by the 
secondary antibody.  Perhaps the use of the peptide on the DAO Dynal beads 
resulted in the antibody elution during the stage prior to loading on the SDS-
PAGE gel. 
 The immunoprecipitation procedure using DAO antibodies coupled to 
Dynal beads was further validated using rat cerebellar lysates in order to ensure 
that the antibody was capable of recognizing native human and rat DAO and that 
the DAO enzyme may be detected at physiological levels as it is in the rat 
cerebellum and for it to be specifically pulled-down from a lysate solution.  This 
was critical to enable immunoprecipitation of native DAO protein complexes. 
The results from western blotting analysis of immunoprecipitation from 
rat cerebellar lysate are presented in Figure 3.9.  In lanes 3 through 7, a lysate 
gradient ranging from 25 g to 500 g was presented with an increasing retention 
of DAO protein.  The 500 g of rat cerebellar lysate (lane 7) corresponded to the 
amount of DAO captured from 100 g of human DAO Hek293 (lane 10) 
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suggesting that around 500 g of rat cerebellar lysate was necessary to saturate 
the beads with DAO.  Since it only takes 100 g of human DAO Hek293 lysate 
but 500 g of rat cerebellar lysate this outcome suggests that there were 
approximatelly five times as much DAO expressed in the stable line as in the 
cerebellum per g of total protein.  Such an outcome was expected as in general, 
stable lines heterologously expressing proteins are more likely to express at a 
much higher than it is in native tissue.  The first two lanes of Figure 3.9 show the 
cerebellar lysate itself at 10 g and 50 g both of which show presence of DAO.  
The relative protein band intensity between 500 g immunoprecipitation (lane 7) 
and that of 50 g lysate (lane 2) was about four-fold suggesting that the DAO 
antibody was capable of immunoprecipitating about forty percent of the total 
DAO found in the lysate.  This ratio of the retained DAO on the antibody beads 
could be increased if the immunoprecipitation was carried out for longer then the 
one hour utilized in this experiment.  However, such a retention rate is already 
high and sufficient for experimental needs.  The peptide blocked DAO antibody 
was used in lanes 8 and 9 where either 1 g or 0.1 g of the immunizing peptide 
was used respectively.  As in human DAO Hek293 sample, 1 g of the peptide 
was able to completely block DAO capture by the DAO beads even when highest 
cerebellar lysate, 500 g, was used.  The lower peptide block partially prevented 
DAO capture from the cerebellar lysate. 
 All of the immunoprecipitation samples share the IgG heavy chain band 
around 50 kDa.  Additional background signal was found especially in the peptide 
blocked samples suggesting some antibody elution from the beads and potential 
trace amount of the peptide as discussed previously (Figure 3.8).   
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Figure 3.8: Optimization of DAO immunoprecipitation protocol using DAO 
antibody covalently coupled to protein Dynal beads from hDAO Hek293 stable 
cell line lysate.  The western blot was probed with DAO antibody for presence of 
DAO after immunoprecipitation.  As the concentration of hDAO-Hek293 lysate 
was increased (lanes 2-6) from 50 g to 750 g more DAO was pulled-down until 
the antibody beads were saturated at about 100 g of lysate.  The pull-down was 
completely blocked by preabsorbtion of the antibody with 1 g of immunizing 
peptide, but partially with 0.1 g.  The expected DAO protein separation on the 
SDS-PAGE gel is indicated by the arrow. 
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Legend: 
Ln1:  2.5 g hDAO Hek293 lysate 
Ln2:  IP with 50 g hDAO Hek293 lysate 
Ln3:  IP with 100 g hDAO Hek293 lysate 
Ln4:  IP with 250 g hDAO Hek293 lysate 
Ln5:  IP with 500 g hDAO Hek293 lysate 
Ln6:  IP with 750 g hDAO Hek293 lysate 
Ln7:  IP with 500 g hDAO Hek293 lysate preabsorbed with 1 g peptide 
Ln8:  IP with 500 g hDAO Hek293 lysate preabsorbed with 0.1 g peptide 
 
DAO 
 87 
Figure 3.9: Optimization of the DAO immunoprecipitation from rat cerebellar 
lysate using DAO antibody covalently coupled to protein A Dynal beads.  As the 
concentration of the cerebellar lysate increases (lane 3-7) per antibody-bead 
sample the amount of immunoprecipitated DAO increases.  The amount of DAO 
immunoprecipitated from 500 g rat cerebellar lysate is equivalent to the DAO 
immunoprecipitated from 100 g of hDAO-Hek293 suggesting saturation of the 
beads.  DAO is not pulled-down when the beads are preabsorbed with 1 g of the 
immunizing peptide, but see partial pull-down with 0.1 g peptide.  The expected 
DAO protein separation on the SDS-PAGE gel is indicated by the arrow. 
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Legend: 
Ln1:  10 g rat cerebellar lysate  Ln6:  IP from 250 g cerebellar lysate 
Ln2:  50 g rat cerebellar lysate  Ln7:  IP from 500 g cerebellar lysate 
Ln3:  IP from 25 g cerebellar lysate Ln8:  IP from 500 g cerebellar lysate preabsorbed with 
1 g peptide 
Ln4:  IP from 50 g cerebellar lysate Ln9:  IP from 500 g cerebellar lysate preabsorbed with 
0.1 g peptide 
Ln5:  IP from 100 g cerebellar lysate Ln10:IP from 100 g hDAO-Hek293 lysate 
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3.8 Conclusions 
Two N-terminal rat DAO peptides were used to generate polyclonal 
antibodies in rabbits.  One of the two antiserums was shown to recognize DAO 
lysates from both rat and human DAO stable lines while the second peptide did 
not yield useful DAO antiserum.  The serum from the positively reactive rabbit 
was purified against the immunizing peptide.  Due to the likely presence of 
contaminating antiserum a second purification against human DAO purified 
enzyme resulted in a very clean DAO antibody preparation.  The purified 
antibody was successfully tested against DAO KO mice and in 
immunoprecipitation experiments with both rat DAO stable line and rat cerebellar 
lysate.  Immunoprecipitation conditions for Dynal protein A beads were 
optimized for the maximum DAO binding capacity.  These conditions were 
deemed suitable to be applied for a DAO interactor study.  
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4. Identification of putative DAO interactors through DAO antibody pull-
down from rat cerebellum  
 
 4.1  Introduction 
Protein-protein interactions are at the center of cellular processes 
including DNA replication, transcription, translation, splicing, secretion, cell 
cycle control, signal transduction and intermediary metabolism.  Those 
interactions have varying degrees of affinity and specificity.  The weaker 
interactions termed transient protein-protein interactions regulate fundamental 
processes such as cell growth, cell cycle, metabolic pathways and signal 
transduction.  Thus study of protein-protein interactions plays an important role in 
understanding biological systems (Phizicky and Fields, 1995).   
In identifying protein-protein interactions, it is important to maintain the 
native state of proteins to ensure identification of genuine interactors rather than 
aggregates of denatured proteins (Phizicky and Fields, 1995).  Techniques used to 
asses the degree of protein interaction ultimately influence the outcome of the 
interactor study.  Several methodologies (outlined in Table 4.1) have been widely 
used for the purpose of identification interacting proteins.  Each of the techniques 
has specific benefits and disadvantages associated with them.   
 An understanding of the DAO interactome may give us an insight into its 
function and also perhaps its role in schizophrenia etiology.  Knowledge of DAO 
interacting proteins may better allow us to understand what DAO does and the 
means by which its activity may be regulated through pathways which DAO has 
not previously been considered part of.  Should DAO be found to interact with 
proteins known not to be expressed in the peroxisome, for example, we may be 
able to test its localization in relation to the new interacting partners through the 
likes of immunocytochemistry and electron microscopy.  Such an observation 
would allow us to address the controversial DAO localization.  Hence we propose 
that identification of DAO interactome, or the entire set of proteins DAO interacts 
with, is a valuable tool in studying the function of this enzyme.  
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Table 4.1: Methods used in identification of protein-protein interactions. Adapted 
from Howell (Howell et al., 2006) 
 
Interaction method Description  
Yeast-2-hybrid A high throughput screen involving use of a library fusions 
where the protein of interest, the bait, is fused to a DNA-
binding domain and the potential interacting proteins, the 
prey, are fused to an activation domain.  Upon a physical 
interaction of the bait and the prey active transcription 
factor is restored allowing yeast colonies  to synthesize key 
amino acids and survive on selective media.  DNA is 
extracted from the surviving colonies and sequenced to 
identify the interacting polypeptide.  This approach is 
challenging to identify large protein interactors as those are 
unlikely to be part of the fusion library and may not be 
properly expressed.  
 
Co-immunopre- Involves specific antibody to pull-down the bait protein of  
cipitation (co-IP)  interest from a protein pool or lysate and 
coimmunoprecipitate with it interacting proteins.  After 
extensive washing to remove nonspecific proteins the 
constituents are resolved by SDS-PAGE and identified 
through mass spectroscopy. 
 
Affinity  Instead of using an antibody to pull-down the bait, the bait  
chromatography  is tagged such as with GST, TAP or His in a fusion 
construct.  A tag-specific matrix is used to retain the bait 
and any interacting proteins of the bait.  The tag may alter 
the confirmation of the bait protein thus potentially 
changing associated interactome. Interactors are identified 
via mass spectroscopy. 
 
Phage display A library-based method where the prey peptides are 
expressed as fusion proteins with the viral coat reflecting 
the genetic content of  the virus.  The phage library is 
exposed to the bait allowing for selection of prey virus 
carrying peptides capable of interacting with the bait.  The 
genetic content of the interacting viruses is sequenced 
identifying the interacting peptide. 
 
Cross-linking This is a preferable method for identification of weaker or 
transient interactions.  Cross-linkers quickly permeate cells 
and tissues allowing for stabilization of weak interactions.  
The preserved protein complexes containing the bait 
protein are separated and analyzed through mass 
spectroscopy.  The interactome is likely dependent on the 
type of cross linker used. 
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Protein chip arrays The bait protein is immobilized on a chip surface and 
exposed to potential prey proteins.  Mass spectroscopy can 
be used to identify positive interactions.   
 
 
Far-western Involves immobilization of known prey peptides to a 2-D  
blotting/ELISA  surface followed by addition of bait protein and detection 
of presence of the bait with a primary/secondary antibodies.  
Use of denatured proteins may alter the degree of 
interaction between the proteins. 
 
Biophysical Fluorescence resonance energy transfer is in vivo  
Techniques  measurement of proximity between known and tagged 
interacting proteins.  This technique is distance dependent 
measurement of electronic excited states of two dye 
molecules in which excitation from a donor is transferred 
onto the acceptor as long as the two are in a close 
proximity. 
__________________________________________________________________ 
 
    The co-immunoprecipitation (co-IP) technique for the identification of 
DAO interacting proteins was chosen.  The use of a specific antibody allows for 
retention of the antigen even when the stringency of the washes are increased 
allowing for selection of the most robust and thus most likely true interacting 
proteins.  This technique allows for the pull-down of DAO in its native form 
containing any post-translational modifications in conjunction with any preformed 
complexes of which DAO may be part of.  DAO may not be found in the same 
configuration when it is synthesized with a tag in E. coli cells for the likes of 
affinity chromatography.  The co-IP methodology may be less likely, however, to 
identify interacting proteins which are expressed at low levels (Howell et al., 
2006).  By using adult rat cerebellum, where DAO is highly expressed, as the 
source of the input for the immunoprecipitation the bait and prey concentrations 
are reflective of the native state preventing false positives that may result from 
overexpression of either the bait or the prey as could be the case in phage display.  
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4.2 Schematic flow of the proposed immunoprecipitation study 
 The immunoprecipitation with the DAO antibody and the two negative 
controls (described in section 4.3) led to isolation of protein complexes specific to 
each sample.  As outlined in Figure 4.1, the samples generated through the 
immunoprecipitation were denatured and run on SDS-PAGE gel to separate out 
the proteins based on size.  Each SDS-PAGE gel lane was cut into twenty even 
pieces and the excised bands underwent a tryptic digest resulting in shorter 
polypeptides representing proteins in each sample.  The polypeptides generated 
by the tryptic digest were sequenced by mass spectroscopy and compared with the 
NCBI protein database to translate the identity of the proteins in each sample.  
The proteins identified through DAO antibody pull-down were then compared 
and contrasted with those of the negative controls to derive a list of DAO specific 
putative interacting proteins.   
 
Figure 4.1: Schematic diagram for the proteomics strategy. 
 
 
 
 
Isolation of protein complex 
 
 
Potential candidates 
SDS-PAGE 
A    B    C 
 
Locus Unique Total Unique Total Unique Total GI numbers Description
 BSN 0 0 2 3 53 95 9506427,51315739 bassoon (presynaptic cytomatrix protein)
 PCLO 0 0 0 0 43 83 10048483,27372317,41019528,51094943 piccolo (presynaptic cytomatrix protein)
 ERC1 0 0 0 0 5 6 28972606,30017397 ELKS/RAB6-interacting/CAST family member 1
 ERC2 0 0 0 0 4 5 51701368  ELKS/RAB6-interacting/CAST family member 2
 UNC13A 0 0 0 0 3 3 12408318  unc-13 homolog A (C. elegans)
 UNC13C 0 0 0 0 3 3 21749873,49248545 unc-13 homolog C (C. elegans)
 PPFIA2 1 1 0 0 2 3 42558942,119617781
 protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 2
 RIMS1 0 0 0 0 2 3 34395745  regulating synaptic membrane exocytosis 1; RIM1
 PPFIA3 (includes EG:8541)0 0 0 0 1 1 42558929
 protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 3
 PPFIA4 0 0 0 0 1 1 4240283
 protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 4
 RIMBP2 0 0 1 1 1 1 2224577  RIMS binding protein 2
 RIMS2 0 0 0 0 1 1 71051516  regulating synaptic membrane exocytosis 2; RIM2
Lane
A (IgG) B (Peptide blocked) C (DAO)
Mass Spectroscopy  
Data Analysis  
Biological Validation  
Excise bands and 
carry out in-gel digestion 
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4.3 Rabbit IgG and peptide blocked DAO antibody as negative controls 
Immunoprecipitation experiments are likely to yield many interacting 
proteins only some of which are likely attributable to a direct interaction with the 
bait protein.  Maintaining a balance between stringency parameters to minimize 
nonspecific and matrix-dependent background signal while retaining the true 
interactors is a challenging task.  Thus parameters such as prey protein 
concentration, ionic strength, detergent, volume and frequency of washes, and 
length of time/temperature for bait-prey interactions and techniques used to 
prepare the samples have to be optimized for best outcome (Howell et al., 2006).  
Furthermore, technique specific controls are critical to ascertain the likelihood of 
true interactors.  To control for the non-specific retention of proteins by the Dynal 
Protein A beads or by sticking to the antibody chains two negative controls were 
utilized for the DAO co-immunoprecipitation: rabbit IgG and peptide blocked 
DAO antibody.  The rabbit IgG is commonly accepted as a suitable negative 
control for a rabbit specific antibody so we included it in our experiment (Law et 
al., 2009).  To more thoroughly control for non-specific sticking of proteins to the 
DAO antibody we prevented the capture of DAO by pre- and co-blocking the 
DAO antibody with the immunizing peptide during incubation with the rat 
cerebellar lysate.  This negative control may more thoroughly control for proteins 
that may have affinity to our antibody then a random rabbit IgG control.  As 
expected, both rabbit IgG pull-down and the peptide blocked DAO antibody were 
shown not to immunoprecipitate DAO protein from rat cerebellum as determined 
by SDS-PAGE gel probed with the DAO antibody (Figure 4.2).  The cerebellum 
was used because of highly enriched DAO expression in this brain region (Verrall 
et al., 2007). 
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Figure 4.2: Optimization of negative controls for the co-IP of DAO.  Two 
negative controls, rabbit IgG (lane 3) and peptide blocked DAO antibody (lane 2) 
were used to increase the confidence in the “hits” generated against the DAO 
antibody (lane 1).  The same amount of rat cerebellar lysate was applied to the 
negative controls but no DAO was immunoprecipitated from the lysate.  Rat 
cerebellar lysate, the input for the immunoprecipitation (lane 4) was used at 1/10
th
 
the volume to verify that the lysate is expressing DAO.  The resolved DAO 
protein on the SDS-PAGE gel is indicated by the arrow. 
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4.4 Coomassie stained gels of the eluates 
The interacting proteins retained by the DAO antibody and the two 
negative control columns were examined for differential protein staining on the 
SDS-PAGE gel through visualization by the Coomassie blue stain.  We expected 
to see enhanced protein bands in the DAO immunoprecipitation Coomassie 
stained SDS-PAGE lane corresponding to DAO specific interactors.  This finding 
is especially important since we did not have a positive control.  To date there are 
no known DAO interactors identified outside of the interaction with the product 
of the primate specific gene G72 (Chumakov et al., 2002).    
 A small portion (1/20) of the sample generated by immunoprecipitation 
and used for the mass spectroscopy analysis was separated on SDS-PAGE gel and 
stained with Coomassie stain (Figure 4.3).  The possible presence of DAO in the 
solution from the pull-down was indicated by the green arrow.  This band was not 
found in either of the two negative controls supporting the Western blot findings 
from Figure 4.2.  More importantly several specific bands were present in the 
DAO pull-down sample represented by the greater staining at high molecular 
weight beyond the ~100 kDa size marker.  Several small molecular weight bands 
of less then 20 kDa and between 30 and 40 kDa also appeared to be specific to the 
DAO immunoprecipitation suggesting presence of proteins that were not found in 
the negative controls. 
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Figure 4.3:  Coomassie gel of the rat cerebellar immunoprecipitation input for the 
mass spectroscopy analysis.  One-twentieth of the mass spectroscopy input was 
used for Coomassie stain of immunoprecipitation from rabbit IgG (lane 1), 
peptide blocked DAO antibody (lane 2) and DAO antibody (lane 3).  Green arrow 
indicates band likely corresponding to DAO in the DAO pull-down column.  This 
band is absent in the two negative controls.  Black arrows highlight bands specific 
to the DAO immunoprecipitation sample. 
 
 
 
 
 
 
 
4.5 Identification of novel putative DAO interactors through mass 
spectroscopy using PBS as a washing buffer 
While optimizing the washing conditions for the antibody containing 
beads we were challenged to identify an optimal procedure which would include 
retention of DAO interacting proteins but removal of sticky, nonspecific proteins.  
This was difficult to optimize because we did not have a positive control on which 
to rely.  As a result, we decided to be conservative and use very mild washing 
conditions using phosphate buffered solution (PBS) in an attempt to make sure 
that we did not lose any of the interacting proteins.  Using two negative controls 
we would be able to subtract out nonspecific proteins from the pool of DAO 
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putative interacting proteins.  At the same time, having the results from the 
Coomassie stained SDS-PAGE gels (Figure 4.3) we had reason to believe that 
DAO specific interacting proteins were identified through the proposed co-
immunoprecipitation from rat cerebellum. 
Based on the PBS washing conditions a total of 198 putative DAO 
interacting proteins were identified (Table 4.2).  This number represents proteins 
that were found in the DAO antibody immunoprecipitation column but not in 
either of the two negative controls. Exceptions were made for proteins that were 
found at very low levels (no more then two hits) in both of the two negative 
controls if they were identified at high concentrations in the DAO pull-down 
lysate.  Bassoon is an example of such an exception where 52 and 94 unique and 
total hits respectively were identified in the DAO immunoprecipitation column 
but in addition 2 and 3 unique and total hits were found in the peptide blocked 
control respectively.  The interacting proteins are highlighted in Table 4.2, where 
each pull-down experiment lists the abbreviated protein name, and the number of 
hits for each pull-down.  The hits were divided into the number of unique and 
total hits.  Unique hits were represented by the number of different polypeptides 
that were sequenced and identified by the mass spectroscopy and recognized as 
belonging to the identified protein.  The greater number of unique hits may be 
suggestive of a stronger interacting protein or be representative of a larger protein 
which was digested into more fragments.  Table 4.3 highlights the top 24 
interacting proteins based on the number of identified hits along with their full 
name and molecular weight.  As expected the proteins with the most hits were 
large proteins.  Hence it was important to examine unique hits in conjunction with 
the total hits which represent all of the hits identified for that protein when all of 
the unique hits and the frequency of each unique hit were compiled together.  The 
ideal outcome for a strong interacting protein is for a high number of unique hits 
to be accompanied by an even higher number of total hits.  An arbitrary cut off of 
at least four unique hits was used to come up with the 198 interacting proteins. 
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Table 4.2: Putative DAO interacting proteins identified from co-
immunoprecipitation experiments. 
 
 Sample 
Protein PBS Wash RIPA Supplemented Wash 
Name A (IgG) 
B (Peptide 
blocked) 
C (DAO) 
D (Peptide 
blocked) 
E (DAO) 
  Unique Total Unique Total Unique Total Unique Total Unique Total 
DYNC1H1 4 4 2 2 149 202 2 2 41 53 
BSN 0 0 2 3 52 94 0 0 32 60 
BAT2D1 0 0 0 0 46 100 0 0 19 46 
PCLO 0 0 0 0 41 79 0 0 16 27 
SACS 0 0 0 0 29 30 0 0 3 3 
MYH10 0 0 0 0 20 22 2 2 4 4 
ACZ 0 0 0 0 19 47 0 0 15 27 
ATP6V0A1 1 1 2 2 17 51 0 0 0 0 
DEPDC2 0 0 0 0 15 19 0 0 2 3 
 ATP6V1A 2 2 0 0 15 18 2 2 1 1 
AP2A1 1 1 0 0 14 16 2 2 5 7 
 PRKCG 0 0 1 1 14 16 0 0 5 5 
IMMT 0 0 0 0 14 16 1 1 2 3 
SNIP 0 0 0 0 13 24 0 0 17 24 
PC 0 0 1 1 13 14 0 0 6 7 
DAO 0 0 0 0 13 28 0 0 5 7 
ATP6V1B2 1 1 0 0 13 15 4 4 4 4 
SDHA 2 2 0 0 13 16 0 0 0 0 
NDUFA9 1 1 1 1 12 19 0 0 1 1 
ANK1 1 1 0 0 12 12 0 0 1 1 
AP2B1 1 1 0 0 11 11 2 2 7 8 
RPS3 0 0 0 0 11 13 1 1 0 0 
RAPGEF4 0 0 1 1 10 11 1 1 12 14 
CEP97 0 0 0 0 10 12 0 0 4 4 
SLC4A4 0 0 1 1 10 17 1 1 3 4 
ARBP 0 0 1 2 10 23 1 1 1 1 
MAP1A 1 1 1 1 10 13 1 1 1 1 
LOC684558 0 0 0 0 10 12 0 0 1 1 
SLC12A5 0 0 1 1 10 21 0 0 0 0 
ERLIN2 0 0 0 0 10 13 0 0 0 0 
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CNTNAP1 1 1 0 0 10 13 0 0 0 0 
NDUFS2 0 0 2 2 10 10 0 0 0 0 
AP2A2 0 0 1 1 9 10 3 3 6 8 
AP1B1 1 1 0 0 9 9 2 2 6 6 
PHYHIP 0 0 0 0 9 18 0 0 5 7 
MAP1B 0 0 0 0 9 12 0 0 4 4 
PABPC1 1 1 2 2 9 12 0 0 4 4 
PYGB 0 0 0 0 9 9 3 3 4 4 
1BG3B 0 0 0 0 9 9 3 3 2 2 
C1QBP 0 0 0 0 9 11 0 0 1 1 
AQP4 0 0 0 0 9 85 0 0 0 0 
NCAM1 1 1 0 0 9 11 1 1 0 0 
ANK1 0 0 0 0 9 9 0 0 0 0 
YLPM1 0 0 0 0 8 12 0 0 16 26 
YLPM1 0 0 0 0 8 11 0 0 16 25 
AP1B1 1 1 0 0 8 8 1 1 6 6 
NAPB 1 1 0 0 8 10 2 2 4 4 
DAO 0 0 0 0 8 16 0 0 2 2 
TFSM 0 0 0 0 8 18 0 0 1 1 
NDUFA9 1 1 1 1 8 13 0 0 1 1 
MYO5A 0 0 0 0 8 9 1 1 1 1 
MYH9 0 0 0 0 8 8 0 0 1 1 
SLC1A2 1 1 0 0 8 21 0 0 0 0 
MTCH2 0 0 0 0 8 14 0 0 0 0 
ATP8A1 0 0 0 0 8 14 0 0 0 0 
NDUFB5 0 0 0 0 8 10 0 0 0 0 
ATP6V1C1 0 0 0 0 8 9 0 0 0 0 
PRKCB 0 0 0 0 8 8 0 0 0 0 
NDUFV1 0 0 1 1 8 8 1 1 0 0 
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ARF5 1 1 1 2 7 12 2 3 7 8 
RAPGEF4 0 0 0 0 7 8 0 0 7 8 
SFXN3 1 1 0 0 7 14 1 1 4 4 
PPP1CB 0 0 0 0 7 7 0 0 4 6 
NAPA 1 1 1 1 7 8 2 2 3 3 
PYGB 0 0 0 0 7 7 2 2 3 3 
RPS18 0 0 0 0 7 13 0 0 1 1 
SFXN1 1 1 0 0 7 12 0 0 1 1 
RAB7A 0 0 0 0 7 8 0 0 1 1 
ANK2 0 0 0 0 7 7 0 0 1 1 
KIF5C 0 0 0 0 7 7 0 0 1 1 
NDUFB10 0 0 0 0 7 10 0 0 0 0 
NEGR1 0 0 0 0 7 10 0 0 0 0 
ILF2 0 0 0 0 7 9 0 0 0 0 
RPS8 0 0 0 0 7 9 0 0 0 0 
FLOT1 0 0 0 0 7 8 0 0 0 0 
IGSF8 0 0 1 1 7 7 1 1 0 0 
NDUFV2 0 0 0 0 7 7 0 0 0 0 
CRMP1 1 1 0 0 6 8 1 1 16 26 
CRMP1 1 1 0 0 6 8 1 1 13 24 
ARF4 1 1 1 2 6 10 2 3 5 6 
CHAINA 0 0 1 1 6 8 2 4 5 6 
ERC1 0 0 0 0 6 8 0 0 5 5 
GNB4 1 2 1 2 6 10 1 1 3 5 
MAP1B 0 0 0 0 6 9 0 0 3 3 
PPP1CC 0 0 0 0 6 6 1 1 3 4 
MFF 0 0 0 0 6 7 0 0 2 2 
ANK2 0 0 0 0 6 6 0 0 2 2 
DMX2 0 0 0 0 6 6 0 0 2 2 
MAP1B 0 0 1 1 6 9 0 0 1 1 
ELALV1 0 0 1 1 6 8 0 0 1 1 
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ATP6VH1 0 0 1 1 6 8 0 0 1 1 
DNM1L 0 0 0 0 6 7 1 1 1 1 
RBM14 0 0 0 0 6 6 0 0 1 1 
NDUFS4 0 0 0 0 6 6 0 0 1 1 
NDUFB7 0 0 0 0 6 10 0 0 0 0 
NDUFA12 0 0 0 0 6 9 0 0 0 0 
RPS19 1 1 0 0 6 8 0 0 0 0 
MAOA 0 0 0 0 6 7 0 0 0 0 
DDX5 1 1 0 0 6 7 1 1 0 0 
MTX2 0 0 0 0 6 7 0 0 0 0 
STOML2 0 0 0 0 6 7 0 0 0 0 
NDUFB8 0 0 0 0 6 6 0 0 0 0 
RPL7 0 0 0 0 6 6 0 0 0 0 
NDUFB11 0 0 0 0 6 6 0 0 0 0 
CACNA2D1 0 0 0 0 6 6 0 0 0 0 
DPP6 0 0 0 0 6 6 0 0 0 0 
BIN1 0 0 0 0 6 6 0 0 0 0 
CACNA2D2 0 0 0 0 6 6 0 0 0 0 
SCCPDH 0 0 0 0 6 6 0 0 0 0 
CLINT1 0 0 0 0 5 6 0 0 4 4 
RAB2A 0 0 0 0 5 7 0 0 3 5 
ENTH 0 0 0 0 5 6 0 0 3 3 
EEF1A2 0 0 1 1 5 5 3 3 3 5 
ANK2 0 0 0 0 5 5 0 0 3 3 
DNM3 0 0 0 0 5 5 3 3 2 2 
LMNB1 0 0 0 0 5 5 2 2 2 2 
SYN1 1 1 0 0 5 5 2 2 2 2 
RPL30 0 0 1 1 5 10 0 0 1 1 
RPL14 0 0 0 0 5 6 0 0 1 1 
PYGM 0 0 0 0 5 5 1 1 1 1 
ELAVL1 0 0 1 1 5 5 0 0 1 1 
UQCRB 1 1 0 0 5 5 0 0 1 1 
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NDUFA5 0 0 0 0 5 5 0 0 1 1 
ATP2A3 1 1 0 0 5 10 0 0 0 0 
RAP1B 0 0 0 0 5 9 2 2 0 0 
NDUFS8 0 0 0 0 5 7 0 0 0 0 
NFASC 0 0 0 0 5 6 1 1 0 0 
HP1BP3 0 0 1 1 5 6 0 0 0 0 
CAR4 0 0 0 0 5 6 0 0 0 0 
KCTD12 0 0 0 0 5 5 0 0 0 0 
GRIA4 0 0 0 0 5 5 0 0 0 0 
RPS4X 0 0 0 0 5 5 0 0 0 0 
RAA 0 0 0 0 5 5 0 0 0 0 
NDUFC2 0 0 0 0 5 5 0 0 0 0 
  0 0 0 0 5 5 0 0 0 0 
YLPM1 0 0 0 0 4 7 0 0 9 14 
DYNLL2 0 0 1 1 4 5 0 0 6 6 
NCOA6 0 0 0 0 4 4 0 0 4 5 
IDH3B 0 0 0 0 4 4 3 3 4 4 
PURB 0 0 0 0 4 4 1 1 3 3 
SLC1A6 1 1 0 0 4 7 0 0 2 2 
LOC679221 1 1 0 0 4 6 0 0 2 3 
MYL6 0 0 0 0 4 6 0 0 2 2 
RGD1565289 0 0 1 1 4 6 0 0 2 2 
GNAQ 0 0 0 0 4 6 2 2 2 2 
RAB5C 0 0 0 0 4 5 1 1 2 2 
RTN4 0 0 0 0 4 5 0 0 2 2 
TUFM 0 0 0 0 4 4 0 0 2 2 
MGST3 0 0 0 0 4 4 0 0 2 2 
VAPA 0 0 0 0 4 8 1 1 1 1 
TARDBP 0 0 1 1 4 7 0 0 1 1 
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GJA1 0 0 0 0 4 7 0 0 1 1 
RPLP2 1 1 0 0 4 7 0 0 1 1 
LOC685320 0 0 0 0 4 6 0 0 1 1 
SEC22B 0 0 0 0 4 5 1 1 1 1 
ERC2 0 0 0 0 4 5 0 0 1 1 
LOC679739 0 0 0 0 4 4 0 0 1 1 
DDX3X 0 0 0 0 4 4 0 0 1 1 
CADM3 0 0 1 1 4 4 1 1 1 1 
ANKG119 0 0 0 0 4 4 0 0 1 1 
CYFIP2 0 0 0 0 4 4 0 0 1 1 
NDUFA11 0 0 0 0 4 4 0 0 1 1 
UQCRFS1 1 1 0 0 4 4 0 0 1 1 
FAM162A 0 0 0 0 4 4 0 0 1 1 
GRIA1 0 0 0 0 4 4 0 0 1 1 
APOE 1 1 0 0 4 7 0 0 0 0 
RPS2 1 1 0 0 4 6 0 0 0 0 
SLC32A1 0 0 0 0 4 6 0 0 0 0 
THY1 1 1 0 0 4 6 0 0 0 0 
INPP5A 0 0 1 1 4 5 0 0 0 0 
LOC683655 0 0 1 1 4 5 0 0 0 0 
SDHB 0 0 0 0 4 5 0 0 0 0 
RPL3 0 0 0 0 4 5 0 0 0 0 
ITPR3 1 1 0 0 4 5 0 0 0 0 
MAOA 0 0 0 0 4 5 0 0 0 0 
MAOB 0 0 0 0 4 5 0 0 0 0 
STX7 0 0 0 0 4 5 0 0 0 0 
AMPH 0 0 0 0 4 5 1 1 0 0 
NTM 0 0 0 0 4 5 0 0 0 0 
MYH14 1 1 0 0 4 4 0 0 0 0 
RGD1562953 1 1 0 0 4 4 0 0 0 0 
CHCHD3 0 0 0 0 4 4 1 1 0 0 
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ARL8A 0 0 0 0 4 4 0 0 0 0 
FINB 0 0 0 0 4 4 0 0 0 0 
RPS9 0 0 0 0 4 4 0 0 0 0 
RPL14 0 0 0 0 4 4 0 0 0 0 
RPL22 0 0 1 1 4 4 0 0 0 0 
RPS9 0 0 0 0 4 4 0 0 0 0 
SLC23A12 0 0 0 0 4 4 0 0 0 0 
DDOST 0 0 0 0 4 4 0 0 0 0 
OGT 0 0 0 0 4 4 0 0 0 0 
RPS6 0 0 0 0 4 4 0 0 0 0 
DYNC1LI2 0 0 0 0 4 4 0 0 0 0 
TRIM3 0 0 0 0 4 4 0 0 0 0 
STX13 0 0 0 0 4 4 0 0 0 0 
UNC13A 0 0 0 0 4 4 0 0 0 0 
RPS6 0 0 0 0 4 4 0 0 0 0 
SAMM50 0 0 0 0 4 4 0 0 0 0 
DSP 0 0 0 0 0 0 0 0 11 18 
DSP 0 0 0 0 0 0 0 0 6 11 
CHAINB 0 0 0 0 0 0 0 0 5 5 
HRNR 0 0 0 0 0 0 0 0 4 10 
PFN1 0 0 0 0 0 0 0 0 4 4 
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Table 4.3: List of the top 24 DAO-interacting-proteins identified through the PBS 
washing protocol as determined by the number of unique hits.  Generally there 
appears to be a correlation between the molecular size of the protein and the 
number of hits.   
 
Abbreviation Protein Name Size (kDa) 
DYNC1H1 Dynein heavy chain 532 
BSN Bassoon 418 
BAT2D1 HBxAg transactivated protein 2 313 
PCLO Piccolo 553 
PRKCG Protein kinase C, Gamma 78 
SNIP SNAP-25-interacting protein 130 
PC Pyruvate carboxylase, mitchondrial 130 
RAPGEF4 Exchange factor directly activated by cAMP 2 123 
CEP97 Centrosomal protein 97 94 
PHYHIP Phyhip protein 48 
MAP1B Microtubule-associated protein 1B 270 
PABPC1 Poly(A) binding protein, cytoplasmic 1 71 
YLPM1 YLP motif containing 1 241 
AP1B1 Adopted-related protein complex 1, beta 1 106 
PPP1CB Protein phosphate 1 37 
CRMP1 Crmp 1 protein 74 
ERC1 
ELKS/RAB6-interacting/CAST family 
member 
128 
CLINT1 Clathrin interactor 1 68 
DYNLL2 Dynein, light chain 24 
NCOA6 
Peroxisome proliferator activater receptor 
interacting protein 
218 
DSP Desmoplakin 1 332 
CHAINB 
Chain B, perchloric acid soluble protein-a 
translational inhibi 
14 
HRNR Homeric precursor 282 
PFN1 Profilin 1 15 
 
 
4.6 Optimization of harsh washing conditions 
The number of putative interacting proteins identified through the mild 
PBS wash was much greater then could be reasonably evaluated experimentally 
making it difficult to select direct DAO interactors.  Proteins identified in the 
DAO pull-down lysate may be part of larger protein complexes which were 
retained because a mild washing procedure was employed.  A schematic of such 
interaction is depicted in Figure 4.4.  Alternatively, some of the hits were non-
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specific but retained because a mild wash was employed.  Consequently, a more 
stringent washing was optimized to narrow down the number of interacting 
proteins and focus on the strongest of interactors. 
 
 
Figure 4.4: A schematic diagram depicting a direct interaction of DAO (back 
circle) with protein x (green oval) result in immunoprecipitation of two other 
proteins (red and blue rectangles) which are not in a direct contact with DAO 
itself. 
 
 
 
 
 
 
 While using the PBS wash as a control other conditions including RIPA 
buffer alone and in combination with higher salt (NaCl) and SDS were tested.  
Initially the harsher washing options were tested to determine if DAO protein was 
washed away.  This was shown not to be the case as DAO was retained during 
every washing condition (Figure 4.5).  Subsequently, the sensitivity of the Silver 
stain was used to observe differences between the PBS wash and the other 
washes.  The SDS-PAGE lane corresponding to the PBS washed samples 
contained the most silver staining (Figure 4.6) out of all of the samples.  
Consequently, the RIPA buffer supplemented with 500 mM NaCl and 0.1% SDS 
was selected for a repeat of the DAO immunoprecipitation from adult rat 
cerebellum (six weeks of age), and precipitates were separated on SDS-PAGE gel 
and Coomassie stained (Figure 4.7).  In this gel, the DAO immunoprecipitation 
sample is darker with specific pronounced 200 kDa and higher molecular weight 
bands suggesting pull-down of specific DAO interactors.  Consistent with this 
observation several high molecular DAO specific interacting proteins such as 
DAO antibody/bead 
complex 
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bassoon, piccolo and dynein heavy chain were identified in the DAO pull-down 
lysate but not in the negative controls (Table 4.2).  A total of 24 hits with the 
more stringent washing conditions were identified (Table 4.2).  Thus the harsher 
wash conditions likely eliminated transient or weak interacting proteins and 
proteins that were part of a larger complex resulting in a core of proteins which 
are likely interacting with the DAO enzyme directly when the cerebellar cell 
membranes are ruptured and all of the proteins are free to interact with each other.   
 The proteins identified in the two immunoprecipitation experiments were 
grouped based on bioinformatics analysis of function and localization.  This 
analysis resulted in identification of distinct groups consisting of presynaptic 
active zone, vesicle, syntaxin, RAB, NADH dehydrogenase, and ATPase/proton 
transporting protein subunits.  Each group is described below. 
 
    
Figure 4.5: Optimization of washing conditions for the DAO antibody beads 
using SDS-PAGE gel probed with the DAO antibody.  DAO is 
immunoprecipitated under all of the washing conditions suggesting that once 
captured by the antibody it does not easily dissociate from the antibody-bead 
complex.  DAO was immunoprecipitated from 800 g  of rat cerebellar lysate and 
subsequently washed with PBS (lane 1), RIPA (lane 2), Ripa supplemented with 
500 mM NaCl (lane 3), RIPA with 0.1% SDS (lane 4), RIPA with 500 mM NaCl 
and 0.1% SDS (lane 5), RIPA with 0.5% SDS (lane 6), and the input lysate 1/10
th
 
volume (lane 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   1            2          3          4           5           6         7 
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Figure 4.6: Optimization of washing conditions for the DAO antibody beads 
using SDS-PAGE gel stained with Silver stain.  The immunoprecipitate using 
DAO specific antisera beads were washed with several stringent washing buffers 
to remove weak interacting proteins.  The PBS wash (lane 1) leaves the most 
proteins on the beads as reflected by higher staining between 28 and 39 kDas then 
in any of the other washes: RIPA (lane 2), RIPA supplemented with 500 mM 
NaCl (lane 3), RIPA with 0.1% SDS (lane 4), RIPA with 500 mM NaCl and 0.1% 
SDS (lane 5), RIPA with 0.5% SDS (lane 6), and the input lysate (lane 7).  The 
DAO band is visible just above the 39 kDa marker reflecting the observations 
made in Figure 4.5 with the DAO antibody.  The expected DAO protein 
separation on the SDS-PAGE gel is indicated by the arrow.   
 
 
 
 
 
 
MW 
 
191 
 
 
97 
 
 
 
64 
 
 
 
51 
 
 
39 
 
28 
 
 
17 
   1         2          3          4         5         6      7 
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Figure 4.7: SDS-PAGE gel stained with Coomassie blue representing the samples 
generated using the high stringency wash for the mass spectroscopy analysis.  The 
DAO immunoprecipitation sample, in lane 2, is darker with specific pronounced 
200 kDa and higher molecular weight bands suggesting pull-down of specific 
DAO interactors.  The expected DAO protein separation on the SDS-PAGE gel is 
indicated by the arrow.   
 
 
 
 
 
 
 
 
 
 
 
 
 
               1                    2 
MW 
DAO 
Legend: 
Ln 1: IP from 800 g cerebellum preabsorbed with 1 g peptide 
Ln 2: IP from 800 g cerebellum  
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4.6.1 Presynaptic active zone interacting proteins 
The presynaptic active zone, also known as „cytomatrix assembled at 
active zone‟ (CAZ) consists of a complex network of proteins involved in the 
organization of docking and priming of synaptic vesicles for their release into the 
synaptic cleft (Figure 4.8).  Thus at the CAZ electrical signals are converted into 
chemical messages which are propagated in the form of neurotransmitter release 
mediating communication with the postsynaptic membrane on adjacent neurons 
(Rizo and Rosenmund, 2008).  Proteins including Munc13s, RIMs, ELKS, PCLO 
and BSN have been shown to be enriched in the active zones where they play 
diverse functions in vesicle fusion and neurotransmitter release (Schoch and 
Gundelfinger, 2006).   
Many of the above mentioned proteins were identified as putative DAO 
interactors (Table 4.4) suggesting DAO localization within the active zone where 
it may contribute to D-serine metabolism or take on alternative functions.  The 
presynaptic active zone proteins were found to be the strongest set of interacting 
proteins identified in both immunoprecipitation experiments as determined by the 
greatest number of unique and total hits as well as by the percent of the protein 
identified by the mass spectroscopy (Table 4.5).  Out of the presynaptic proteins 
identified in the DAO interactome, BSN stood out as the most likely interacting 
protein with DAO as 29% of the entire BSN protein was identified in the DAO 
immunoprecipitate.  This coverage is very close to that of DAO itself (30%) 
implying a significant interaction between the two proteins.  A 30% coverage 
suggests a good retention of the DAO by its antibody as others have reported 18% 
in case of TRAF2 and NCK interacting kinase (TNIK) self immunoprecipitation 
(Mahmoudi et al., 2009).  The percent protein coverage is not a function of a 
protein‟s size as other large proteins such as PCLO were found to be recovered 
and sequenced at a rate of 18%.  Hence the larger the amount of any given protein 
that is being immunoprecipitated the greater the percent of that protein being 
sequenced by mass spectroscopy because the tryptic fragments are more abundant 
and are more likely to be picked up as hits.  Finally, the CAZ interactors suggest a 
novel DAO localization, potentially outside of the peroxisome. 
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Figure 4.8: Diagram of the presynaptic active zone including the proteins that 
were identified through the DAO immunoprecipitation highlighted in red.  
Adopted from Schoch (Schoch and Gundelfinger, 2006).  
 
 
 
 
Table 4.4: Summary of the presynaptic active zone proteins identified by the 
mass spectroscopy from the DAO immunoprecipitation experiments from adult 
rat cerebellum using both mild and harsh washing conditions. 
 
 Sample 
Protein PBS Wash RIPA Supplemented Wash 
Name A (IgG) 
B (Peptide 
blocked) 
DAO 
D (Peptide 
blocked) 
DAO 
  Unique Total Unique Total Unique Total Unique Total Unique Total 
BSN 0 0 2 3 52 94 0 0 32 60 
PCLO 0 0 0 0 41 79 0 0 16 27 
STXBP1 7 7 4 4 28 36 7 11 13 17 
DNM1  2 2 1 1 11 12 4 4 11 11 
ERC1 0 0 0 0 6 8 0 0 5 5 
DNM1L 0 0 0 0 6 7 1 1 1 1 
DNM3 0 0 0 0 5 5 3 3 2 2 
ERC2 0 0 0 0 4 5 0 0 1 1 
UNC13A 0 0 0 0 4 4 0 0 0 0 
RUMS1 0 0 0 0 2 3 0 0 1 1 
PPFIA3 0 0 0 0 2 3 0 0 0 0 
RIMS3 0 0 0 0 1 2 0 0 0 0 
Proteins coprecipitating 
with DAO 
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Table 4.5: The strength of the interaction was measured in terms of the percent 
protein coverage for the presynaptic active zone constituents.  As a control DAO 
was found at 30% suggesting that Bassoon at 29% may be a strong interacting 
partner. 
 
 
 
Protein 
Protein MW 
(kDa) 
% Protein 
Coverage 
Bassoon  418 29 
Piccolo 552 18 
Epac2 123 25 
ELKS 128 12 
Munc13-1 196 5 
RIM1 110 10 
Liprin- -3 149 3 
DAO 39 30 
 
 
 
4.6.2 Vesicle-associated membrane proteins (VAMPs) 
The vesicle-associated membrane proteins (VAMPs) are soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins 
that are required for synaptic vesicle fusion (Chen and Scheller, 2001).  Eight 
VAMP proteins (1-8) have been cloned and identified many of which were co-
immunoprecipitated with DAO (Table 4.6).  VAMP 1 and 2 (also known as 
synaptobrevins), found on membrane of synaptic vesicles, trigger vesicle fusion 
with the presynaptic membrane through an interaction with presynaptically 
expressed syntaxin-SNAP25 (Wang and Tang, 2006).  Some of the VAMPs 
appear to be more critical then others.  VAMP3 knockout mice were found not to 
be adversely affected (Yang et al., 2001) while VAMP2 knockout mice died 
immediately after birth and embryonic hippocampal neurons from the VAMP2 
animals displayed 100-fold decrease in calcium mediated synaptic vesicle fusion 
as compared to hippocampal neurons from wildtype animals (Schoch et al., 2001).  
The difference may be due to functional redundancy in one instance but not the 
other.    
 The VAMPs represent a potential group of DAO interacting proteins 
which are part of the active zone.  These proteins, however, are not as robustly 
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pulled-down as the active zone constituents outlined in Table 4.4 or the syntaxins 
in Table 4.7, especially with the harsh washing conditions.  Furthermore, the 
VAMPs are much more likely to non-specifically interact with the matrix or the 
rabbit IgG since there are substantial hits in either the rabbit IgG or the peptide 
blocked negative controls as compared to the DAO pull-down (Table 4.6).   
 
 
 
Table 4.6:  Summary of the vesicle-associated membrane proteins identified by 
the mass spectroscopy from the DAO immunoprecipitation experiments from 
adult rat cerebellum using both mild and harsh washing conditions.   
 
 
 
 
 
4.6.3 Syntaxin interacting proteins 
 
The syntaxin family consists of 15 genes in mammals, many of which are 
expressed as different isoforms depending on the tissue and developmental stage 
(Teng et al., 2001).  Syntaxin 1A interacts with SNAP-25 at the presynaptic 
membrane to form the target-membrane SNARE which forms a tight bond with 
VAMPs found on the synaptic vesicles allowing for release of neurotransmitters 
(Wang and Tang, 2006).  The syntaxins are restricted in expression with syntaxin 
18 localized to the endoplasmic reticulum, syntaxin 5 to the cis-Golgi and 
syntaxins 7, 8, 11, 12 and 13 to endosomes (Teng et al., 2001).  
The identification of syntaxins in the DAO immunoprecipitates look 
relatively specific to the DAO pull-down with the exception of the strongest two 
 Sample 
Protein PBS Wash RIPA Supplemented Wash 
Name A (IgG) 
B (Peptide 
blocked) DAO 
D (Peptide 
blocked) DAO 
  Unique Total Unique Total Unique Total Unique Total Unique Total 
VAMP2 3 3 1 1 5 8 2 4 4 9 
SEC22B 0 0 0 0 4 5 1 1 1 1 
VAMP1 0 0 0 0 2 2 0 0 2 2 
VAMP3 2 2 1 1 5 7 2 4 2 6 
SV2B 0 0 1 1 1 5 0 0 0 0 
VAMP5 0 0 1 1 1 1 0 0 1 1 
VAPB 0 0 0 0 1 1 0 0 0 0 
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interacting proteins STX1B1 and STS1B which where also found in the negative 
controls (Table 4.7).  Since all of the hits retained after the mild wash were 
removed by the harsh wash, the syntaxins may represent a transient group of 
DAO interacting proteins or they may have been retained by indirectly interacting 
with DAO. 
 
 
 
Table 4.7: Summary of the syntaxins identified by the mass spectroscopy from 
the DAO immunoprecipitation experiments from adult rat cerebellum using both 
mild and harsh washing conditions.   
 
 Sample 
Protein PBS Wash RIPA Supplemented Wash 
Name A (IgG) 
B (Peptide 
blocked) 
DAO 
D (Peptide 
blocked) 
DAO 
  Unique Total Unique Total Unique Total Unique Total Unique Total 
STX1B1 2 2 0 0 9 19 0 0 1 1 
STS1B 3 5 2 3 7 32 0 0 0 0 
STX7 0 0 0 0 4 5 0 0 0 0 
STX12 0 0 0 0 4 4 0 0 0 0 
STX13 0 0 0 0 4 4 0 0 0 0 
STXBP1 1 1 0 0 3 4 0 0 0 0 
STX16 0 0 0 0 2 2 0 0 0 0 
STX6 0 0 0 0 2 2 0 0 0 0 
STX3 0 0 0 0 1 1 0 0 0 0 
STXBP5 0 0 0 0 1 1 0 0 0 0 
STXBP5L 0 0 0 0 1 1 0 0 0 0 
STX1A 0 0 0 0 1 1 0 0 1 1 
 
 
 
4.6.4 RAS oncogene family (Rab) interacting proteins 
 
Unlike the CAZ proteins, Rabs are small (20-29 kDa) ubiquitously 
expressed proteins belonging to the Ras superfamily of monomeric G-proteins 
with more then 60 members found in mammalian cells, 28 of which were 
identified on neuronal synaptic vesicles (Fukuda, 2008; Schultz et al., 2000).  
Rabs have specific functions, for example, Rab1 and Rab 2 are involved in vesicle 
creation in the Golgi, while Rab3 and Rab27 assist in transport along the actin and 
tubulin framework and assist vesicle membrane fusion (Fukuda, 2008).  Rabs 
cycle between cytoplasm and the membrane of the targeting organelles where 
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conformational changes associated with guanidine-nucleotide binding and 
hydrolysis regulate the activity of Rabs.  GTP coupled Rabs are in the active form 
and are membrane bound where they are recognized by effectors while Rabs in 
the GDP-form are inactive (Lang and Jahn, 2008).  Rabs have been shown to play 
a role in regulation of membrane docking, priming and stimulus dependent fusion 
(Grosshans et al., 2006) highlighting a potential DAO involvement in 
neurotransmitter release.  
Among the Rabs identified through the immunoprecipitation, Rab7A and 
Rab2A,  (Table 4.8) are more likely to represent DAO interactors because they 
are only found in the DAO pull-down lysate in both of the immunoprecipitation 
experiments and at a fairly high level given their relatively small size.  Rab7A 
have been found to associate with Charcot-Marie-Tooth (CMT) type 2 neuropathy 
which is an autosomal-dominant axonal disorder (Spinosa et al., 2008).  Rab2A 
was found to be essential for protein transport from the endoplasmic reticulum to 
the Golgi complex (Tisdale and Balch, 1996).   
 
 
Table 4.8:  Summary of the Rabs identified by the mass spectroscopy from the 
DAO immunoprecipitation experiments from adult rat cerebellum using both mild 
and harsh washing conditions.   
 
 Sample 
Protein PBS Wash RIPA Supplemented Wash 
Name A (IgG) 
B (Peptide 
blocked) 
DAO 
D (Peptide 
blocked) 
DAO 
  Unique Total Unique Total Unique Total Unique Total Unique Total 
Rab7A 0 0 0 0 7 8 0 0 1 1 
ERC1 0 0 0 0 6 8 0 0 5 5 
Rab35 2 3 2 2 6 11 2 3 2 3 
Rab2A 0 0 0 0 5 7 0 0 3 5 
Rab6B 1 2 2 4 5 9 3 7 2 8 
Rab3A 1 2 4 6 5 15 3 3 5 6 
Rab6A 1 2 1 1 5 9 2 2 2 3 
Rab10 2 3 2 2 5 10 2 3 2 3 
Rab1B 2 3 2 2 4 10 2 3 3 4 
Rab1A 2 3 2 2 4 12 2 3 3 4 
Rab14 1 2 1 1 4 8 1 1 2 3 
Rab5C 0 0 0 0 4 5 1 1 2 2 
Rab5B 0 0 0 0 3 4 1 1 1 1 
Rab11B 0 0 1 1 3 5 1 1 1 1 
Rab21 0 0 0 0 3 4 0 0 0 0 
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Rab2B 0 0 0 0 3 4 0 0 1 1 
Rab8A 2 3 2 2 3 8 2 3 2 3 
Rab39 1 2 1 1 2 5 1 1 1 2 
Rab23 0 0 0 0 2 2 0 0 0 0 
Rab3C 1 2 1 1 2 5 1 1 1 2 
Rab39B 1 2 1 1 2 5 1 1 1 2 
Rab5A 0 0 0 0 1 2 0 0 1 1 
Rab3IP 0 0 0 0 1 1 0 0 0 0 
Rab15 0 0 0 0 1 2 0 0 0 0 
Rab18 0 0 0 0 1 1 0 0 1 1 
 
 
4.6.5 Nicotinamide adenine dinucleotide dehydrogenase (NADH) interacting 
proteins 
The nicotinamide adenine dinucleotide dehydrogenase interacting proteins 
identified through the DAO co-immunoprecipitation are part of the mammalian 
mitochondrial respiratory complex I.  This complex consists of at least 46 
subunits, seven of which are encoded by mitochondrial DNA (Carroll et al., 
2003).  Complex I is embedded in the inner mitochondrial membrane where it 
transfers electrons from NADH to ubiquinone (Benit et al., 2001).  Deficiency in 
the complex I leads to neurological disorders such as Parkinson‟s disease 
(Schapira et al., 1990), Alzheimer‟s disease (Coskun et al., 2004), Huntington 
disease (Arenas et al., 1998) and most commonly Leigh syndrome (Iuso et al., 
2006). 
Most of the apparent interactions between DAO and NADH 
dehydrogenase proteins are weak at best as the complex I subunits were for the 
most part only immunoprecipitated when the weak wash was used (Table 4.9).  
None of the proteins were retained with the harsh wash.  Furthermore, the 
potential expression of DAO within the mitochondria suggested by this data is in 
contrast to what has been published in cultured human astrocytes (Sacchi et al., 
2008).  Hence the likelihood of the interaction between DAO and NADH 
dehydrogenase proteins in vivo may be low.  An interaction in vitro between 
NADH complex and DAO may explain the quantity of proteins identified through 
the mass spectroscopy in the immunoprecipitated lysate. 
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Table 4.9:  Summary of the NADH dehydrogenase proteins identified by the 
mass spectroscopy from the DAO immunoprecipitation experiments from adult 
rat cerebellum using both mild and harsh washing conditions.   
 
 Sample 
Protein PBS Wash RIPA Supplemented Wash 
Name A (IgG) 
B (Peptide 
blocked) 
DAO 
D (Peptide 
blocked) 
DAO 
  Unique Total Unique Total Unique Total Unique Total Unique Total 
NDUFS1 4 4 1 1 18 31 1 1 0 0 
NDUFA9 1 1 1 1 12 19 0 0 1 1 
NDUFS2 0 0 2 2 10 10 0 0 0 0 
NDUFS3 2 2 1 1 8 11 0 0 1 1 
NDUFB5 0 0 0 0 8 10 0 0 0 0 
NDUFV1 0 0 1 1 8 8 1 1 0 0 
NDUFB10 0 0 0 0 7 10 0 0 0 0 
NDUFV2 0 0 0 0 7 7 0 0 0 0 
NDUFS4 0 0 0 0 6 6 0 0 1 1 
NDUFB7 0 0 0 0 6 10 0 0 0 0 
NDUFB8 0 0 0 0 6 6 0 0 0 0 
NDUFB11 0 0 0 0 6 6 0 0 0 0 
NDUFA13 1 1 1 1 4 4 0 0 1 1 
NDUFA5 0 0 0 0 5 5 0 0 1 1 
NDUFS7 1 1 1 1 5 10 0 0 0 0 
NDUFS8 0 0 0 0 5 7 0 0 0 0 
NDUFC2 0 0 0 0 5 5 0 0 0 0 
LOC679739 0 0 0 0 4 4 0 0 1 1 
NDUFA11 0 0 0 0 4 4 0 0 1 1 
NDUFB4 1 1 0 0 3 3 0 0 1 1 
NDUFS5 0 0 0 0 3 5 0 0 0 0 
NDUFB9 0 0 0 0 3 4 0 0 0 0 
NDUFA8 0 0 0 0 3 4 0 0 0 0 
CYB5R3 0 0 0 0 3 4 0 0 0 0 
CYB5R1 0 0 0 0 3 4 0 0 0 0 
NDUFAB1 0 0 0 0 3 3 0 0 0 0 
ND4 0 0 0 0 2 7 0 0 0 0 
NDUFA7 0 0 0 0 2 3 0 0 0 0 
ND1 0 0 0 0 2 2 0 0 0 0 
NDUFA2 1 1 0 0 2 2 0 0 0 0 
NDUFA6 0 0 0 0 1 3 0 0 1 1 
NDUFB6 0 0 0 0 1 2 0 0 0 0 
ND3 0 0 0 0 1 1 0 0 0 0 
ND2 0 0 0 0 1 1 0 0 0 0 
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4.6.6 ATPase/H+ transporting subunits interacting proteins 
 
Proton transporting proteins are involved in acidification of intracellular 
organelles including clathrin coated vesicles, endosomes, lysosomes, synaptic 
vesicles and others.  The function of the proton pumping allows for protein 
processing and degradation, intracellular targeting, and receptor-mediated 
endocytosis (Nishi et al., 2003).  
Many of the proton transporting proteins identified are not specific to the 
DAO immunoprecipitation suggesting non-specific interaction with the Protein A 
beads or to the antibody (Table 4.10).  A notable exception is ATP6V0A1 which 
is robustly immunoprecipitated specifically with DAO pull-down. However the 
observed pull-down of ATP6V0A1 and of other proton transporting proteins is 
reduced with a harsh wash.   
 
4.7 Conclusions 
The immunoprecipitation experiment with the purified DAO antibody 
utilizing rat cerebellum lysate from six weeks old rats resulted in a robust pull-
down of DAO (Table 4.2).  This methodology in conjunction with a mild PBS 
wash resulted in identification of 198 putative DAO interactors which were co-
immunoprecipitated with DAO but were not found at significant levels in either of 
the two negative controls, the rabbit IgG or the peptide blocked DAO antibody.  
The extent of the interacting proteins identified necessitated use of means by 
which only a handful of interacting proteins representing the strongest interactors 
would be selected.  To this end, harsher washing conditions utilizing RIPA buffer 
supplemented with salt (NaCl) and SDS were used in subsequent 
immunoprecipitation experiments.  The harsh wash allowed DAO retention by the 
DAO antibody but led to significantly fewer interacting proteins (Figure 4.5 and 
4.6).  The list of 198 interacting proteins identified with the mild wash was 
reduced to 24 proteins through application of the RIPA supplemented buffer 
which are likely representing stronger DAO interactors.  The putative interacting 
proteins were grouped based on function and localization suggesting DAO 
presence within the active zone potentially interacting with BSN.  The focus of 
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the next chapter will be on elaboration of the interaction between those two 
proteins. 
 
Table 4.10:  Summary of ATPase/H+ transporting proteins identified by the mass 
spectroscopy from the DAO immunoprecipitation experiments from adult rat 
cerebellum using both mild and harsh washing conditions.   
 
 
 
 
 
 
 
 
 
 Sample 
Protein PBS Wash RIPA Supplemented Wash 
Name A (IgG) 
B (Peptide 
blocked) 
DAO 
D (Peptide 
blocked) 
DAO 
  Unique Total Unique Total Unique Total Unique Total Unique Total 
ATP6V0A1 1 1 2 2 17 51 0 0 0 0 
ATP6V1A 2 2 0 0 15 18 2 2 1 1 
ATP6V1B2 1 1 0 0 13 15 4 4 4 4 
ATP6V0D1 2 2 2 2 11 23 1 1 1 1 
ATP50 5 5 5 5 11 15 5 8 6 9 
ATP6V1E1 2 3 1 1 8 10 2 2 5 5 
ATP6V1C1 0 0 0 0 8 9 0 0 0 0 
ATP5H 2 2 0 0 7 11 2 2 3 7 
ATP6V1H 0 0 1 1 6 8 0 0 1 1 
ATP5L 2 4 3 3 5 6 0 0 4 5 
ATP12A 0 0 0 0 3 5 2 7 1 9 
ATP4A 1 2 1 1 3 5 1 5 1 2 
ATP5I 0 0 2 2 3 4 0 0 0 0 
ATP6V1E2 0 0 0 0 3 3 0 0 0 0 
ATP5J2 1 1 1 1 2 3 1 2 2 2 
ATP6V0C 1 1 0 0 2 5 0 0 0 0 
ATPF8 0 0 0 0 2 3 0 0 1 1 
ATP5C1 1 1 1 1 2 3 1 1 1 1 
ATP12A 1 1 0 0 2 2 1 1 1 1 
ATP6V1D 0 0 0 0 2 2 0 0 0 0 
ATP6AP1 0 0 0 0 2 2 0 0 0 0 
ATP6AP2 0 0 0 0 1 1 0 0 0 0 
ATP6V0D2 0 0 0 0 1 1 0 0 0 0 
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5. The Synapse 
5.1  Introduction 
 The synapses of the central nervous system are contact points between 
neurons where messages are relayed from the presynaptic axon across the 
synaptic cleft to the postsynaptic dendrites.  At the synapse, an electrical signal is 
converted into a chemical message through release of neurotransmitters from 
synaptic vesicles which cross the synaptic cleft and induce an electrical signal on 
the postsynaptic end through neurotransmitter receptors (Specht and Triller, 
2008).  Both the presynaptic and the postsynaptic plasma membranes at the 
synaptic junctions are characterized by electron-dense meshworks of proteins.  
The cytoskeletal protein matrix on the presynaptic side is called the „cytometrix 
assembled at the active zones‟ (CAZ) (Garner et al., 2000).  The CAZ is a 
specialized region where synaptic vesicles are anchored and primed prior to the 
membrane fusion and neurotransmitter release (Owald and Sigrist, 2009).  This 
region is composed of dense network of filaments which extend out from the 
presynaptic membrane into the cytoplasm (Figure 5.1).  The CAZ is thought of as 
a “core scaffold” for the presynaptic, cytosolic and membranous protein 
constituents as it is especially resistant to extraction procedures (Schoch and 
Gundelfinger, 2006).  Despite the apparent stability of the CAZ many of its 
members including bassoon were found to be more fluid and “jump” between 
neighboring active zones (Kalla et al., 2006; Tsuriel et al., 2009).  Five protein 
families have been found to be highly enriched in the active zone including 
Munc13s, which are essential for neurotransmitter release (Betz et al., 2001; 
Varoqueaux et al., 2002), scaffolding proteins including RIMs (Schoch et al., 
2002; Wang et al., 2000), and ELKS (Takao-Rikitsu et al., 2004), liprin- and 
BSN and PCLO (Schoch and Gundelfinger, 2006).  BSN and PCLO are large 
proteins (>400 kDa) and play a major role in the organization of the CAZ likely 
as scaffolding elements (Fenster et al., 2000; tom Dieck et al., 1998).  Many of 
these and other proteins have been shown to physically associate in the active 
zone.  For example, Munc13 has been shown to interact with RIM (Betz et al., 
2001) while BSN and PCLO interact with ELKS (Takao-Rikitsu et al., 2004).   
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 The presynaptic components are transported from the trans-Golgi to the 
designated axonal regions through specialized vesicular organelles that contain at 
least two classes of transport vesicle (Goldstein et al., 2008).  The PCLO-BSN 
transport vesicles are dense-core 80 nm vesicles which were shown to carry the 
two large proteins into the nascent synapses (Zhai et al., 2001).  The synaptic 
vesicle precursors are more heterogeneous and carry other synaptic proteins (Jin 
and Garner, 2008).  The presynaptic proteins have been shown to be preassembled 
in the transport vesicles thus a functional synapse can be formed within minutes 
upon fusion of the vesicles in the axon.    
 
Figure 5.1: An electron micrograph image of the synapse.  The presynaptic 
terminus is marked by the presence of synaptic vesicles in the central part of the 
image (labeled with a green arrow).  The synapse is between the dark stained 
region which represents the pre and post synaptic density (labeled with the red 
arrow).    Taken from Siksou (Siksou et al., 2007) 
 
 
 
5.2 Bassoon 
 In an effort to determine the bassoon region responsible for synaptic 
targeting GFP-tagged BSN truncation mutants were generated based on functional 
domains (Dresbach et al., 2003).  Intact full-length BSN C-terminally labeled with 
GFP was targeted to the axonal synapses where it was incorporated into the 
cytoplasmic active zone.  When transiently transfected in cultured hippocampal 
neurons 72% of the BSN-GFP co-localized with PCLO.  This construct, however, 
generated diffuse fluorescence in dendrites and nuclei which corresponded to a 
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GFP cleavage product. A BSN construct lacking the first 94 amino acids had the 
same presynaptic targeting properties as the full length protein but lacked the 
diffuse GFP cleavage product.  Subsequent deletion constructs showed that 
neither the N-terminus (1691 amino acids) nor the C-terminus (675 amino acids) 
of BSN were required for presynaptic targeting.  The central portion of BSN 
containing amino acids 1692-3263 was targeted to the presynapse and retained by 
the active zone (Dresbach et al., 2003).  This finding is consistent with data 
obtained from bassoon transgenic mice lacking amino acids 505-2889 in which 
BSN was absent from the synapse (Altrock et al., 2003). 
 The N-terminal BSN construct, consisting of the first 609 amino acids, 
expression resembled synaptic vesicle clusters in shape and size suggesting that it 
may be involved in binding of synaptic organelles such as synaptic vesicles 
(Dresbach et al., 2003).  This observation is consistent with previous studies 
where bassoon was found to be associated with synaptophysin-positive vesicles in 
a synaptic vesicle preparation (Sanmarti-Vila et al., 2000).  The two double zinc 
finger domains found within the first 609 amino acids of bassoon are most likely 
to mediate the interaction with synaptic vesicles as was shown to be the case with 
zinc fingers of PCLO binding PRa-1 (Fenster et al., 2000) and resulting in an 
interaction with synaptic vesicles.  The functional domains of BSN are outlined in 
Figure 5.2. 
 The BSN functional knockout (Bsn Ex4/5) mice were found to have 
significantly reduced concentration of N-acetyl aspartate and glutamine in the 
cortex and hippocampus but not cerebellum.  N-acetyl aspartate is a neuron 
specific metabolite and its reduced concentration is indicative of a decreased 
neuronal population in the cortex of these mice (Angenstein et al., 2008).  It is 
interesting that no apparent changes were found in the cerebellum since BSN was 
found to be widely expressed in the brain (Richter et al., 1999). 
 The active zone precursor vesicle hypothesis suggests that the active zone 
proteins are preassembled at the Golgi apparatus from where they are shipped as a 
complex to form presynapses (Ziv and Garner, 2004).  This hypothesis is 
consistent with observations of an intact Golgi apparatus as necessary for delivery 
of BSN and PCLO to nascent synapses (Dresbach et al., 2006). 
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Figure 5.2: Functional domains of BSN and their published expression and 
localization in transiently transfected rat hippocampal neurons.  Taken from 
Dresbach (Dresbach et al., 2003). 
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5.3  Co-immunoprecipitation of BSN with DAO from rat cerebellum 
 Bassoon was found to be one of the strongest, most specific, and 
consistent interacting proteins in the two DAO immunoprecipitation experiments.  
An interaction of the two proteins implies DAO presence in the presynaptic active 
zone where BSN has been shown to be exclusively localized (Richter et al., 
1999).  However, in the past DAO has been thought of as a peroxisomal enzyme 
(Usuda et al., 1986).  Consistent with localization at the cellular periphery recent 
immunohistological examination of DAO in the cortex and cerebellum of human 
brains showed a pericellular DAO distribution (Verrall et al., 2007).  This novel 
observation suggests DAO presence outside of the peroxisome and fits with our 
immunoprecipitation data suggested by interaction with non-peroxisome 
complexes.  Consequently we chose to focus on these two proteins and study the 
likelihood of their interaction in vivo and the implications of such interactions. 
 Initial experiments to understand the DAO and BSN interaction were 
conducted from rat adult cerebellum lysate where the DAO antibody was used to 
immunoprecipitate DAO and the resulting isolated proteins were separated by 
SDS-PAGE and probed with an anti-BSN antibody (Figure 5.3).  
Immunoprecipitation with both DAO antibody and BSN antibody successfully 
pulled down BSN from adult rat cerebellum reinforcing the mass spectroscopy 
study and showed that the BSN antibody was capable of self 
immunoprecipitation.  The immunoprecipitation was blocked by DAO blocking 
peptide.  The reciprocal of this experiment where the BSN antibody was used to 
pull down BSN from the rat cerebellar lysate and the SDS-PAGE gel containing 
the respective precipitate was probed with the DAO antibody (Figure 5.3) was 
successful as well.  Immunoprecipitation with BSN antibody but not mouse IgG 
resulted in the co-immunoprecipitation of DAO confirming a physical interaction 
between the two proteins in rat cerebellar lysate.  This data was encouraging 
because both DAO and BSN antibodies were able to immunoprecipitate their 
respective target proteins and retain the interacting proteins as well.  These data 
suggest that this apparent interaction was specific and not due to antibody 
reactivity with non-specific protein and that the observed co-immunoprecipitation 
results were instead due to a physical interaction of the two proteins. 
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Figure 5.3:  Co-immunoprecipitation of BSN with DAO antibody from rat 
cerebellar lysate. A) Immunoprecipitation with both DAO antibody and BSN 
antibody but not their respective negative controls successfully pulled down BSN 
from rat cerebellum reinforcing the mass spectroscopy study and showing that the 
BSN antibody was capable of self immunoprecipitation.  B) DAO was 
immunoprecipitated with the DAO antibody and co-immunoprecipitated with 
BSN antibody but not with either of the two negative controls.   
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5.4 Does BSN serve as a scaffold for DAO, ASC-1 and SRR? 
 The identification of an interaction between DAO and BSN suggested that 
BSN, given its size, may act as a scaffolding protein for DAO, ASC-1 and SRR to 
interact and modulate D-serine concentration.  This suggestion is possible since 
ASC-1 has been localized to cerebellar neurons and the synapse specifically 
(Matsuo et al., 2004).  Likewise, SRR has been primarily localized in neurons 
(Takayasu et al., 2008; Yoshikawa et al., 2007).  Hence, rat cerebellar lysates 
were immunoprecipitated with the BSN antibody and the immunoprecipitates 
were probed with ASC-1 and SRR antibodies (Figure 5.4).  Neither ASC-1 nor 
SRR were found to interact with BSN.   
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Figure 5.4: ASC-1 and SRR do not co-immunoprecipitate with BSN.  
Immunoprecipitates generated from rat cerebellar lysate against bassoon antibody 
were separated on SDS-PAGE gel and probed with BSN, ASC-1 and SRR 
antibodies for evidence of an interaction among the proteins.  Two ASC-1 
antibodies were utilized, both of which detected ASC-1 in the input lysate.  ASC-
1 was found not to co-immunoprecipitate with bassoon.  Similarly robust SRR 
expression in the cerebellar lysate was identified and confirmed to be that of SRR 
through application of SRR peptide which blocked the signal.  However SRR was 
found not to co-immunoprecipitate with bassoon. 
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5.5  Immunohistochemistry localization of BSN and DAO in rat cerebellum 
slices 
 While the co-immunoprecipitation results from the rat cerebellar lysate 
were very encouraging, further evidence that DAO and BSN physically interact in 
vivo and are expressed in the same cerebellar regions was sought.  
Immunohistochemistry with the DAO and BSN antibodies was used to test if the 
two proteins are localized to the same cerebellar cell types.  DAO 
immunofluorescence was found to be primarily localized to the Purkinje cellular 
layer, the granular layer and to a lesser extent to the molecular layer (Figure 5.5 
A).  The signal generated with the DAO antibody was completely blocked by 
preabsorbing the antibody with the peptide towards which it was generated 
suggesting that the staining identified with the antibody is that of DAO (Figure 
5.5 B).  Rat spleen does not express DAO (Figure 3.5) hence rat spleen slices 
were generated and examined with the DAO antibody as an additional negative 
control.  The spleen did not display any more immunofluorescence with the DAO 
antibody than it did with the secondary antibody only (Figure 5.5 C and D) further 
suggesting DAO antibody selectively recognized DAO.  Finally, the DAO 
immunofluorescence data was consistent with published immunostaining in the 
rat cerebellum (Moreno et al., 1999) but differed in respect to Purkinje cell 
staining from human cerebellar immunostaining utilizing DAO antibody made 
against the C-terminal end of human DAO (Verrall et al., 2007).  While some 
mRNA was detected in human Purkinje cells no DAO protein was found (Verrall 
et al., 2007).  This discrepancy may be species dependent.  BSN 
immunofluorescence was primarily localized to the molecular layer and to a lesser 
extent to the granule layer with no staining detected in the Purkinje cellular layer 
(Figure 5.5 E).  A peptide against which BSN was generated was not available so 
no primary antibody was used as a negative control (Figure 5.5 F).  In addition, 
the BSN antibody was previously shown to detect BSN specifically (Tao-Cheng, 
2007).  When the rat cerebellar slices were co-stained with the DAO and the BSN 
antibodies the granule layer emerged as a likely region of co-localization with the 
molecular layer also possible but less likely as little yellow signal was visible 
(Figure 5.5 G). 
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Figure 5.5: Immunofluorescence localization of DAO (red) and BSN (green) in 
rat cerebellar and spleen slices.  DAO was primarily detected in the Purkinje 
cellular layer, the granule layer and to a lesser extent in the molecular layer (A).  
This signal was completely blocked (B) by preabsorption of the antibody with the 
DAO peptide toward which the antibody was generated suggesting a DAO 
specific immunofluorescence.  Rat spleen slices were used because no DAO was 
found in this organ when tested on SDS-PAGE gel.  Lack of DAO signal on the 
rat spleen slices (C) as compared to secondary antibody only (D) further validated 
the purity of the DAO antibody.  BSN was found to be localized to the molecular 
layer and to a lesser extent to the granule layer (E).  BSN peptide was not 
available for antibody quenching but secondary antibody alone did not have any 
background signal (F).  A merged image co-stained with DAO and BSN shows 
that the two proteins may co-localize in the granule layer and/or in the molecular 
layer but not likely in the purkinje cellular layer (G). ML = molecular layer; GR = 
granule layer; PCL = purkinje cell layer 
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5.6  Cerebellar fractionation and localization of DAO in synaptic junction 
membrane fraction 
 While the co-immunoprecipitation and immunofluorescence results from 
the rat cerebellar lysate suggested colocalization of DAO and BSN, further 
evidence was required to prove that the two proteins physically interact in vivo.  
In order to test if the two proteins were found in synaptic junction membrane 
fraction free of peroxisomal markers, a subcellular fractionation experiment 
(schematically outlined in Figure 5.6) was employed.  This approach was adopted 
from Altrock (Altrock et al., 2003) and results in the isolation of neuronal pre and 
post synaptic terminus. 
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Figure 5.6:  Schematic diagram of the fractionation protocol employed to show 
presence of DAO in the synaptic junction membrane fraction without any 
contaminating catalase, a peroxisomal marker.  The green indicates fractions that 
were advanced while the red shows those that were left behind. 
 
 
 
 
 
 
 
 The results of the fractionation are found in Figure 5.7. Each fraction was 
probed for presence of markers of sub-cellular organelles including BSN, PSD-
95, microtubule associated protein 2 (MAP2), DAO and catalase.  BSN and PSD-
95 are known pre and post synaptic markers respectively and were used to verify 
that the final fraction contained the proteins which this procedure is designed to 
purify.  MAP2 is a neuron-specific cytoskeletal protein enriched in dendrites but 
not in the active zone.  MAP2 is also comparable in size to BSN and PSD-95 
making it a particularly suitable negative control.  Catalase is a peroxisomal 
marker used to determine if any of the fractions were free of catalase but still 
contained DAO.  Both BSN and catalase blots were overexposed to better 
illustrate presence or absence of the two proteins in various fractions which are 
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described below.  All of the proteins probed for were found in the starting 
solution from the rat cerebellar lysate (Figure 5.7 lane 1).  During the sequential 
fractionation MAP2 was lost when the synaptosome fraction was isolated (Figure 
5.7 lane 4) but BSN, PSD-95, DAO and catalase were retained.  While no BSN or 
PSD-95 was found in the synaptosomal cytoplasm both DAO and catalase 
positively identified in this fraction (Figure 5.7 lane 5). All four proteins were 
also found in the synaptosomal membranes (Figure 5.7 lane 6) suggesting 
peroxisomal association with this fraction.  When the synaptosomal membranes 
were further fractioned to yield a pure synaptic junction membrane fraction BSN, 
PSD-95 and DAO were retained while catalase was lost.  This finding suggests 
DAO localization outside of the peroxisome and within the synaptic junction 
membrane fraction where it may interact with BSN. 
 
Figure 5.7:  Fractionation of rat cerebellum suggests DAO localization outside of 
the peroxisome and among the synaptic membrane junction proteins.  Three rat 
adult cerebellums were fractioned and analyzed for key proteins presence through 
Western blot.  The fractions examined included S1, S2, P1, synaptosomal fraction 
(SnpF), S3, P3, S4, P4 and synaptic junction membrane proteins (Sjmp).  
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5.7  Immunohistochemistry localization studies in cerebellar granule neurons 
 
 Since mouse DAO cerebellar expression was shown to follow a 
neurodevelopmental pattern with no detectable DAO activity from birth until 3
rd
 
week of age  (Wang and Zhu, 2003) rat cerebellar samples from two week old 
pups were probed for expression of DAO (Figure 5.8).  Postnatal 14 day old pups 
were found to express cerebellar DAO albeit at about a fourth of the amount 
found in adult rat cerebellum.  To follow up on the fractionation studies and 
examine DAO localization in relation to BSN, oil immersion 
immunocytochemistry imaging was utilized with samples from two week old 
cerebellar granule neurons (CGNs) from two week old rat pups.  The DAO 
antibody showed staining within the neuronal processes (Figure 5.9 A) while the 
secondary antibody alone (Figure 5.9 B) and peptide blocked DAO antibody 
(Figure 5.9 B) did not give rise to a meaningful signal. 
 
 
Figure 5.8: Verification of rat cerebellar DAO expression in two week old pups.  
Cerebellar DAO expression was compared between adult (ln1; 15 g) and two 
week old pup (ln2; 30 g) lysates on SDS-PAGE gel.  The pups were found to 
express DAO at about a fourth of the amount found in the adult rat cerebellum.  
This data is consistent with published reports. 
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Figure 5.9: Immunocytochemistry of rat cerebellar granule neurons (CGNs) with 
DAO antibody (A), secondary antibody only (B) and peptide blocked DAO 
antibody (C).  A fluorescent secondary antibody was used for visualization of the 
DAO probed CGN cells.  The DAO immunofluorescence suggests punctuate 
DAO localization within the neuronal processes. 
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 Antibodies against synaptophysin, a synaptic vesicle protein uniquely 
expressed at the synapse, were used in conjunction with DAO antibody to help 
determine DAO localization in relation to the synapses in CGNs and to compare 
with those of DAO and BSN.  In the merged and enlarged image (Figure 5.10) 
DAO appears in close proximity to synaptophysin but not overlapping as would 
be implied by yellow spots.  The lack of DAO co-localization with synaptophysin 
is consistent with the mass spectroscopy data as synaptophysin was not one of the 
putative DAO interacting proteins. However, these data suggest DAO presence 
within the synapse because the red fluorescence signal associated with the DAO is 
found within the neuronal processes. 
 
Figure 5.10:  Cerebellar granule neurons (CGNs) were cultured for two weeks 
before they were fixed with paraformaldehyde and used for 
immunocytochemistry.  In the merged image, DAO and synaptophysin, a synaptic 
marker, were found in a proximity to each other but not co-localizing as 
determined by lack of yellow spots.  This lack of co-localization is to be expected 
given that synaptophysin was not one of the DAO interactors.  The fluorescence is 
attributable to the secondary antibody. 
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 Having established initial evidence of the presence of DAO through 
fractionation and immunocytochemistry in neuronal presynaptic terminus we 
were interested if this novel DAO localization overlapped with that of BSN.  
CGNs were probed with DAO and BSN antibodies.  While most of the DAO does 
not appear to overlap with BSN some co-localization between the two proteins 
exists as depicted by the yellow fluorescence (Figure 5.11).  This moderate level 
of the two proteins colocalized suggests that not all BSN need be complexed with 
DAO. 
 
 
Figure 5.11:  Cerebellar granule neurons (CGNs) were cultured for two weeks 
before they were fixed with paraformaldehyde and used for 
immunocytochemistry.  In the merged image, DAO and BSN may be co-
localizing at the synaptic termini as depicted by the yellow spotting indicative of 
the two proteins in a very close proximity to each other. 
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 Unlike paraformaldehyde fixation which immobilizes both soluble and 
attached proteins in place at the time of the fixation, methanol fixation is known 
to wash out soluble proteins (Hoetelmans et al., 2001).  The methanol fixation 
was shown not to wash out DAO from the presynaptic terminus (Figure 5.12) 
suggesting that DAO is firmly attached in the matrix.  In the merged, zoom-in 
image DAO localization appears to partially co-localize with BSN reinforcing the 
data generated with paraformaldehyde fixation in Figure 5.11. 
  
 
Figure 5.12:  Cerebellar granule neurons (CGNs) were cultured for two weeks 
before they were fixed with ice cold methanol and used for 
immunocytochemistry.  Unlike paraformaldehyde fixation, methanol fixation 
washes away free floating proteins.  With this fixation method DAO continues to 
be present at the synaptic junctions.  In the merged image, DAO and BSN may be 
co-localizing at the synaptic termini as depicted by the yellow spotting indicative 
of the two proteins in a very close proximity to each other. 
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5.8 Immunoprecipitation from Hek293 cells 
 Hek293 cells were derived from human embryonic kidney cells hence they 
are unlikely to express the five members of the CAZ described in section 5.1.  
Consequently this immortalized cell line provides means of ascertaining a direct 
interaction between DAO and BSN when both proteins are co-transfected.  The 
proposed direct interaction hypothesis is valid at least when the CAZ members are 
taken into account but other common proteins found in both cerebellar neurons 
and Hek293 cells may still be responsible for facilitating the interaction between 
the two proteins and cannot be ruled out as irrelevant to the described interaction.  
A GFP-tagged BSN construct (kind gift from Dr. Gundelfinger, Germany) 
encoding BSN amino acids 95 through 3963 was transiently transfected into 
rDAO Hek293 stable line.  The resulting lysate was shown to express the BSN 
fusion protein with an expected molecular weight of 397 kDa (Figure 5.13 A lane 
2) and resulted in immunoprecipitation with the GFP antibody (Figure 5.13 A 
lane 4) but not with mouse IgG (Figure 5.13 A lane 3).  The same samples were 
shown to co-immunoprecipitate DAO with the GFP-BSN construct (Figure 5.13 
B).  DAO and BSN were shown to co-localize through immunocytochemistry in 
the Hek293 cells overexpressing both proteins suggesting that the proteins 
associate in these cells (Figure 5.14).     
Truncation mutants of BSN were generated to identify the region 
responsible for the interaction.  All of the BSN truncation mutants contain N-
terminal GFP tag and include amino acids 95-609, 95-3263, 1692-3263, 2715-
3263 and 3263-3963 (for reference see Figure 5.2).  While the zinc finger domain 
containing 95-609 BSN amino acids was well expressed and immunoprecipitated 
by GFP antibody it did not co-immunoprecipitate with DAO (Figure 5.15).  The 
predicted coiled-coiled regions found in construct 95-3263 may play a role in the 
interaction with DAO as this BSN truncation mutant was able to co-
immunoprecipitate DAO from rDAO Hek293 lysate (Figure 5.16).  Construct 
1692-3263, containing two of the three coiled-coiled regions was also able to co-
immunoprecipitate DAO from the rDAO Hek293 stable line (Figure 5.17) as well 
as construct 2715-3263 containing a single predicted coiled-coiled region (Figure 
5.18).  The final 3263-3963 amino acids construct characterized by a long 
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glutamine chain did not express in rDAO Hek293 stable line (Figure 5.19) so we 
can not conclusively rule out whether this region is important for BSN-DAO 
interaction.  We were however able to identify 2715-3263 BSN polypeptide as an 
important potential interaction site with DAO. 
 
5.9 Functional effect of rBSN on rDAO enzymatic activity 
 The rDAO Hek293 stable line was used to ascertain if transiently 
transfected full length and truncation mutants of GFP-rBSN had any effect on 
DAO‟s functional activity.  About 30% inhibition of DAO‟s enzymatic activity 
was observed with the full length BSN, 95-3263, 1692-3263, and 2715-3263 but 
not with BSN 95-609 as compared to GFP only transiently tranfected cells after 3 
days post transfection (Figure 5.20).  This data suggests that BSN may regulate 
DAO‟s enzymatic activity within the presynaptic active zone. 
 
5.10 Conclusions 
 Following up on the mass spectroscopy results, BSN was confirmed to 
interact with DAO in rat cerebellar lysate through co-IP.  The DAO antibody 
pulled-down BSN along with DAO and likewise the BSN antibody pulled-down 
DAO with BSN.  Through a fractionation experiment of rat cerebellum DAO was 
found in the synaptic junction membrane fraction which contained BSN but no 
catalase suggesting that DAO may be found in the presynaptic terminus outside of 
the peroxisome where it may interact with BSN in vivo.  Immunocytochemistry of 
CGNs confirmed the likely localization of DAO in neuronal processes co-
localizing with BSN.  In rat cerebellar slices DAO may be co-localizing with BSN 
in the granule and molecular layer as determined by immunohistochemistry.  BSN 
was co-immunoprecipitated with DAO from Hek293 cells overexpressing both 
proteins suggesting that the two may directly interact as none of the other 
members of the presynaptic active zone are expressed in the Hek293 cells (Figure 
5.21).  Within the DAO Hek293 cells overexpression of BSN was found to inhibit 
DAO‟s enzymatic activity.  Furthermore BSN region spanning amino acids 2715-
3263 representing predicted single coiled coiled region was found to co-IP with 
DAO when both were overexpressed in Hek293 cells.   
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Figure 5.13: Immunoprecipitation of full-length bassoon from rDAO stable line 
transiently transfected with rat GFP-BSN construct and probed with GFP 
antibody (A) and DAO antibody (B).  The bassoon fusion construct was 
successfully transfected into rDAO Hek293 cell line as evidenced by the presence 
of expected 397 kDa band in GFP-bassoon transiently transfected rDAO Hek293 
cells (A, lane 2) but not in mock transfected rDAO Hek293 cells (A, lane 1).  The 
GFP antibody was able to immunoprecipitate the fusion construct as evidenced by 
the presence of BSN (A, lane 4) but absence in mouse IgG immunoprecipitation 
(A, lane 3).  DAO was found to co-immunoprecipitate along with BSN (B, lane 4) 
but not with mouse IgG (B, lane 3).  The expected GFP-BSN truncated protein 
molecular weight on the SDS-PAGE gel is indicated by the arrow.   
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Figure 5.14: Co-localization of DAO and BSN through immunocytochemistry in 
Hek293 cells.  When both proteins were overexpressed in Hek293 cells they 
displayed a level of co-localization and proximal localization along the cell 
membrane (C).  While BSN was found primarily along the cell membrane (B), 
DAO was found along the membrane and in the cytoplasm (A). 
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Figure 5.15: Immunoprecipitation of BSN from rDAO stable line transiently 
transfected with rat GFP-BSN 95-609 construct and probed with GFP antibody 
(A) and DAO antibody (B).  The BSN fusion construct was successfully 
transfected into rDAO Hek293 cell line as evidenced by the presence of expected 
92 kDa band in GFP-BSN transiently transfected rDAO Hek293 cells (A, lane 1).  
The GFP antibody was able to specifically immunoprecipitate the GFP-BSN 
fusion construct as shown by the presence of BSN (A, lane 3) but absence in 
mouse IgG immunoprecipitation (A, lane 2).  DAO was found not to co-
immunoprecipitate along with BSN (B, lane 3) or with mouse IgG (B, lane 3).  
The expected GFP-BSN truncated protein molecular weight on the SDS-PAGE 
gel is indicated by the arrow.   
 
 
 
 
 
 
 
 
 
 
 
 
 
                  1           2           3                      1            2           3 
Legend:  
Ln 1: Input lysate 1/10
th
 volume 
Ln 2: Mouse IgG immunoprecipitation 
Ln 3: GFP immunoprecipitation 
 
A B 
MW 
 
191 
 
 
97 
 
 
 
64 
 
 
51 
 
 
39 
 
 
28 
 
 
17 
 
MW 
 
191 
 
 
97 
 
 
 
64 
 
 
51 
 
 
39 
 
 
28 
 
 
17 
 
BSN 
DAO 
 143 
Figure 5.16: Immunoprecipitation of BSN from rDAO stable line transiently 
transfected with rat GFP-BSN 95-3263 construct and probed with GFP antibody 
(A) and DAO antibody (B).  The BSN fusion construct was successfully 
transfected into rDAO Hek293 cell line as evidenced by the presence of expected 
377 kDa band in GFP-BSN transiently transfected rDAO Hek293 cells (A, lane 
1).  The GFP antibody was able to immunoprecipitate the fusion construct as 
evidenced by the presence of BSN (A, lane 3) but absence in mouse IgG 
immunoprecipitation (A, lane 2).  DAO was found to co-immunoprecipitate along 
with BSN (B, lane 3) but not with mouse IgG (B, lane 2).  The expected GFP-
BSN truncated protein molecular weight on the SDS-PAGE gel is indicated by the 
arrow.   
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Figure 5.17: Immunoprecipitation of BSN from rDAO stable line transiently 
transfected with rat GFP-BSN 1692-3263 construct and probed with GFP 
antibody (A) and DAO antibody (B).  The BSN fusion construct was successfully 
transfected into rDAO Hek293 cell line as evidenced by the presence of expected 
204 kDa band in GFP-BSN transiently transfected rDAO Hek293 cells (A, lane 
1).  The GFP antibody was able to immunoprecipitate the fusion construct as 
evidenced by the presence of BSN (A, lane 3) but absence in mouse IgG 
immunoprecipitation (A, lane 2).  DAO was found to co-immunoprecipitate along 
with BSN (B, lane 3) but not with mouse IgG (B, lane 2).  The expected GFP-
BSN truncated protein molecular weight on the SDS-PAGE gel is indicated by the 
arrow.   
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Figure 5.18: Immunoprecipitation of BSN from rDAO stable line transiently 
transfected with rat GFP-BSN 2715-3263 construct and probed with GFP 
antibody (A) and DAO antibody (B).  The BSN fusion construct was successfully 
transfected into rDAO Hek293 cell line as evidenced by the presence of expected 
64 kDa band in GFP-BSN transiently transfected rDAO Hek293 cells (A, lane 1).  
The GFP antibody was able to immunoprecipitate the fusion construct as 
evidenced by the presence of BSN (A, lane 3) but absence in mouse IgG 
immunoprecipitation (A, lane 2).  DAO was found to co-immunoprecipitate along 
with BSN (B, lane 3) but not with mouse IgG (B, lane 2).  The expected GFP-
BSN truncated protein molecular weight on the SDS-PAGE gel is indicated by the 
arrow.   
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Figure 5.19: Immunoprecipitation of BSN from rDAO stable line transiently 
transfected with rat GFP-BSN 3263-3963 construct and probed with GFP 
antibody (A) and DAO antibody (B).  The BSN fusion construct was found not to 
express as evidenced by lack of presence of expected 111 kDa band in GFP-BSN 
transiently transfected rDAO Hek293 cells (A, lane 1).  Blot B was probed with 
DAO antibody.   
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Ln 1: Input lysate 1/10
th
 volume 
Ln 2: Mouse IgG immunoprecipitation 
Ln 3: GFP immunoprecipitation 
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Figure 5.20: Transiently transfected GFP-BSN inhibits DAO‟s enzymatic activity 
as measured by the AmplexRed assay.  Transiently transfected full length GFP-
BSN (95-3963), 1692-3263 BSN, and 2715-3263 BSN partially inhibited DAO‟s 
acitivity in relation to GPF only and 95-609 BSN. 
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Figure 5.21: No evidence of BSN, PCLO or Liprin- -3 expression in Hek293 
cell lysate.  SDS-PAGE gel containing Hek293 and rat cerebellar lysates was 
probed for presence of the above mentioned presynaptic active zone proteins with 
respective antibodies.  Anti-actin antibody was used to show equal protein 
concentration in the two samples.   
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Legend: 
Ln 1: 20 g rat cerebellar lysate 
Ln 2: 20 g Hek293 lysate  
* * * 
* P < 0.01 as compared to the GFP control based on One-way  ANOVA according 
to Dunnett‟s method. 
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6.  Yeast-two-hybrid screen for identification of DAO interacting proteins 
from human fetal brain 
 
6.1 Introduction 
 Yeast-two-hybrid (Y2H) is a high-throughput technique used to identify 
protein-protein interactions (Young, 1998).  As summarized in Table 4.1 and 
illustrated in Figure 6.1, this molecular biology tool relies on the observation that 
the GAL4 transcriptional factor may be divided into functional regions, the 
binding domain (BD) and the activating domain (AD), which act coordinately to 
activate reporter gene(s) under control of the GAL upstream activating sequence 
(UAS).  The BD interacts with GAL4 UAS while the activating domain initiates 
transcription (Joung et al., 2000). Neither the AD nor the BD on its own can 
activate the reporter genes but when both are in a close physical proximity they 
form a functional transcriptional factor (Verschure et al., 2006).  Since the AD 
and BD are two separate entities which otherwise do not interact with each other, 
they can be brought together by fusion with proteins that have an affinity for each 
other.  Hence in a yeast-two-hybrid screen, plasmids containing the BD are 
constructed as fusion with known proteins, e.g. DAO, which serves as a “bait” 
protein.  The AD plasmid is engineered with DNA encoding protein fragments 
representing a pool of proteins transcribed from a given organism or tissue which 
represents the “prey” in this instance from human brain.  The AD containing 
fusion protein with an affinity for the BD-DAO fusion protein will allow for the 
AD and BD to come to a close proximity and initiate transcription of reporter 
genes.  The yeast strains utilized in the Y2H screen are genetically modified to 
lack key biosynthetic enzymes essential for amino acids or nucleic acids 
synthesis.  When grown on dropout media, or media lacking the necessary 
nutrients, the strains will not grow unless the transcription factor is functional 
through an interaction of the bait with the prey which promotes expression of 
enzymes need for the biosynthesis of essential nutrients and survival on the drop 
out media.  Y2H is a commonly used technique has been repeatedly and 
successfully used in identifying physiological relevant protein-protein interactors 
(Millar et al., 2005).   
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 While this approach has been successful it has been plagued with 
occasional shortcomings including a high degree of false positives and negatives.  
Amongst the explanations is that the proteins are over expressed which may force 
an interaction which otherwise would not be possible.  Since the proteins are 
expressed as fusion constructs their three dimensional configuration may be 
altered.  Large proteins are unlikely to be expressed at a full length and may be 
represented as fragments resulting in lack of interaction in cases where the protein 
must be intact to form the interacting domain.  Both bait and prey proteins may 
undergo posttranslational modifications in vivo which may not happen in the yeast 
cells altering affinity between proteins.  The proteins may never be expressed in 
the same cell type in vivo or in the same cellular compartment or alternatively 
they may be co-expressed in a certain organelle while they have to be expressed 
in the yeast nucleus to come up as a hit.  All of these factors contribute to false 
positive rates of as much as 50% and necessitate further confirmatory studies and 
independent methodologies such as co-immunoprecipitation to confirm the 
preliminary findings (Deane et al., 2002).  
 
 
Figure 6.1: Schematic diagram of the yeast-two-hybrid principle.  Two proteins, 
the bait and the prey, are separately expressed in yeast as fusion constructs with 
the BD and the AD respectively.  In an event of an interaction between the bait 
and the prey the GAL4 transcriptional factor is reconfigured by virtue of physical 
proximity of the BD and the AD resulting in transcription of reporter gene(s). 
 
 
Taken from Clontech Matchmaker user manual. 
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6.2 The Matchmaker Pretransformed Library 
 A fetal brain library generated through poly-T primer by Clontech 
Laboratories (#638831) was used for the yeast-two-hybrid screen.  The poly-T 
primer is complementary to the poly-A tails found on mRNAs allowing for 
reverse transcription of the mRNA found in the human fetal brain.  The poly-T 
primer generates a library encoding mostly C-terminal fragments of proteins 
especially in case of large proteins.  Through application of this approach we 
would be highly unlikely to identify large DAO interactors or those that may be 
interacting at the N-terminus.  The poly-T library was cloned into pACT2 vector 
and transformed into Y187 MAT  yeast strain.  Human DAO lacking the 
peroxisomal targeting sequence was cloned into pGBKT7 vector and transformed 
into AH109 MATa strain (Figure 6.2).  The yeast strains used in this screen were 
genetically engineered to lack capabilities of synthesizing adenine (Ade), histidine 
(His), leucine (Leu), and tryptophan (Trp).  Thus they cannot survive on media 
lacking any one of those nutrients unless they have been transformed with both 
the bait and prey vectors conferring expression of tryptophan and leucine 
biosynthetic enzymes respectively as selectable markers for maintaining the 
presence of the plasmids within the cells and fusion proteins that interact with 
each other conferring transcription of adenine and histidine biosynthetic enzymes.  
When the strains express interacting proteins they also can break down X- -Gal 
through expression of MEL1 and LacZ enzymes transforming otherwise white 
colonies into blue colonies (Figure 6.2).   
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Figure 6.2:  Schematic for the yeast-two-hybrid mating and selection.  The two 
yeast haploid strains, AH109 and Y187, were transformed with pGBKT7-DAO 
and pACT2-library vectors respectively and mated.  The resulting diploids 
expressing proteins conferring interaction with DAO survived on quadruple 
dropout media and turned blue color. 
 
 
Taken from Clontech Matchmaker user manual. 
 
 
This plate is an example of successful mating and a 
robust interaction between the bait and the prey 
resulting in growth of blue colonies. 
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6.3 Yeast-two-hybrid Control Experiments 
 Prior to the Y2H screen the pGBKT7-DAO construct was tested for auto 
activation.  This is a critical experiment in which the bait construct was 
transformed into the AH109 yeast strain and plated out on tryptophan dropout and 
quadruple dropout media.  In our case, the yeast strain transformed with the 
pGBKT7-DAO construct grew on tryptophan dropout media while mock 
transformed yeast did not, confirming successful transformation of cells.  More 
importantly, no colonies were identified on the quadruple dropout medium even 
after seven days post transformation suggesting that the BD-DAO on its own 
cannot activate the transcription of reporter genes. 
 The DAO construct was also tested for toxicity.  Growth rates of 
transformed yeast cells with the pGBKT7-DAO were compared to those 
transformed with the bait vector without DAO.  The number of colonies and the 
colony sizes between the two transformations did not differ when grown on 
tryptophan dropout media suggesting that the DAO bait construct is not toxic to 
the yeast cells.  Through this set of control experiments we determined that DAO 
was a suitable candidate for a Y2H screen. 
 
6.4 DAO Truncation Mutants 
 DAO truncation mutants were generated to assist in identification of the 
DAO interacting site with the yeast-two-hybrid interacting proteins.  An 
interacting site is a polypeptide or a single amino acid within the protein 
responsible for the interaction with the interacting protein.  Identification of an 
interactor with a truncated DAO protein may be used as a confirmation step for 
the Y2H screen and allows for an eventual recognition of the amino acids 
responsible for the physical interaction.  DAO truncation mutants were generated 
through polymerase chain reaction (PCR) of the 5‟ primer and a 3‟ primer 
progressively closer to the 5‟ end.  This resulted in generation of progressively 
shorter DAO fragments in increments of about 50 amino acids for a total of five 
truncation mutants and the full length DAO without the peroxisomal targeting 
sequence (Figure 6.3).  The PCR bands generated during the synthesis of the 
DAO truncation are illustrated in Figure 6.4 while the corresponding Western blot 
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with the fusion protein between DAO and the transcriptional factor binding 
domain are in Figure 6.5.  
 
 
Figure 6.3: Schematic diagram of the DAO truncation mutants.  The DAO 
fragments were synthesized in increments of about 50 amino acids extending out 
from the 5‟ end until the entire protein length was covered.    
 
 
 
 
 
 
Figure 6.4:  DNA fragments generated through PCR during synthesis of DAO 
truncation mutants.  Primers complementary to the 5‟ end and a truncated 3‟ end 
of the DAO sequence were used to synthesize truncated DAO encoding 
constructs.  Sample of the constructs are shown below on ethydium bromide agar 
gel visualized under UV light. 
 
 
 
 
 
1 6 
3’ 5’ 
DAO gene 
 
 
 
      1      2     3     4     5     6 
Legend: 
Ln 1: DAO truncation 1 ~150bp 
Ln 2: DAO truncation 2 ~ 300bp 
Ln 3: DAO truncation 3 ~ 450bp 
Ln 4: DAO truncation 4 ~ 600bp 
Ln 5: DAO truncation 5 ~ 750bp 
Ln 6: Full length DAO ~ 1000bp 
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Figure 6.5:  Western blot showing expression of the truncated DAO fusion 
proteins.  The DAO fragments generated through PCR were cloned into the 
pGBKT7 vector resulting in expression of the DAO fusion proteins of the 
expected molecular weight.  This blot was probed with Gal4 antibody. 
 
 
 
6.5 Results from the Mating Screen 
 A pretransformed human fetal brain library from Clontech (#638831) was 
used to mate with the DAO AH109 yeast cells.  A mating efficiency of 9% was 
obtained between the DAO AH109 and human fetal brain library in 
Y187 yeast.  A total of 1.85 million colonies were screened. One million colonies 
is the minimum recommended by Clontech to screen the entire library.   Sixteen 
colonies were identified, fifteen of which were blue on the quadruple dropout 
media after three to four days post mating.  The prey vectors were extracted, 
amplified and sequenced to identify the interactors.  Yeasts were retransformed 
with the isolated prey vector to test for auto activation and in conjunction with the 
DAO bait vector to verify the initial observations.  None of the sixteen colonies 
displayed auto activation and all of them grew on the quadruple dropout media.   
 Out of the sixteen colonies that grew on the quadruple dropout media, two 
colonies were represented by WW domain binding protein 2 (WBP-2).  The 
remaining fourteen colonies ranged in size from 5 to 153 polypeptides when 
configured in frame with the AD but did not have corresponding protein 
     1     2     3      4      5      6      
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Legend: 
Ln 1: DAO truncation 1 ~ 23kDa 
Ln 2: DAO truncation 2 ~ 28kDa 
Ln 3: DAO truncation 3 ~ 33kDa 
Ln 4: DAO truncation 4 ~ 38kDa 
Ln 5: DAO truncation 5 ~ 43kDa 
Ln 6: Full length DAO ~ 49kDa 
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sequences in the NCBI library.  The two WBP-2 clones identified encoded in-
frame 124 amino acid peptide suggesting that both originated from the same 
colony.  Similarly three 94 amino acid peptides corresponding to an unknown 
protein from a chromosome 1 genomic contig probably originated from the same 
starting colony as each had the exact same sequence.  Eight of the peptides 
without a corresponding NCBI sequence were identifiable proteins in a different 
reading frame from that of the expected based on the prey vector cloning.  
However, since it is unlikely for any of the constructs to be expressed in other 
frame then the expected we did not pursue analysis of the impact of the unknown 
polypeptides on DAO.  None of the clones displayed auto activation on their own 
or when expressed with pGBKT7 vector suggesting that in yeast they formed a 
physical interaction with the DAO protein.     
 
6.6 Characterization of DAO and WBP-2 interaction 
 WBP-2 is a 139 amino acid protein.  Through the yeast-two-hybrid screen 
we identified a 124 amino-acid peptide which represents nearly 90% of the entire 
length of the protein.  There was a perfect homology between the yeast-two-
hybrid protein and that of the expected NCBI WBP-2 sequence (Figure 6.6). 
WBP-2 has been shown to play an important role in activation of progesterone 
receptor and estrogen receptor (Dhananjayan et al., 2006).  It has been shown to 
interact with and activate Pax8, a protein required for morphogenesis of the 
thyroid gland (Nitsch et al., 2004).  WBP-2 has also been shown to interact with 
Yes kinase-associated protein (Sudol et al., 1995). 
 Both WBP-2 fragments identified were tested with the DAO truncation 
mutants to ascertain if any portion of the DAO protein was responsible for the 
physical interaction with WBP-2.  Neither the vector nor the N-terminal 50 amino 
acids of DAO interacted with the WBP-2 fragment as no colonies grew on the 
quadruple dropout media post mating.  However, longer DAO fragments of 100, 
150, 200 and 250 amino acids successfully interacted with the WBP-2 (Figure 
6.7).  This suggests that the portion of DAO responsible for the interaction with 
WBP-2 in yeast cells is between n-terminal 50 and 100 amino acids.  
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Figure 6.6: Alignment of the NCBI WBP-2 amino acid sequence and that of our 
yeast-two-hybrid polypeptide.  WBP-2 is a 139 amino acid long protein which 
was identified as a putative DAO interacting protein based on identification of 
124 interacting polypeptide.  The identified polypeptide has a complete homology 
to the WBP-2 sequence. 
 
 
  
 
 
Figure 6.7: Mapping of the DAO interacting site with WBP-2.  C-terminal DAO 
truncation mutants every 50 amino acids were used to ascertain the DAO region 
responsible for the physical interaction with WBP-2.  Neither the vector nor the n-
terminal 50 amino acid long DAO fragment formed an interaction with WBP-2.  
However, longer DAO fragments of 100, 150, 200 and 250 amino acids 
successfully interacted with the WBP-2.  These data suggest that the DAO region 
responsible for the interaction with WBP-2 is found between n-terminal 50 and 
100 amino acids. 
 
 Vector DAO 1 DAO 2 DAO 3 DAO 4 DAO 5 DAO C 
WBP2 X X Y Y Y Y Y 
WBP2 X X Y Y Y Y Y 
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 Through the Allen Brain Atlas which shows mRNA expression profiles 
we were able to conclude that WBP-2 is likely to be expressed in the cerebellum 
where DAO expression is especially high (Figure 6.8).  This data suggests that the 
two proteins may exist in the same tissue and be relevant interactors in vivo.   
 
Figure 6.8:  The mouse mRNA expression profile of WBP-2 
 
Taken from Allen Brain Atlas. 
 
 
 A FLAG-tagged C-terminal full length human WBP-2 was expressed in 
hDAO stable line to ascertain its effect on the DAO activity.  Increasing amounts 
of the WBP-2 construct ranging from 1 to 100 ng per 50,000 DAO cells in 96-
well plate were transiently transfected but the DAO enzymatic activity remained 
unchanged (Figure 6.9). 
 Expression of the flag-tagged WBP-2 was confirmed in the hDAO 
Hek293 lysate by probing SDS-PAGE gel with a flag antibody.  However, WBP-
2 was not immunoprecipitated with DAO by DAO antibody from the DAO stable 
line lysate over expressing WBP-2 (Figure 6.10). 
 The mass spectroscopy data described in chapter 4 was examined for 
presence of WBP-2.  Interestingly, WBP-2 was found to be co-
immunoprecipitated with DAO by DAO antibody from rat cerebellar lysate when 
the mild wash conditions were utilized (Figure 6.11).  WBP-2 was not identified 
in any of the negative controls or in the DAO immunoprecipitate with the harsh 
washing.  The Y2H and the co-immunoprecipitation screens suggest that WBP-2 
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may be a relevant DAO interacting protein.  However it is likely that WBP-2 a 
very weak DAO interactor or WBP-2 has a very low cerebellar expression profile. 
 
Figure 6.9: Analysis of functional impact of WBP-2 expression on DAO activity.  
Overexpression of WBP-2 in hDAO stable line did not effect the DAO enzymatic 
activity. 
 
 
 
 
 
 
 
 
 
 
Figure 6.10: WBP-2 does not immunoprecipitate with DAO when over expressed 
in the hDAO stable line.  DAO was immunoprecipitated with the DAO antibody 
and probed for the flag-WBP-2 presence.  While WBP-2 was detected with FLAG 
antibody in the input lysate, none was found in the immunprecipitation lanes.  The 
expected molecular weight of WBP-2 is designated with the arrow. 
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Figure 6.11: The mass spectroscopy data suggest that WBP-2 is specifically 
immunoprecipitated with DAO via DAO antibody from rat cerebellar lysate.  
Despite the specificity of WBP-2 to DAO column the single polypeptide 
identified may be a random event, representing a very weak interaction or 
indicative of a low WBP-2 expression. 
 
 Sample 
Protein PBS Wash RIPA Supplemented Wash 
Name A (IgG) 
B (Peptide 
blocked) 
C (DAO) 
D (Peptide 
blocked) 
E (DAO) 
  Unique Total Unique Total Unique Total Unique Total Unique Total 
WBP-2 0 0 0 0 1 1 0 0 0 0 
 
 
6.7 Y2H screening of human adult brain library  
 To complement our Y2H screen of human fetal brain library we 
collaborated with Hybrigenics to perform a Y2H screen on a human adult brain 
library.  A different library was tested to account for DAO developmental 
expression changes described in chapter 1.  While Hybrigenics used the same 
GAL4 screening strategy as we have they used a library synthesized through 
random primers instead of the poly-T primer.  The difference between the two 
libraries is that with a random primer approach potentially a better coverage of the 
library is possible especially with large proteins.  Through the Hybrigenics screen 
four hits were identified.  An important advantage to the Hybrigenics screen is the 
proprietary algorithm used to determine the strength of and likelihood of the 
interaction allowing for a ranking of the hits.  Of the four putative interacting 
proteins, mitochondrial tumor suppressor-1 (MTUS1) was identified as having a 
very high likelihood of interaction, one unidentified protein with a moderate 
likelihood of an interaction and TAF1 and COPS5 with a very low likelihood.  
None of these proteins were identified in either the Y2H fetal brain library screen 
or the rat brain immunoprecipitation. 
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6.8 Conclusions 
 The Matchmaker pretransformed human fetal brain library and 
collaboration with Hybrigenics were successfully used in identification of DAO 
interacting proteins through yeast-two-hybrid screens.  Through these approaches 
twenty colonies on the quadruple dropout media were identified representing 
seventeen putative DAO interacting proteins.  Of the group four corresponded to 
identifiable proteins based on the NCBI alignment matching with a perfect 
homology.  Our confirmatory experiments focused on WBP-2.  The interaction 
between DAO and WBP-2 was characterized through DAO truncation mutants 
suggesting that WBP-2 interacts between amino acid 50 and 100 of DAO protein.  
mRNA expression pattern suggests that WBP-2 may be highly transcribed in the 
cerebellum suggesting that it may be found in the same tissue as DAO.  However, 
WBP-2 was shown not to affect activity of DAO when both proteins were over 
expressed in Hek293 cells.  More importantly, the interaction identified in the 
yeast-two-hybrid did not confirm in co-immunoprecipitation from the over 
expressed Hek293 cell lysates.  Interestingly, WBP-2 was found to be a very 
weak DAO interacting protein through the DAO immunoprecipitation from rat 
cerebellar lysate suggesting that the two proteins may have a weak affinity for 
each other. 
 
6.9 Conclusions and Future Studies 
 I started my doctorate work by focusing on necessary tools for 
identification and characterization of DAO interacting proteins.  As such, one 
specific DAO antibody was generated, purified and validated.  This antibody was 
shown to detect human, rat and mouse DAO on SDS-PAGE gel and to 
immunoprecipitate DAO protein from lysate.  The DAO antibody in conjunction 
with Dynal beads was used to co-immunoprecipitate DAO and its interacting 
proteins from rat cerebellar lysate.  The interacting proteins were then identified 
through mass spectroscopy.  As part of this experiment, two negative controls 
were used, a rabbit IgG and a peptide blocked DAO antibody, to eliminate sticky, 
non-specific proteins from being considered as putative DAO interacators.  
Furthermore, the co-immunoprecipitation was performed with a mild and a harsh 
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washing conditions to identify the strongest DAO interacting proteins.  DAO 
yeast expression constructs were also generated to explore DAO interacting 
proteins through a Y2H methodology.    Additional tools generated for validation 
and characterization of the interacting proteins include purified human DAO 
enzyme, and rat and human DAO stable lines.  Amplex Red assay was found to 
reliably measure DAO‟s activity and was used to ascertain effect of DAO‟s 
interacting proteins on DAO‟s activity. 
Through co-IP and Y2H approaches many putative DAO interacting 
proteins have been identified.  Those interacting proteins represent several 
different groups of proteins suggesting DAO expression outside of the 
traditionally assumed peroxisome region and speculate to explore consequences 
of such an altered expression and potentially alternative DAO functions.  The 
number of interacting proteins identified made it difficult to pursue them all hence 
we focused on WBP-2 and BSN.  WBP-2 was identified in both Y2H and the co-
IP experiments.  The interation between the two proteins was confirmed in Y2H 
and it is likely that WBP-2 interacts between DAO‟s 50th and 100th amino acid.  
However, no functional effects were observed on DAO‟s activity when both 
proteins were over expressed in Hek293 cells.  The DAO antibody did not 
immunoprecipitate WBP-2 from Hek293 lysate over expressing both proteins 
either suggesting that in the context of Hek293 cells there is no relevant 
interaction between the two proteins.  On the other hand, the outcome of co-IPs, 
fractionations, and immunocytochemistry studies suggest that DAO interacts with 
BSN within the presynaptic active zone where its enzymatic activity is modulated 
by BSN.   It is yet unknown what function DAO plays at the presynaptic active 
zone.  If DAO is FAD bound then it is likely to be enzymatically active but this 
has to be explored in future studies as well as any other functions DAO may have 
at the synapse.  Such DAO localization may directly play into modulating 
synaptic D-serine concentration as this neurotransmitter is reabsorbed from the 
synapse by Asc-1 into neurons.  Before D-serine is recycled back into the 
synapses some of it may be degraded by DAO.  However, metabolism of D-serine 
at the CAZ poses a threat of oxidative stress on the synapse due to the hydrogen 
peroxide synthesis.  Hence DAO‟s activity, if unchecked can lead to excessive 
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synaptic pruning.  Does this occur, to what extent, and does it contribute to 
schizophrenia?  Do the interacting proteins represent dirct interactors and if so are 
those interactions true for other species than rat DAO?  The DAO KO mice 
represent a tool to start addressing these questions in the future. 
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Chapter 7: Discussion 
 
7.1: Dynein: a potential DAO interacting protein 
We used Spotfire software designed in-house by Andrew Hill to cluster 
the putative DAO interacting proteins resulting in the main six groups described 
in sections 4.6.1 through 4.6.6.  In addition to these six clusters, individual 
proteins such as the heavy and light chains of dynein have been identified in the 
co-immunoprecipitation experiments with the DAO antibody utilizing both PBS 
and modified RIPA buffer washes (Table 4.2).  The robust retention of dynein 
polypeptide chains by the DAO antibody, which was abrogated by immunogenic 
peptide and absent in non-immune IgG control experiments (Table 4.2), suggests 
a potential interaction between DAO and dynein.  Nevertheless, we did not pursue 
this finding because we were interested in the novelty posed by presynaptic active 
zone proteins in the context of DAO localization.  However, DAO transport to the 
CAZ may be explained by an interaction with dynein.  Since dynein is a motor 
protein that uses ATP-derived energy for transport of intracellular cargo from the 
cell center to the periphery (Mallik et al., 2004; Reck-Peterson et al., 2006; Vallee 
et al., 2004), a DAO interaction with dynein may be relevant for DAO movement 
from the cytoplasm into the CAZ.   
 
7.2: Discrepancies with published literature 
 As depicted in Figure 5.5, DAO immunofluorescence in the rat cerebellar 
sections appears to be concentrated to the Purkinje cells of the Purkinje cell layer.  
This observation is further supported by DAO specific immunofluorescence in the 
molecular layer originating from Purkinje cell dendrites.  It is unlikely that the 
immunofluorescence attributable to the Purkinje cells stems from other cells that 
may be either synapsing upon or in a close proximity to the Purkinje cells.  Our 
findings are supported by a published report showing DAO immunoreactivity in 
Purkinje cells (Moreno et al., 1999) but the DAO antibody used in this study was 
later shown to cross-react with D-aspartate oxidase (Shleper et al., 2005) 
suggesting that the Purkinje cell immunoreactivity may not be specific to DAO 
itself.  In contrast to our findings, other reports, examining mRNA and protein 
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DAO expression in human and rat, reported a distinct lack of DAO presence in 
the Purkinje cells (Ono et al., 2009; Verrall et al., 2007).  Furthermore, we failed 
to show DAO immunoreactivity in Bergmann glia, which was reported earlier 
(Ono et al., 2009; Verrall et al., 2007).  To understand this apparent discrepancy 
we could examine DAO expression through the avidin-biotin-peroxidase 
technique using the Vectastain Elite ABC kit (Vector Labs, Burlingame, CA), as 
in aforementioned published reports, instead of the immunofluorescence.  
Alternatively, we could test for DAO mRNA expression in the Purkinje cells 
through in situ hybridization.  We chose to do the former.  When the same tissue 
used for immunofluorescence was instead visualized with the avidin-biotin-
peroxidase, DAO immunoreactivity was much more consistent with that of the 
above mentioned reports (Figure 7.1).  Specifically, we no longer observed 
Purkinje cell staining but did see predominant Purkinje cell layer 
immunoreactivity likely to be that of Bergmann glia as depicted by the small 
round cells.  In addition we observed moderate staining of small round cells in the 
molecular layer.   
It is hard to reconcile this noticeable difference between the 
immunofluorescence and avidin-biotin-peroxidase immunoreactivity as the only 
difference between the two experiments was the secondary antibody and the 
visualization method.  In each instance the secondary antibody was shown not to 
have any signal of its own suggesting that the observed difference is not due to 
the secondary antibody.   
 The DAO expression utilizing the avidin-biotin-peroxidase visualization 
do not preclude it from co-localization with BSN as rat cerebellar slices also 
displayed immunoreactivity to small round cells in the Purkinje cell layer and the 
molecular layer (Figure 7.1).  However, this method does not allow for co-
staining with both antibodies so we cannot be completely sure of their co-
localization. 
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Figure 7.1:  DAO and BSN immunoreactivity in rat cerebellar slices.  When the 
rat cerebellar slices were prepared in the exact same way as for the 
immunofluorescence but visualized using avidin-biotin-peroxidase technique the 
DAO was mainly shown to localize to small cells likely to be Bergmann glia 
within the Purkinje cell layer but not to the Purkinje cells themselves and 
modestly to small round cells in the molecular layer (A).  This immunoreactivity 
was abolished when rabbit IgG was used instead of the DAO antibody (B).  A 
zoom in of DAO stained image (C) clearly shows immunoreactivity of small 
round cells surrounding the Purkinje cell (*).  BSN immunoreactivity also was 
found in small round cells of the Purkinje cell layer, small round cells of the 
molecular layer and modestly to the Purkinje cells and small round cells in the 
granule layer (D).  No immunoreactivity was observed when a mouse IgG was 
used instead of BSN antibody (E).   
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7.3:  Additional imaging studies 
 In the past, substantial discrepancies have emerged with respect to DAO 
localization on regional, cellular and subcellular levels (described earlier and 
review in (Verrall et al., 2010).   As depicted in this thesis the detection method 
utilizing the same antibody may result in a different outcome.  To build 
confidence in DAO localization it would be ideal to probe for DAO with multiple 
DAO antibodies generated against different regions of the DAO polypeptide.  
Also, an Electron microscopy imaging of the rat cerebellum may more definitely 
pinpoint DAO localization and address its likely presynaptic localization. In 
particular, Electron microscopy immunogold would allow us to pinpoint the 
subcellular localization, cell types, and address co-localization with BSN. 
 
7.4: Thesis summary 
Through a co-immunoprecipitation and mass spectrometry approach we 
have identified twenty-four putative DAO interacting proteins from rat 
cerebellum (Table 4.3).  Many of the proteins, including BSN, PCLO, SNIP, 
ERC1, and RAPGEF4 are enriched in the presynaptic active zone (Chin et al., 
2000; Dresbach et al., 2003; Li et al., 2006; Wang et al., 1999; Wang et al., 2002) 
suggesting an alternative subcellular localization for DAO to that of the widely 
accepted astrocytic, peroxisome bound DAO (Cristiano et al., 2001; Usuda et al., 
ml = molecular layer, pcl = Purkinje cell layer; gr = granule layer; * = Purkinje cell 
D                                                                 E 
ml ml 
pcl pcl 
gr 
gr 
 
 167 
1986; Wanders and Waterham, 2006).  Our findings are supported by recent 
observations of DAO expression 1) in neurons, as exemplified by reports of DAO 
expression in Golgi and Purkinje cells of the rat cerebellum (Moreno et al., 1999) 
and pyramidal neurons of human hippocampus and cerebral cortex (Verrall et al., 
2007); 2) in the extra-peroxisomal space, as exemplified by a pericellular 
distribution of DAO in human brain combined with the lack of an overlap 
between DAO and peroxisomal markers in human astrocyte cultures (Sacchi et 
al., 2008; Verrall et al., 2007).  Thus, since published reports hint at DAO 
localization outside of the peroxisome, we explored an alternative localization for 
DAO at the presynaptic active zone by virtue of its interaction with BSN.   
BSN was confirmed to interact with DAO in rat cerebellar detergent 
extracts through co-immunoprecipitation combined with western blotting using 
DAO- and BSN-specific antibodies (Figure 5.3).  Subcellular fractionation studies 
of rat cerebellum showed that DAO is present in the synaptic junction membrane 
fraction which contained BSN but not catalase (Figure 5.7).  This data suggests a 
DAO localization outside of the peroxisome, where DAO was historically 
believed to be localized (De Duve and Baudhuin, 1966).  In light of our 
immunoprecipitation findings, these fractionation data suggest that DAO may be 
found in the presynaptic terminus where it may interact with BSN in vivo.  
Immunocytochemistry of cultured CGNs confirmed the localization of DAO in 
neuronal processes partially colocalizing with BSN (Figures 5.11 and 5.12).   
BSN was co-immunoprecipitated with DAO from HEK293 cells over 
expressing both proteins (Figure 5.13) suggesting that the two may directly 
interact as none of the major members of the presynaptic active zone are 
expressed in the HEK293 cells (Figure 5.21).  The presence of other presynaptic 
active zone proteins in the DAO immunoprecipitate suggests that they may have 
been pulled-down with DAO or indirectly through an interaction with BSN itself 
(Wang et al., 2009).  While the carboxyl terminus of BSN was shown to be 
responsible for an interaction with many of the other presynaptic active zone 
proteins (Wang et al., 2009), the BSN region spanning amino acids 2715-3263, 
representing a predicted single coiled coil domain, was found to co-
immunoprecipitate with DAO when both were over-expressed in HEK293 cells 
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(Figure 5.18).  This data suggests that an interaction of BSN with other members 
of the presynaptic active zone would not be disrupted by a DAO-BSN interaction 
as it involves a different region of BSN. 
The presynaptic cytoskeletal protein matrix, called the „cytometrix 
assembled at the active zones‟ (CAZ) (Garner et al., 2000), is a specialized 
subcellular domain where synaptic vesicles are anchored and primed prior to 
membrane fusion and neurotransmitter release (Owald and Sigrist, 2009).  BSN 
and PCLO play a major role in the organization of the CAZ likely as scaffolding 
elements (Fenster et al., 2000; tom Dieck et al., 1998).  Another member of the 
presynaptic terminus, Asc-1, a D-serine uptake transporter, has a major role in D-
serine clearance from the synapse in forebrain and cerebellum (Fukasawa et al., 
2000; Helboe et al., 2003; Matsuo et al., 2004; Nakauchi et al., 2000; Rutter et al., 
2007; Shao et al., 2009).  The presence of DAO at the CAZ suggests that some of 
the reabsorbed D-serine may be metabolized; further fine-tuning the D-serine 
concentration within the synapse and influencing NMDAR activation.  Our 
findings are important in light of a recent report of D-serine release from neurons 
via a nonvesicular mechanism (Rosenberg et al., 2010), suggesting that this 
nonvesicular pool of D-serine might be readily metabolized by presynaptically-
localized DAO.   
The interaction of DAO with BSN may be especially relevant in the 
forebrain where DAO has been reported to be predominantly expressed in 
neurons (Kapoor et al., 2006; Sacchi et al., 2008; Verrall et al., 2007).  Such 
expression, in conjunction with our observation of an inhibitory effect of BSN on 
the activity of DAO, may in part explain why the enzymatic activity of DAO has 
been consistently undetectable in the forebrain (Neims et al., 1966; Weimar and 
Neims, 1977).  In the hindbrain, however, where DAO is more likely to be 
expressed in glia rather than in neurons, BSN would not be expected to influence 
DAO‟s activity since BSN is not expressed in glia.  In fact, within the brain, DAO 
activity is most robust in hindbrain when compared to all other brain regions 
(Arnold et al., 1979; Horiike et al., 1994; Madeira et al., 2008; Weimar and 
Neims, 1977).  
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A loss of the inhibitory effect of BSN on neuronal DAO activity may also 
explain observations made in BSN functional knockout mice(Altrock et al., 
2003).  These mice express a fragment of BSN that lacks amino acids 505-2889, a 
region that partially overlaps with the DAO binding site identified in the present 
study (Figure 5.18).  Moreover, this BSN fragment only partially partitions 
(between 10 and 30%) with the synaptic protein fraction.  Hippocampal cultures 
derived from these mice have been shown to express twice as many functionally 
silent synapses than wild-type mice (Altrock et al., 2003).  The functional silence 
may be a direct consequence of lack of sufficient NMDAR activation as 
exemplified by reduced LTP in striatal medium spiny neurons of the BSN mutant 
mice (Ghiglieri et al., 2009).  Therefore, in the neuronal hippocampal cultures 
from the BSN functional knockout mice, DAO may still act within the 
presynaptic active zone without the inhibitory effect elicited by BSN.  It is 
tempting to speculate that presynaptic DAO, in the absence of the inhibitory 
influence of BSN, as would be the case in these BSN mutant mice, is functionally 
overactive, metabolizing synaptic D-serine and resulting in NMDAR 
hypoactivity.   
The mechanism underlying the inhibition of DAO enzymatic activity by 
BSN is yet unknown.  Since human DAO catalytic activity has been shown to be 
absent in flavin adenine dinucleotide-unbound DAO (Caldinelli et al., 2009), BSN 
may compete with flavin adenine dinucleotide (FAD) binding rendering DAO 
inactive.  BSN inhibition of presynaptic active zone DAO may be critical to 
maintaining healthy synapses.  Uncontrolled and excessive DAO catalytic activity 
may be cytotoxic through hydrogen peroxide production (Park et al., 2006), 
resulting in excessive synaptic pruning and a reduction of synapses.  However, the 
connection between BSN and these molecular and cellular consequences have yet 
to be experimentally established. 
It is as yet unknown what function DAO plays at the presynaptic active 
zone.  If DAO is FAD-bound, then it is likely to be enzymatically active but must 
be explored directly in future studies.  The metabolism of D-serine by DAO at the 
CAZ poses a threat of oxidative damage to synaptic components due to excessive 
hydrogen peroxide synthesis.  Hence the catalytic activity of DAO, if unchecked, 
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can lead to excessive synaptic pruning as well as other pathological cellular 
consequences.  BSN may be playing an important homeostatic role, inhibiting 
excessive DAO activity at the presynaptic active zone.  Whether this occurs, to 
what extent, and whether it may serve as a contributing factor to NMDAR 
hypofunction are critical questions that need to be addressed. 
 
7.5: Relevance of our findings 
 Synaptic D-serine is critical to NMDAR activity.  Our findings of DAO 
localization at the CAZ, outside of the peroxisome, suggest a direct involvement 
of DAO in modulating how much D-serine is available for synaptic release.  In 
the absence of an inhibitory effect mediated by BSN on DAO, the presynaptic 
DAO activity may excessively metabolize D-serine resulting in a decreased 
concentration of readily releasable D-serine into the synaptic cleft.  This 
decreased level of D-serine, in turn, may contribute to the NMDAR hypofunction 
observed in schizophrenic patients.  Our data suggests that a potent DAO inhibitor 
may at least in part reverse NMDAR hypofunction by increasing synaptic D-
serine concentration. 
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8.  Materials and Methods 
 
8.1  Molecular Biology 
 
8.1.1  Bacterial and yeast strains  
Subcloning and PCR cloning were performed unless otherwise stated using the 
One Shot
R
 MAX Efficiency
R
 DH5
TM – T1R Chemical Competent E. coli 
(Invitrogen; 12297-016).   
 
BL21 (DE3) competent cells were purchased from Stratagene for the purpose of 
generating purified hDAO enzyme. 
 
Saccharomyces cerevisiae host strain Y187 pretransformed with the human fetal 
brain library were purchased from Clontech Laboratories.  For mating and 
subcloning untransfected AH109 (Clontech; 630444) and Y187 yeast strains 
(Clontech; 630457) were used. 
 
8.1.2 Growth media and agar plates 
Luria-Bertani (LB) broth containing 1% tryptone, 0.5% yeast extract and 0.5% 
NaCl (Gibco; 10855) was used to grow all of the bacterial cultures.  For plasmids 
encoding Ampicillin resistance, Ampicillin (amp) (EMD Biosciences; 171254), 
was added to a concentration of 100 g/ml and for Kanamycin resistance, 
Kanamycin (kan) (EMD Biosciences; 420311) was added to a concentration of 50 
g/ml. 
 
Luria-Bertani (LB) agar plates containing antibiotic were purchased from 
Teknova (50 g/ml Ampicillin – L1150-02; 50 g/ml Kanamycin – L1025). 
 
S.O.C medium (2% Tryptone, 0.5% Yeast Extract, 10 mM NaCl, 25 mM KCl, 10 
mM MgCl2, 10 mM MgSO4, 20 mM glucose) was purchased from Invitrogen 
(15544-034). 
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Yeast media purchased from Clontech include YPD (a blend of yeast extract, 
peptone, and dextrose) medium (630409), YPD agar medium (630410), minimal 
synthetically defined (SD) base medium (630411), minimal SD agar base 
(630412), Trp dropout (DO) supplement (630413), Leu DO supplement (630414), 
His DO supplement (630415), Ura DO supplement (630416), Leu/Trp DO 
supplement (630417), His/Leu DO supplement (630418), His/Leu/Trp DO 
supplement (630419) and Ade/His/Leu/Trp DO supplement (630428).   
 
8.1.3 Chemical transformation protocol 
Competent bacterial cells were thawed out on ice and 0.1-1 g (in a total volume 
of 1 l) of plasmid was mixed into 50 l of cell solution in 14 ml Falcon tubes 
(Beckton Dickinson; 352059), incubated on ice for 30 min, heat shocked for 45 
seconds at 42
o
C and cooled on ice for 2 min.  The cells were removed from ice 
bath and mixed with 200 l of S.O.C medium and incubated for 45 min at 37
o
C in 
a shaker at 150 rmp.  The entire solution and 1/10 and 1/100 dilutions there of 
were spread out on selective LB plates for incubation overnight at 37
o
C.  
Individual colonies were selected the following day. 
 
8.1.4 DNA electrophoresis 
See Sambrooke et al (1989) chapter 6 
Briefly, agarose was added 1x TAE (Invitrogen; 15558-042) and melted in a 
microwave oven.  The concentration of agarose used depended on the size of 
fragments to be resolved, on a scale of 0.6% for large fragments (>5kb) up to 
2.5% for small fragmens (<0.5 kb).  Ethydium bromide (BioRad; 161-0433) was 
added to a concentration of 100 ng/ml.  A 6x loading buffer (Promega; 25223001) 
was added to samples prior to loading on the gel.  Samples were run in 1x TAE 
buffer at a constant voltage of 60-130V depending on the gel box size.  DNA was 
visualized by placing the gel on the UV transilluminator. 
 
8.1.5 Ethanol precipitation of DNA 
To concentrate DNA from aqueous solution, 0.1 volume of 3M Sodium Acetate 
pH 5.2 (Rockland; RLMB-041) followed by 2 volumes of 100% ethanol were 
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added, and incubated in -20
o
C for at least 10 min.  For small amounts of DNA, 
such as ligations and preparation of fragments prior to ligation, 1 l of glycogen 
(1mg/ml) was added before the salt and ethanol.  After centrifugation at 13,000 
rpms for 15 min, the pellet was washed with 70% ethanol and dried at room 
temperature for 5 min before it was resuspended in sterile water.  
 
8.1.6 Gel extraction 
The QIAquick Gel Extraction Kit (Qiagen; 28704) was used to extract DNA from 
agar.  Briefly, the DNA sample was run on agarose and the band of interest was 
excised and weighted.  The sample was dissolved in three times its weight in 
buffer QG at 42
o
C before isopropyl alcohol was added at one times the sample 
weight.  The solution was spun down at 13,000 rpm at room temperature for 1 
min in the QIAquick spin column before 500 l of buffer QG was reapplied to the 
filter QIA tubes. The tubes were again spun down at 13,000 rpm for 1 min and the 
DNA containing filter was washed with 750 l of buffer PE spun down for 1 min.  
The residual solution was discarded followed by one more spin.  The sample was 
eluted off with 20 l of sterile water into an eppendorf tube.  
 
8.1.7 PCR purification 
The QIAquick PCR purification kit (Qiagen; 28104) was used to purify PCR 
product from contaminating enzymes and oligos.  Briefly, five volumes of buffer 
PBI were added to one volume of PCR sample.  The mixture was centrifuged for 
1 min at 13,000 rpms in the QIAquick column.  The column was washed with 750 
l of buffer PE and centrifuged at 13,000 rpm for 1 min.  Flow through was 
discarded and the sample was spun down for another minute.  DNA was collected 
by applying 20 l and spinning the sample for 1 min. 
 
8.1.8 Subcloining with TOPO TA and Zero Blunt TOPO 
When cloning, PCR constructs were first cloned into the TOPO TA pCR
R
II-
TOPO
R
 (Invitrogen; K4620-01) or Zero Blunt
R
 TOPO
R
 PCR cloning vector 
(Invitrogen; K2800-20).  The TOPO TA allows for a one-step cloning strategy of 
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Taq polymerase-amplified PCR products into the TOPO vector without ligase 
because the TOPO vector contains topoisomerase facilitating the ligation reaction.  
The Zero Blunt TOPO allows for direct insertion of a blunt-end PCR products 
into the plasmid vector.  Both vectors allowed for a quick and convenient 
selection of plasmid containing cells and growth for a mini-DNA preparation for 
sequencing.  Upon sequencing results, mutation-free clones where digested out of 
the TOPO vector with restriction endonucleases and ligated into expression 
vectors. 
 
The PCR reaction was run on agarose gel and the band of interest was excised 
using gel extraction kit (Qiagen) and resuspended into 20 l of sterile water 
(EMD; 7732-18-5).  For the TOPO reaction, 4 l of the PCR product was mixed 
with 1 l with salt solution (included in the kit) and 1 l of TOPO vector.  The 
mixture was incubated at room temperature for 5 min.  Chemically competent 
bacteria cells were transformed with 1 l of the TOPO solution. 
 
8.1.9 DNA Maxi- and mini-preparations 
For preparation of purified DNA on both small and large scale Qiagen mini 
(27106) and maxi (12662) kits were utilized.  5 ml or 150 ml of bacterial culture 
containing plasmid of choice were grown on selective media overnight for the 
mini or the maxi DNA preparations respectively.  The cells were centrifuged at 
5,000 rpm for 20 min at 4
o
C and the resulting pellets were resuspened in 250 l or 
10 ml of buffer P1.  Cells were lysed with 250 l or 10 ml with buffer P2 for no 
more then 5 min.  The lysis buffer was neutralized with equal volume of buffer 
P3.  For the mini kit the solution was centrifuged at 13,000 rpm for 10 min at 
room temperature to remove genomic DNA and cellular debris.  The solution was 
captured in a filter through a 1 min spin in the provided collection tubes, washed 
with buffer PE and finally eluted off of the filter with 20 l of sterile water.   For 
the maxi kit the resulting solution was passed through a filter to remove genomic 
DNA and cell debris, washed with 60 ml of buffer QC.  The DNA was eluted off 
with 15 ml of buffer QF and precipitated with 10.5 ml of isopropyl alcohol.  This 
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solution was passed through the QIA filter which retained the DNA plasmid.  It 
was washed with 70% ethanol before a final elution into 1 ml of sterile water.  
 
8.1.10 DNA digestion with restriction endonucleases 
All of the restriction endonucleases unless otherwise stated were purchased from 
New England Biosciences. 
 
Approximately, 5-10 g of DNA was digested in a total volume of 25 l with the 
appropriate restriction enzymes and buffer.  Approximately, 2 l or 40 units were 
used per digest carried out at 37
o
C for 2 hrs.  In a double digestion, if the enzymes 
had compatible buffer requirements then both digestions were concurrently run 
otherwise single digestion was prepared.  The resulting fragment was run on 
agarose gel and excised through gel extraction kit before the second digestion 
with another restriction enzyme. 
 
8.1.11 DNA ligation 
All of the ligation reactions were 5 min reactions at room temperature utilizing 
Rapid DNA Ligation kit (Roche; 11635379001).  For the ligation, 7 l of insert 
DNA was mixed with 1 l of the vector DNA and 2 l of DNA dilution buffer.  
An additional 10 l of T4 DNA ligation buffer was added and 1 l of T4 DNA 
ligase.   
 
8.1.12 Polymerase chain reaction (PCR) 
To generate fusion proteins containing either bassoon truncations or the full 
length DAO construct, regions were amplified by the polymerase chain reaction 
(PCR) using primers to introduce restriction sites into the products which would 
allow for in-frame cloning into the appropriate pcDNA 3.1 (Invitrogen; V790-20) 
and pTYB2 (New England Biolabs; N6702S)(for DAO), pCSM-EGFP 
(Clonetech; 6101-1)(for bassoon). 
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8.1.12.1 Preparation of vector fragments 
Both human and rat DAO were cloned into pcDNA3.1 vector (Invitrogen).  EcoRI 
(5‟) and NotI (3‟) were used for the rDAO and HindIII (5‟) and XbaI (3‟) were 
used for the hDAO.   
 
Primers for rDAO include 
5‟ AAAAGAATTCACCATGCGCGTGGCCGTGATTGGAGCG 
3‟ TTTTGCGGCCGCTCAGAGGTGGGATGGAGGCATC 
 
Primers for hDAO include 
5‟ AAAGCTTACCATGCGTGTGGTGGTGATT 
3‟ TTTTCTAGATCAGAGGTGGGATGGTGGCATTCTG 
  
The pCSM-EGFP vector containing rat Bsn95-3963 was obtained kindly from the 
lab of Dr. Gundelfinger (Leibniz Insitute for Neurobiology, Germany).  The 
bassoon construct was cloned into the vector using HindIII (5‟) and SacII (3‟) 
with the GFP fused at the N-terminus.  This construct was subsequently used by 
me to synthesize truncation mutants representative of various functional domains 
of this protein. 
 
8.1.12.2 Preparation of inserts synthesized by PCR 
PCR reactions were carried out with the following KOD Xtreme
TM
 Hot Start 
DNA Polymerase reaction mixture from Novagen (71975): 
12.5 l    2x Xtreme buffer 
5 l         dNTPs (2 mM each) 
7 l          PCR grade water 
0.4 l       Sense (5‟) primer (100 M) 
0.4 l       Anti-sense (3‟) primer (100 M) 
0.1 l       Template DNA 
0.5 l       KOD Xtreme hot start DNA polymerase 
Reaction was run in a total volume of 26 l. 
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The reaction mixture was subject to 25 cycles of the following program on a 
BioRad Gene Cycler: 10 sec at 98
o
C, 30 sec at 55
o
C, 1 min per kb length at 68
 o
C. 
 
The PCR reaction was run on agarose gel (section 6.1.6), appropriate DNA band 
was extracted from gel (section 6.1.6) and subcloned into TOPO vector (section 
6.1.8).   
 
List of primers used for synthesizing bassoon PCR cloning inserts each containing 
5‟ HindIII and 3‟ SacII restriction sites.   
All are written in a 5‟ to 3‟ direction. 
Bsn95-609   
5‟ CAGATCTCGAGCTCAAGCTTCTGCTACTGCTCCT 
3‟ TTTTTCCGCGGGATCCCTGTCTTCTTTTCCGGG 
 
Bsn2715-3014             
5‟ AAAAAAGCTTATGGGCAGGCTCAGGGTGTGGCTGGGCC 
3‟  TTTTCCGCGGCCGCAGCTGGTTGAGCTCGCTGTCAGACA 
 
Bsn1692-3263            
5‟  AAAAAAGCTTTTCCAGGCCGCCAGTCAACCGCCGTGCA 
3‟       TTTTCCGCGGGGGATCCTTCCCGGGACGCCCACTGA 
 
Bsn95-3263  
5‟ CAGATCTCGAGCTCAAGCTTCTGCTACTGCTCCT 
3‟    TTTTCCGCGGGGGATCCTTCCCGGGACGCCCACTGA 
 
Bsn3263-3963   
5‟ AAAAAAAAGCTTAGAGAACCAGCTGTCCTAGAGGGACCC 
3‟    TTTTTCCGCGGCCAGAATGAGGAAAATTTTTTGCC 
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8.1.13 Sequencing 
All of the samples were sent out to internal Wyeth sequencing department.  
Sequences of the inserts were sent back electronically indicating the exact content 
of the insert which was compared to the template to make sure that it reflected the 
expected sequence. 
 
8.1.14 Preparation of competent yeast cells 
Streaked yeast on YPDA agar and incubated upside down for 3 days at 30
o
C.  
Inoculated 3 mls YPDA medium in sterile 15 Falcon tube with single colony with 
a diameter of 2-3 mm.  Incubated at 30
o
C for 8-12 hrs and shaked at 200 rpm.  
Tranfered 5 l of the culture to 250 ml flast containing 50 mls of YPDA.  
Incubated the cells at 30
o
C while shaking for ~16 hrs until OD600 reached 0.15-
0.3.  Centrifuged down the cells for 5 min at 700 g at room temperature and 
resuspend the pellet in 100 mls of fresh YPDA.  Incubated the cells at 30
o
C while 
shaking until they reach OD600 of 0.4 – 0.5 (about 3-5 hrs).  Spun 50 mls of 
culture as before and resuspend the pellet in 30 mls of sterile, deionized water.  
Spun the cells again and resuspend the pellet in 1.5 ml of 1.1xTE/LiAc.  Pelleted 
the cells in a table top centrifuge at top speed for 15 sec.  Resuspend the pellet in 
600 l of 1.1xTE/LiAc.   
 
8.1.15 Yeast transformation 
In a prechilled 1.5 ml microfuge mixed 100 ng of plasmid DNA with 5 l Herring 
Testes Carrier DNA (10 ml/ml) and 50 l of competent cells.  Added 0.5 ml 
PEG/LiAc and gently mixed.  Incubated for 30
o
C for 30 min with occasionally 
mix of the cells. Added 20 l DMSO and mixed.  Incubated at 42
o
C for 15 min 
with an occasional mix.  Pelleted the cells in a table top centrifuge at top speed for 
15 sec.  Resuspend the pellet in 1 ml of YPD liquid medium and incubated with 
shaking at 30
o
C for 90 min.  Pelleted the cells in a table top centrifuge at top 
speed for 15 sec.  Resuspended cells in 1 ml of 0.9% (w/v) NaCl and plated out 
the cells on appropriate dropout plates.  Incubate upside down at 30
o
C. 
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8.1.16 Yeast mating 
Streaked out yeast cells containing the prey vector and the bait vector on 
appropriate single dropout media and grew at 30
o
C for 3 days.  Picked single 
colony about 2-3 mm from each plate (one for bait and one for prey containing 
strain) into 1.5 ml centrifuge tube containing 500 l of 2xYPDA and vortexed to 
mix.  Incubated overnight while shaking at 200 rpm at 30
o
C.  Spreaded the mated 
culture on double and quadruple dropout media and incubated at 30
o
C for 3 to 5 
days.  The double dropout was used to determine mating efficiency while the 
quadruple dropout for interactor study. 
 
8.1.17 Yeast DNA extraction 
Done with the Yeastmaker yeast plasmid isolation kit (Clontech; 630441).  
Inoculated single colony into 0.5 ml of appropriate SD liquid mdium and 
incubated at 30
o
C overnight with vigorous shaking (250 rpm).  Pelleted the cells 
through centrifugation at 14,000 rpm for 5 min.  Resuspended in 50 l of 
potassium phosphate (67 mM KH2PO4; pH 7.5) and mixed with 10 l of Lyticase 
solution.  Incubated at 37
o
C fro 30 min.  Added 10 l of 20% SDS and vortexd 
for 1 min.  Prepared a Chroma Spin-1000 DEPC-water column by vortexing the 
spin column until resuspended the gel matrix, removed the cap and broke off the 
tip, placed the column into 2 ml polypropylene tube, centrifuged column for 5 
min at 700 x g and saved the column in a fresh microcentrifuge tube.  Applied the 
cell sample to the center of the gel bed‟s flat surface.  Spun the column for 5 min 
at 700 x g.  The purified DNA was in the eluate. 
 
8.2 Biochemistry 
 
8.2.1 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
SDS-PAGE sample buffer (3x) (80 mM Tris-HCl pH 6.8, 100 mM DTT, 10% 
glycerol, 2% SDS and 0.1% bromophenol blue) was added to samples before they 
were boiled for 3 min and loaded onto gels. 
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Samples were run in 4-12% gradient w/v polyacrylamide 
(Invitrogen;NP0321BOX).  gels were run in MOPS (NuPage; NP0001) at 130V 
for about 2 hrs.   
 
8.2.1.1  Coomassie Blue staining 
If proteins were to be visualized directly, gel was fixed and stained with 1% 
Coomassie Blue (BioRad; 161-0436) in 10% acetic acid and 20% methanol for 30 
min at room temperature.  The gels were destained in 10% acetic acid and 20% 
methanol. 
 
8.2.1.2  Silver stain 
For more sensitive protein detection Silver stain was utilized.  A brief protocol for 
Silver stain kit (Invitrogen; LC6100) includes fixing the SDS-PAGE gels with 
200 ml of fixing solution for 10 min, 2 x 10 min x 100 ml washes in sensitizing 
solution, 2 x 5 min x 200 ml washes in pure water, 15 min incubation in 100 ml of 
staining solution, 2 x 5min x 200 ml of rinse with pure water, 5 min incubation in 
developing solution, and stopping the reaction with 5 ml of the stopping solution.   
 
8.2.2 Western blotting 
The SDS-PAGE gel was placed against pre-wetted 0.45 m nitrocellulose 
(BioRad; 162-0215) with two pieces of Whatman 3mm filter paper on each side 
into a BioRad western blot cassette.  Transfer was carried out in a BioRad western 
blotting apparatus with 1x Transfer buffer at 30V.  Transfer normally lasted 
between 60 and 90 min.  After transfer the positions of proteins lanes and 
molecular weight markers were indented.  The blot was blocked with blocking 
buffer (Rockland; MB-070) for 30 min.  The antibodies were diluted at 1:1000 
dilution unless otherwise stated into the blocking buffer and applied to the filter 
for at least 1 hr with vigorous shaking.  Excess antibody was washed off with 
0.1% Tween-20 in 100 mM PBS (Gibco; 14190) 5min x 3.  Secondary antibody 
was conjugated to red fluorescence or green fluorescence (Invitrogen; A21109; 
Rockland; 610-131-121).  The blots were visualized on the Odyssey (Li-Cor). 
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8.2.2.1 Primary antibodies used in this study for western blotting 
DAO (rabbit polyclonal custom made through OpenBiosystems as described in 
chapter 2) 
Catalase   Sigma; C0979 
Bassoon  StressGen; VAM-PS003 
PSD-95  UC Davis/NINDS/NIMH NeuroMab ; 75-028 
MAP2   Sigma; M2320 
Actin   Sigma; A-2066 
Synaptophysin Sigma; S5768 
GFP   Clontech; 632375 
GAL4 DNA-BD Clontech; 630403 
Mouse IgG  SantaCruz; sc-2025 
Rabbit IgG  Abcam; ab37415-5 
 
8.2.3 Synaptic junction membrane fractionation experiments 
The fractionation experiment was derived from tom Dieck (tom Dieck et al., 
1998), Wyneken (Wyneken et al., 2001) and Carlin (Carlin et al., 1980).  Rat 
cerebellum from four animals was collected for a total weight of about 2 g of wet 
tissue was homogenized by hand 10 times in 8 ml of solution A (320 mM sucrose/ 
5 mM HEPES / protease inhibitors).  The resulting lysate was centrifuged for 10 
min at 1,000g at 4
o
C.  The resulting supernatant (S1) was centrifuged at 12,000g 
for 20 min at 4
o
C.  For every 1 g of pellet (P2), 2.4 ml of solution A was used to 
resuspend it into solution.  This solution was layered onto a sucrose gradient 
consisting of 10 ml each of 0.85 M, 1.0 M, and 1.2 M.  The gradient was 
centrifuged for 2 hrs at 82,500g.  The synaptosomal fraction was collected 
between the 1.0M and 1.2M and it was layered on top of the 1.0M fraction.  This 
fraction was lysed for 30 min on ice in 5x volume of solution B (5 mM Tris-HCl 
pH 8.1/ 1 mM DTT).  The solution was centrifuged at 33,000g for 30 min and the 
resulting pellet (P3) was resuspended in solution C (320 mM sucrose / 2 mM DTT 
/ 12 mM Tris-HCl pH 8.1) at a volume of 60 ml/ 10 g of starting material.  The 
resuspended P3 was mixed with equal volume of 320 mM sucrose / 1% Triton X-
100 and incubated on ice for 15 min.  The sample was centrifuged at 4
o
C for 30 
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min at 33,000g and the resulting pellet (P4) was resuspended in solution A.  The 
resuspended P4 was layered on top of sucrose gradient composed of 1.0 M, 1.5 M 
and 2.0 M and centrifuged at 4
o
C for 2 hr at 201,000g.  The pellet resulting from 
this centrifugation represents the synaptic junction membrane fraction. 
 
8.2.4 Amplex Red DAO assay 
The hDAO enzymatic assay was run in 20 mM Tris-HCl pH 7.5, 1.0 % glycerol, 
0.01% Brij-35 and 0.01% BSA buffer.  Each 384 well in 384 well plate (Matrix; 
4328) was loaded with 20 l of purified DAO enzyme at 7 ng per well, 10 l of 
4x compound in 8% DMSO (WAY-396964 or just buffer) and following 5-10 
minute incubation 10 l of D-alanine (5 mM) (VWR; IC10028025), Amplex Red 
(100 M)(Invitrogen; A36006), HRP (1 U/ml)(Sigma; P8375-100KU) was added.  
The reaction took place in the dark at room temperature for 30 min before the 
RFU were read on Victor2 (PerkinElmer) using 544nm excitation, and 590 nm 
emission.   
 
For the hDAO and rDAO stable line 20 k cells per well in 384 well plates were 
plated overnight.  The media was replaced with 35 l of 50 mM NaHPO4 pH 7.4 
and 5 l of 10x compound in 3% DMSO or just assay buffer was added for 5-10 
min incubation prior to adding 10 l of 50 mM D-alanine, 100 M Amplex Red, 
1 U/ml HRP.  The cells were incubated at room temperature for 45-60 min in the 
dark prior to reading the fluorescence on Victor2 with 544 nm excitation 
wavelength and 596 nm emission. 
 
8.2.5 Bacterial culture preparation and chitin column hDAO purification 
BL21 (DE3) E. coli cells were transiently transfected with the hDAO/pTYB2 
construct and plated on LB amp plates overnight at 37
o
C.  A single colony was 
selected and incubated at 37
o
C in 100 ml of LB amp at 175 rpm until the solution 
reached optical density of 0.6 at 600 nm.  The solution was then ten fold diluted 
into LB amp supplemented with 0.5 mM IPTG.  The cells grew overnight at 30
o
C 
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in a shaker at 200 rpms.  The following day the cells were centrifuged at 5,000 
rpms for 20 min and the pellet was frozen and kept at -80
o
C. 
 
The cell pellet was processed according to Raibek (2000).  For every 10g of wet 
pellet 80 ml of cold 50 mM Tris-HCl pH 8.0, 1 mM sodium benzoate, 1 mM 
EDTA, 1 mM ATP, and protease inhibitor solution was used to resuspend the 
cells. The solution was thoroughly sonicated and centrifuged at 13,000 rpms for 
15 min at 4
o
C to remove cellular debris.  The remaining supernatant was 
normalized with NaCl (to a concentration of 1 M) before the solution was applied 
to an equilibrated 5-ml affinity column (Chitin beads from Stratagene) with 
solution A (50 mM Tris-HCl pH 8.0, 1 mM sodium benzoate, 1 mM EDTA, 1 M 
NaCl).  The beads were subsequently washed with 100 ml of buffer A and 20 ml 
of buffer B (buffer A without the NaCl or sodium benzoate).  Finally, the column 
was washed with 10 ml of buffer C (buffer B with 50 mM hydroxylamine) and 
left at 4
o
C overnight in buffer C solution.  The cleaved hDAO was collected the 
following day and examined for purity on SDS-PAGE gel stained with Coomassie 
Blue and for activity with the Amplex Red assay.   
 
8.2.6 Protein assay 
Protein concentration was determined based on a standard protein curve as 
measured with BioRad DC protein assay.  A total of 20 l of reagent S per 1.0 ml 
of reagent A were added to make the working reagent.  Several dilutions of a 
protein standard containing 0.2 mg/ml to 1.5 mg/ml protein were prepared 
(Pierce; prediluted protein standards).  A total volume of 100 l of standards and 
samples were added to cuvetts and mixed with 500 l of working reagent 
followed by addition of 4 ml of reagent B.  The samples were incubated for 15 
min at room temperature before absorbance was read at 750 nm on Spectromax. 
 
8.3 Cell Culture 
8.3.1 Maintenance of HEK293 cells 
Human embryonic kidney cell fibroblasts were grown at 37
o
C with 5% CO
2
 in 
Dulbecco‟s Modified Eagles Medium (DMEM; Gibco) containing 10% (v/v) fetal 
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calf serum (FCS; Gibco) and 1% (v/v) penicillin and streptomycin (Gibco). At 
approximately 90% confluence, cells were passaged by treatment in 5 ml 
prewarmed trypsin (0.25% w/v) (Gibco).  Once in suspension the cells were 
diluted 1:10 with prewarmed DMEM (as above), and seeded out onto T175 (BD 
Falcon). 
 
8.3.2 Transient transfection of Hek293 
One 10 cm poly-D-lysine coated dish (Becton Dickinson) containing 30-50% 
confluence was used per transfection with Lipofectamine 2000 (Invitrogen).  15 
g of DNA was suspended in 500 l of OptiMem (Gibco) in 5 ml polystyrene 
tube (Falcon).  In another polystyrene tube 30 l of lifopectamine 2000 was 
suspended in 500 l of OptiMem and both solutions were incubated individually 
at room temperature for 5 min.  The tube containing the DNA was then mixed 
with the tube containing the lipofectamine and incubated at room temperature for 
20 min before the solution was added to the dish containing the cells.  The cells 
were harvested 24-72 hr post transfection depending on the expression level of the 
recombinant protein. 
 
8.3.3 Stable line generation 
T175 flast was grown to 90% confluency before the cells were harvested and 
resuspended in 0.5 ml Optimem.  The cells were transferred to a 0.4 cm 
electroporation cuvette (BioRad) and 10 g total plasmid DNA was added.  
Electroporation was carried out with the settings 400 V, 250 Fm The 
cells were then added to 20 ml DMEM and plated out at 100 l and at dilutions of 
1:10 and 1:100 on 96-well plates.  After 24 hr incubation additional 100 l of 
DMEM media containing 1.6 mg/ml of hygromycin or G418 were added.  The 
cells were left in the incubator for 2 weeks before they where examined for 
growth.  Wells containing single colonies per well were selected and screened for 
presence of the recombinant gene through western blotting and functional activity 
screening. 
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8.3.4 Culturing of cerebellar granule neurons 
Animal handling in accordance with animal welfare regulations.  Cerebellum was 
dissected from postnatal day 14-21 rat pups, the meninges were removed under a 
dissecting microscope and the tissue was stored in ice cold PBS.  The tissue was 
dissociated using papain solution (Worthington).  The tissue was incubated for 30 
min at 37
o
C in 250 l of DNase (tube 3) and 5 ml papain (tube 2).  The solution 
was then removed and the tissue was triturated in 2 ml of DNase (vial 3)/ inhibitor 
(vial 4)/ EBSS (vial 1) 10x with a 1 ml tips.  Once the tissue settled down the 
supernatant was removed into a separate tube and the trituration was repeated 3 
more times with 6 more ml on the pelleted tissue sample.  All of the supernatants 
were pulled together and centrifuged at 300g for 5 min.   The pellet was 
resuspended in 2 ml of DNase (vial 3)/ inhibitor (vial 4)/ EBSS (vial 1) and 
layered on top of 6 ml of inhibitor (vial 4).  This solution was centrifuged at 300g 
for 5 min and the pelleted cells were resuspended in Neurobasal complete media 
(500 ml of neurobasal media w/o L-glutamine, 10 ml of B27 supplement 50x, 
0.75 g of KCl, 200 mM glutamine, 6.6 mg/ml Aphidicolin, and 1% penicillin and 
streptomycin.  The cells were counted and plated out at 50,000 cells per 24-well 
poly-D-lysine coated coverslips and incubated at 37
o
C with 5% CO2 for two 
weeks without changing the media.  After the two weeks the cells were processed 
for imaging. 
 
8.4 Immunofluorescence 
 
8.4.1 Cerebellar granule neurons preparation for immunofluorescence 
The CGN containing coverslips were washed 5 x 5 min in cold PBS.  To remove 
autofluorescence the cells were washed with 1% sodium borohydride 3 x 5 min 
and then washed with cold PBS to wash out the sodium borohydride.  They were 
then soaked in 0.5% Triton X-100 in PBS for 1 hr at 4
o
C and washed twice for 5 
min in cold PBS.  1 hr block in 5% normal goat serum (Vector) with 0.2% Triton 
X-100 in cold PBS followed.  Primary antibody was added to the blocking 
solution at 1:100 dilution for 1-3 hr before wash in cold PBS 5 x 5 min.  
Secondary antibody at 1:200 dilution suspended in the blocking reagent was then 
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applied to the coverslips for 1 hr.  It was then washed away with 5 x 5 min PBS.  
The coverslips were mounted onto slides with prolong gold (Invitrogen) and 
visualized under fluorescent microscopy.   
 
8.4.2 Rat cerebellar immunofluorescence preparation 
Fresh 4% paraformaldehyde for rat perfusion was made according to the 
following protocol for 1L: 40 g of paraformaldehyde was mixed into 500 ml of 
water heated to 60
o
C.  NaOH was titrated into this solution until all of the 
paraformaldehyde solubilized from a milky appearance to clear solution.  Then 
500 ml of 0.2 M phosphate buffer was added and the pH was adjucted to 7.4. 
 
Animal handling in accordance with animal welfare regulations.  Animals were 
anestized prior to any work.  Through a cardiac tap 100 ml of PBS was infused to 
wash out blood out of the blood vessels.  After the PBS wash the solution was 
switched to perfusion with 500 ml/animal of 4% paraformaldehyde running at 
about 50 ml per minute.  The intact cerebellum was dissociated and soaked in 4% 
paraformaldehyde for additional 10 min.  The cerebellum was then soaked in 30% 
sucrose solution for about 2 days until the tissue sunk to the bottom of the vessel.   
 
The cerebellar tissue was frozen by application of dry ice on the stage of 
microtome and cut into 20 m slices.  The slices were washed 5 x 5 min in cold 
PBS and treated with 1% sodium borohydrate 3 x 5 min to remove 
autofluorescence.  The slices were washed with cold PBS 2 x 5 min and soaked in 
0.5% Trion X-100 for 1 hr.  They were washed 2 x 5 min in PBS and blocked for 
1 hr in 5% normal goat serum with 0.2% Triton X-100.  Primary antibody was 
added to the blocking buffer at 1:100 dilution and incubated overnight while 
gently racking at 4
o
C.  The following day the slices were washed in cold PBS 5 x 
5 min.  Secondary antibody diluted in the blocking buffer at 1:200 dilution was 
added to the slices for 1 hr and then washed away with 5 x 5 min PBS.  The slices 
were mounted on slides and preserved with prolong gold.  The sections were 
imaged on fluorescent microscope.   
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8.5 Immunoprecipitation 
 
8.5.1 Application of Dynal Protein A beads 
Dynal protein A beads (Invitrogen) have a strong binding capacity for rabbit IgG 
hence they were used to capture DAO antibody and consequently 
immunoprecipite DAO from cellular lysate such as the rat cerebellum or the DAO 
stable line.  More background information on the Dynal beads can be found in 
chapter 2 where the principle is more thoroughly outlined. 
 
The beads were thoroughly mixed through vortexing to make sure that they are in 
solution before 100 l was removed into ependorf tube.  The tube was placed on a 
Dynal MPC magnet which separated the beads out of the solution.  Media was 
removed and replaced with 0.5 ml of 0.1 M NaPO4 pH 8.0.  The beads were 
resuspended and again precipitated with the magnet, sodium phosphate was 
removed and replaced with fresh sodium phosphate solution two more times.  The 
beads were resuspended in 90 l of sodium phosphate buffer and 10 l rabbit 
antibody solution was added to the bead solution.  This solution was gently mixed 
for 10 min at room temperature to all the beads to capture the antibody.  The 
beads were then applied to the magnet and the solution was removed and replaced 
with 0.5 ml of sodium phosphate buffer 3 x 5 min.  The antibody was crosslinked 
to the beads by removing the sodium phosphate buffer and replacing it with 1 ml 
of 0.2 M triethanolamide pH 8.2, 3 x 2 min.  The beads were resuspended in 
freshly made 1 ml of 0.2 M triethanolamide pH 8.2 supplemented with 20 mM 
DMP (dimethyl pimelimidate dihydrochloride) (Pierce) and incubated for 30 min 
at room temperature with a gentle rotation.  The reaction was stopped by 
removing the solution and replacing it with 50 mM Tris pH 7.5 for 15 min at 
room temperature with a gentle rotation.  The beads were washed 3 x 5 min in 
PBS and resuspended in 100 l of PBS.  The protein A beads are now coated with 
the rabbit antibody which is covalently coupled to the beads.  Fresh cellular or 
tissue lysates in RIPA buffer were added to the bead-antibody complex and 
incubated for 1 hr at 4
o
C with gentle rocking.  The lysate was washed away with 
PBS or stronger washing detergents 3 x 5 min at room temperature and the beads 
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were resuspended in 20 l of PBS.  SDS-PAGE loading dye was added to this 
solution and it was boiled for 3 min to extract attached proteins. 
 
8.5.2 Application of Dynal Protein G beads 
Dynal protein G beads (Invitrogen) have a strong binding capacity for monoclonal 
IgG (Akerstrom 1985) hence they were used to capture bassoon and GFP 
antibodies which were then used to immunoprecipite bassoon and GFP-tagged 
bassoon from cellular lysate such as the rat cerebellum or transiently transfected 
cells. 
 
The Dynal protein G beads were vortexed to resuspend them in solution and 100 
l sample was removed.  The beads were separated from the solution via a 
magnet and resuspended in 0.5 ml of 0.1 M citrate-phosphate buffer pH 5.0.  The 
washing was repeated two more times and the beads were resuspended in 50 l of 
the citrate-phosphate buffer.  10 l of monoclonal antibody solution was added to 
the bead solution and incubated for 40 min at room temperature while gently 
rocking.  The supernatant was then removed and the beads were washed 3 x 5 min 
with 0.5 ml of the citrate-phosphate buffer.  The antibody was crosslinked to the 
beads in the same manner as the rabbit IgG was to protein A beads (see 6.5.1).  
After the crosslinking, the beads were resuspended in 100 l of PBS and cellular 
or tissue lysate was added to this solution for 1 hr incubation at 4
o
C with gentle 
rocking.  The beads were then washed with PBS or stronger washing detergent 3 
x 5 min at room temperature and the beads were resuspended in 20 l of PBS.  
SDS buffer was added to this solution and it was boiled for 3 min to extract 
attached proteins. 
 
8.6 Mass spectroscopy 
Immunoprecipitate collected from the DAO immunoprecipitation column was 
loaded and separated on 10-20% Tricine SDS-PAGE gel (Invitrogen).  The 
proteins on the SDS-PAGE gel were stained with Imperial Protein Stain Solution 
(Pierce).  Each gel lane was cut into twenty pieces of about 1 x 1 mm
2
.  The 
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pieces were excised and the stain was removed by dehydration in acetonitrile 
(ACN), rehydrated, and washed in 25 mM sodium phosphate (pH 6.0), and 
dehydrated again in ACN.  Proteins within the gel pieces were digested in a 
solution containing 0.5 g of trypsin in 25 mM sodium phosphate (pH 6.0) at 
37
o
C for 4 hrs.  The trypsonized peptides were extracted from gel with 60% ACN 
/ 1 % fomic acid (FA) followed by extraction with 90 % ACN / 5 % FA.  The 
eluates were concentrated to near dryness by vacuum and reconstituted in 20 l of 
2% ACN / 0.1 % FA in preparation for the mass spectroscopic analysis. 
 
Agilent 1100 nanoflow system connected to a linear ion trap mass spectrometer 
(LTQ, ThermoFinnigan) was used for the mass spectrometric analysis.  The 
peptide samples were pressure-loaded onto a C18 PicoFrit microcapillary column 
(New Objective) packed with Magic C18 beads (5 m, 75 m x 11 cm, Michron 
BioResources) and desalted on-line with solvent A (2% ACN and 0.1% FA).  The 
peptides were eluted with a gradient from 4 to 60% solvent B (90% ACN and 
0.1% FA) over 70 min with a flow rate of 250 nl/min.  The fragment ion spectra 
(MS/MS scan) were acquired in a data-dependent manner in which each fragment 
ion scan was followed by consecutive MS/MS scan on the first three most intense 
ions from the MS scan. 
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